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Abstract 
Peroxiredoxins are a family of multifunctional enzymes that are able to protect 
the cell against oxidative stress. Peroxiredoxins form part of a recently 
discovered peroxide scavenging system along with thioredoxin, thioredoxin 
reductase and sulfiredoxin. 
This study describes the purification of a recombinant human peroxiredoxin II 
from human erythrocytes. The original recombinant clone contained a point 
mutation at the fourth residue from glycine to valine and a number of problems 
were encountered with aggregation during purification. Reverting back to the 
original amino acid sequence allowed the protein to be purified and 
concentrated without aggregation, as well as leading to over-expression in the 
same oligomeric state as the native sample from blood. 
This study also describes the over-expression and purification of the human 
peroxiredoxin II protein in the intermolecular disulfide form as well as the 
subsequent crystallisation and X-ray diffraction studies. The crystal structure for 
this form of the protein was obtained to 3.3 Å resolution revealing the 
peroxiredoxin to be in the decameric form. In addition conformational changes 
in the protein that are necessary for formation of the intermolecular disulfide 
between the peroxidatic (Cys52) and resolving cysteine (Cys172) have been 
observed. The structure also revealed that these movements did not interfere 
with the dimer:dimer interface as had been previously suggested. This then 
allows the disulfide to be seen within the decameric form of peroxiredoxin. 
The production of covalent complexes formed between peroxiredoxin and 
sulfiredoxin, and peroxiredoxin and thioredoxin was also investigated. 
Complexes were stabilised by using DTNB to form a covalent bond between 
specific cysteine residues. The complex binding results from size exclusion 
chromatography showed that decameric peroxiredoxin bound to sulfiredoxin in 
a 1:5 ratio and decameric peroxiredoxin bound to thioredoxin in a 1:10 ratio. 
Cloning, over-expression and purification of the selenocysteine containing 
enzyme thioredoxin reductase was achieved. A minimal selenocysteine 
insertion sequence was added to the 3’ end of the DNA sequence to drive 
selenocysteine insertion in place of the typical stop UGA codon. The activity of 
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this protein was found to be low but was greatly increased when co-expressed 
with a plasmid containing the selA, selB and selC genes. Although the activity of 
this co-expressed thioredoxin reductase was ~20% of the native enzyme 
activity, it was comparable to the activity of other recombinant forms of the 
enzyme. 
These studies report the purification of all of the proteins necessary to reform 
the peroxiredoxin system and allow the production of a working assay for 
peroxiredoxin activity. Together with the first report for a structure of a 
decameric disulfide form of human peroxiredoxin II a greater insight into the 
peroxiredoxin system has been obtained. 
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1. Introduction 
1.1. Reactive oxygen species 
Reactive oxygen species (ROS) are products of normal metabolism and can be 
beneficial or harmful to cells and tissues depending on their concentration. In 
1954 an idea was put forward that oxygen may be toxic to cells and that 
partially reduced forms of oxygen were responsible for this toxicity (Gerschman 
et al., 1954). The next breakthrough in the identification of ROS occurred when 
a weak electron paramagnetic resonance signal was attributed to the presence 
of oxygen free radicals in a number of lyophilized biological materials 
(Commoner et al., 1954). The next major leap forward came in the discovery of 
the antioxidant enzyme superoxide dismutase (SOD) which provided conclusive 
evidence for the presence and importance of the ROS in biological systems 
(McCord and Fridovich, 1969).  
This research has lead to a huge number of papers that have shown biological 
systems are not only able to coexist with ROS but use them to their advantage 
for a number of biological processes. Reactive oxygen species are molecules 
containing oxygen that are highly reactive due to the presence of unpaired 
valence shell electrons that are highly reactive (Halliwell and Cross, 1994). The 
ROS can be split into two groups, the first is the O2-derived free radicals, 
superoxide anion (O2•-), hydroxyl (HO•), peroxyl (RO2•) and alkoxyl (RO•) 
radicals. The second group are the O2-derived non-radical species such as 
hydrogen peroxide (H2O2) (Halliwell and Cross, 1994). 
ROS species can have beneficial effects on biological systems usually in low 
concentrations as they can take part in the cellular signalling and in the defence 
response to infectious agents (Valko et al., 2006). The harmful effects of ROS 
are discussed in much further detail throughout this introduction. 
1.1.1. Superoxide anion 
The superoxide anion (O2•-) is generated by the reduction of molecular oxygen 
(O2). A one electron addition to molecular oxygen is used to create this free 
radical species (equation 1.1) (Raha and Robinson, 2000). Although being a 
free radical the species is thought to be relatively unreactive as it is unable to 
penetrate lipid membranes and so is localized to the place in which it was 
produced. The superoxide anion is mainly produced in mammals in the 
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mitochondrial electron transport chain. The main locations of this in the 
mitochondria are at complex I, where superoxide is generated in the matrix, and 
complex III, where it is produced on both sides of the inner membrane (St-
Pierre et al., 2002). 
O2 + e-  O2•- 
Equation 1.1. The formation of the superoxide anion by a one electron addition to 
molecular oxygen. 
The major enzyme involved in the reduction of the superoxide anion is SOD. 
This enzyme catalyses the disproportionation of the superoxide anion to 
hydrogen peroxide and oxygen (equation 1.2). 
2 O2•- + 2H+  H2O2 + O2 
Equation 1.2. The formation of hydrogen peroxide from the superoxide anion using 
hydrogen ions. 
1.1.2. Hydrogen peroxide 
The major source of hydrogen peroxide in the cell is the dismutation of 
superoxide (equation 1.2). The major source of the latter is the electron 
transport chains and the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases. Hydrogen peroxide is thought to be much more reactive 
than the superoxide anion because of its ability to move through biological 
membranes. Although hydrogen peroxide is thought to pass freely across 
biological membranes this movement is regulated by the lipid and protein 
composition of the membranes, as well as the presence of hydrogen peroxide 
carriers such as aquaporins (Bienert et al., 2007). Although it is not a radical 
species it does play a large role in radical formation, reacting to more reactive 
ROS such as the hypochlorous acid (HOCl) and the hydroxyl radical (HO•). 
H2O2 is known to be removed by at least three antioxidant systems; catalases 
(Alfonso-Prieto et al., 2009), glutathione peroxidases (Battin and Brumaghim, 
2009) and the peroxiredoxins (Chae et al., 1999). Hydrogen peroxide is a very 
good electrophile and participates in substitution reactions. 
1.1.3. Hydrogen peroxide redox signaling 
Hydrogen peroxide is able to modify specific and important amino acid residues. 
These modifications are usually reversible and form the basis of their redox 
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signaling abilities. The redox signaling either occurs by the direct modification of 
amino acid residues or indirectly through the products of their reactions blocking 
important residues that will inhibit the protein function (Salemeen et al., 2003; 
van Montfort et al., 2003). Hydrogen peroxide has also been shown to induce 
conformational changes in target proteins that can also affect protein function 
(Storz et al., 1990).   
1.1.4. The hydroxyl radical 
The hydroxyl radical is thought to be the most reactive and therefore the most 
damaging of all the ROS.  The hydroxyl radical is produced by the reduction of 
the hydrogen peroxide molecule which is catalyzed by the presence of metal 
ions such as iron (Fe2+) and copper (Cu+) in a reaction known as the Fenton 
reaction (equation 1.3) (Winterbourn, 1995). 
H2O2 + Fe2+/ Cu+  HO• + HO- + Fe3+/ Cu2+ 
Equation 1.3. The Fenton reaction. Hydrogen peroxide undergoes a redox reaction 
producing a hydroxyl anion and a hydroxyl free radical in the presence of a metal 
catalyst. 
1.1.5. Sites of production of reactive oxygen species 
Within the eukaryotic cell there are a number of different producers of reactive 
oxygen species with one of the major producers being the mitochondria. Of the 
total O2 consumed by mitochondria 2% is converted to reactive oxygen species 
(Turrens, 2003). It is also the most common site for the dismutase of the 
superoxide anion and the breakdown of hydrogen peroxide in the Fenton 
reaction. Peroxisomes form the major source of cytosolic hydrogen peroxide. 
Peroxisomes are a single membrane organelle present in eukaryotic cells that 
play a major role in lipid metabolism and the metabolism of many other organic 
substrates (Wanders et al., 2010). 
1.1.6. The human erythrocyte 
Erythrocytes, or red blood cells, are the major means of transport for O2 in the 
body, which they take up from the lungs and deliver while moving through 
capillaries (Engelhardt and Arnold, 1975). Erythrocytes are thought to be 
exposed to oxidative stress from a wide range of different sources. Erythrocytes 
are shown to possess large amounts of O2 and haemoglobin as part of their 
function both of which are producers of the reactive oxygen species O2- and 
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H2O2 (Halliwell and Gutteridge, 1999 ; Alayash et al., 2001).  Erythrocytes have 
a 120 day life span and are unable to produce new protein so they require an 
excellent antioxidant pathway to detoxify ROS before any damage can occur to 
the proteins contained within. 
1.2. Antioxidant enzymes 
Cells have developed a number of interacting enzyme networks for the 
detoxification of reactive oxygen species. The first reactive oxygen species 
metabolizing enzyme that was discovered was the previously discussed two 
metal-containing SOD (Dougherty et al., 1978). This enzyme is able to react two 
molecules of the superoxide anion together with two hydrogen ions converting 
them into molecular oxygen and hydrogen peroxide (Liochev and Fridovich, 
2010) (equation 1.4). 
Catalase, another antioxidant enzyme, contains a heme group and will catalyze 
the dismutation of hydrogen peroxide to water and molecular oxygen 
(Deisseroth and Dounce, 1970) (equation 1.5). Catalase can also remove other 
toxins by oxidising them along with hydrogen peroxide (equation 1.6). 
2H2O2  2H2O + O2 
Equation 1.4. The dismutation of H2O2 to water and molecular oxygen. 
H2O2 + RH2  R + 2H2O 
Equation 1.5. The oxidation of toxins in a coupled reduction with hydrogen peroxide. 
Glutathione peroxidases (GPx) are selenocysteine containing enzymes that 
have been found to detoxify organic hydroperoxides by their conversion to 
alcohols while forming a glutathione disulfide (equation 1.7) (Epp et al., 1983). 
ROOH + 2GSH  ROH + GSSG + H2O 
Equation 1.6. The conversion of hydroperoxides to alcohols using GPx   
The system that this study focuses on is the peroxiredoxin system. The 
peroxiredoxin system contains a number of enzymes that interact to reduce 
peroxide substrates using redox active cysteine residues (Hofmann et al., 
2002). 
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1.3. Oxidative stress 
Oxidative stress arises from an imbalance between the reactive oxygen species 
mentioned and the systems in the cell designed to detoxify them. If the 
mechanism by which reactive oxygen species are removed break down then 
this can leave them available to attack and damage all the major groups of 
biomolecules (DNA, lipids and proteins). 
Reactive oxygen species have been shown to have a number of different 
chemical modification affects on DNA such as DNA cleavage, protein-DNA 
cross links and the oxidation of purines (Marnett, 2000). If these alterations 
occur and the DNA repair proteins are not able to correct them this could lead to 
incorrect base pairing and the replication of “faulty” DNA. This has been 
identified as potentially one of the reasons why individuals that have a high 
exposure to oxidative stress show higher rates of cancer (Mates et al., 1999; 
Klaunig et al., 2010). Lipids are susceptible to peroxidation as their 
polyunsaturated fatty acid structures contain a number of double bonds that are 
highly reactive with free radicals (Niki, 2009). Proteins are also highly 
susceptible to reactive oxygen species attack, which often leaves them modified 
with the effects being anything from partial structural changes leaving the 
protein less active, to complete denaturation (Butterfield et al., 1998). 
Oxidative stress is thought to play a role in the process of ageing (McArdle and 
Jackson, 2000) and in the process of diseases such as Alzheimers (Bonda et 
al., 2010), Parkinsons (Zhou et al., 2008), arthritis (Mapp et al., 1995), diabetes 
(Baynes and Thorpe, 1999) and multiple sclerosis (Gilgun-Sherki et al., 2004). 
1.4. The biological redox chemistry of cysteine 
Cysteine (Cys, C) is an amino acid that contains a side chain thiol (SH) group 
(figure 1.1). Cysteine can play an important role in the folding (and therefore 
structure) and stability of some proteins through the formation of disulfide 
bonds.  
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Figure 1.1. The chemical structure of the amino acid cysteine in the thiol (A), sulfenic 
acid (B) and sulfinic acid form (C). 
The thiol group is important in the detection of hydrogen peroxide. The rate of 
reaction between the protein thiol group and hydrogen peroxide is very 
important in redox signalling. The two most important factors in the reactivity of 
the thiol group is the ability of the cysteine residue to be deprotonated to the 
thiolate anion (equation 1.8) and how accessible this thiol group is. 
Protein-S-H  Protein-S- + H+ 
Equation 1.7. Deprotonation of a cysteine residue to form the thiolate group. 
The cysteine residue thiol group is nucleophilic and has a pKa of 8.5. This pKa 
is close to neutral in the cell and so the thiol group is often seen in its reactive 
thiolate (S-) form which is highly nucleophilic (Bulaj et al., 1998). The reactivity 
of the thiol group is highly linked to pH which shows the importance of the 
thiolate form in the reactivity of the cysteine residue (Jocelyn, 1972). 
The structural environment in which the thiol group is located can also play a 
large role in the reactivity of the group (Friedman, 1973) as the environment will 
usually provide a positively charged residue to stabilize the negative charge on 
the thiol group. The structural environment will also play a large role in the 
accessibility of the thiolate anion.  
As well as the thiol there are three other species involving the sulfur atom of the 
cysteine side chain that are of interest in this project, these are the sulfenic acid 
(R-SOH), sulfinic acid (R-S(O)OH) and the disulfide form (R-S-S-R). There is a 
switch in the oxidation state of sulfur between the thiol (-2), sulfenic acid (0) and 
sulfinic acid (+2) states. 
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1.4.1. Reaction of thiol with hydrogen peroxide 
As discussed before the reaction of the thiol group usually proceeds through the 
thiolate ion produced depending on the environment of the cysteine residue. 
This thiolate ion is a highly reactive nucleophile and its oxidation reaction with 
hydrogen peroxide (H2O2) produces a sulfenic acid as well as a molecule of 
water (Jacob et al., 2004). Thiolate ion formation is not the only prerequisite for 
the reaction with H2O2; it was discovered by studying the rates of different thiol 
containing enzymes (Stone, 2004) that the reaction also requires residues 
around the active site cysteine that are able to stabilize the reaction 
intermediate (Tosatto et al., 2008). 
Protein-S- + H2O2 + H+  Protein-SOH + H2O 
Equation 1.8. The oxidation reaction of a thiolate ion with H2O2 forming water 
and a sulfenic acid group. 
1.4.2. Forming the disulfide state 
Sulfenic acid is thought to be an unstable and highly reactive species that is 
heavily involved in redox signaling (Poole et al., 2004). If present with another 
thiol group the sulfenic acid form usually undergoes a rapid reaction forming a 
disulfide bond and a molecule of water (equation 1.9) (Allison, 1976).  
Protein-SOH + Protein’-SH  Protein-S-S-Protein’ + H2O 
Equation 1.9. The reaction of the sulfenic acid with a thiol forming a disulfide 
bond and a molecule of water. 
1.4.3. Forming the sulfinic acid state 
It has been noted that the sulfenic acid form can be reduced back to the thiol 
form if treated with a reducing agent, but a delay in this treatment can cause the 
oxidation to become irreversible suggesting a switch from the sulfenic to the 
sulfinic acid form (equation 1.10) (Little and O’Brien, 1969).  
Protein-SOH + H2O2  Protein-S(O)OH + H2O 
Equation 1.10. The hyper-oxidation reaction of the sulfenic acid with a 
molecule of H2O2 forming the sulfinic acid and a molecule of water. 
 
 
30 
 
1.5. Peroxiredoxin 
Peroxiredoxins (Prxs) are a family of multi-functional enzymes that protect 
against oxidative stress (Hofmann et al., 2002). Prxs are antioxidant enzymes 
that use the redox active cysteine residues to reduce an O-O bond present in 
hydrogen peroxide and a range of organic hydroperoxides (ROOH) (Peshenko 
and Shichi, 2001. Prxs are located mainly in the cytosol but have also been 
found in mitochondria, chloroplasts and peroxisomes (Hofmann et al., 2002). 
This is expected as these are also the major sites of reactive oxygen species 
production. Prxs can be produced at very high levels and are found to be the 
third most abundant protein in erythrocytes (Moore et al., 1991), and in the top 
ten most produced proteins in Escherichia coli (E. coli) (Link et al., 1997). The 
protein is also thought to form between 0.1 and 0.8% of the total soluble protein 
in other types of mammalian cells (Chae et al., 1999). 
The Prxs are a ubiquitous family of enzymes that have been identified in yeast 
(Morgan and Veal, 2007), plant (Dietz, 2003) and animal cells (Miranda-Vizuete 
et al., 2000) as well as in bacteria and archaea (Dubbs and Mongkolsuk, 2007) 
and have been seen to have increased levels of expression under oxidative 
stress conditions (Halliwell, 1999). 
Prxs are split into two categories, the 1-Cys and 2-Cys Prx, based upon the 
number of redox active cysteines they possess. With further structural and 
mechanistic data available the 2-Cys Prx were then further split into two sub-
classes, the typical and atypical 2-Cys Prx. The typical 2-Cys Prx are 
homodimers than contain two identical active sites (Hirotsu et al., 1999a; 
Schroder et al., 2000; Alphey et al., 2000). The atypical 2-Cys Prx are thought 
to behave in the same way but are functionally monomeric with the redox active 
cysteines located on the same protein (Seo et al., 2000). It is thought that all of 
the different classes of Prx have the same first step in the mechanism and it is 
the recycling of the oxidized sulfenic acid form back to the reduced thiol state 
that differs.  
The peroxiredoxin system is a system of enzymes made up of Prx, thioredoxin, 
thioredoxin reductase and sulfiredoxin all of which will be talked about in this 
introduction. There have been six different sub forms of Prx (PrxI – VI) 
discovered in mammals. PrxI – IV are all typical 2-Cys Prx, PrxV is an atypical 
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2-Cys Prx and PrxVI is a 1-Cys Prx. The different sub forms of Prx differ in 
length (ranging from 198 – 271 amino acids), cellular location and the location 
on the human chromosome (Wood et al., 2003b). Prx I, II, III and V are reduced 
solely by thioredoxin (coupled with thioredoxin reductase and NADPH), Prx IV is 
able to use thioredoxin and glutathione where as Prx VI is only able to use 
glutathione. 
Prxs have been shown to have catalytic efficiencies of ~107 M-1 s-1 (Akerman 
and Muller, 2005). This catalytic efficiency is comparable to those of catalase, 
heme peroxidase and selenium-containing glutathione reductase (Wood et al., 
2003b).  
1.5.1. Peroxiredoxin II from human erythrocytes 
Peroxiredoxin II from human erythrocytes (hPrxII) (EC 1.11.1.15) was 
previously known as thioredoxin peroxidase B, natural killer enhancing factor-B 
(Shau et al., 1994)), thioredoxin-linked peroxidase (Cha and Kim, 1995) and is 
known to be the same as calpromotin (Moore et al., 1991) and torin (Harris and 
Naeem, 1981).  The gene encoding PrxII is located on chromosome 19 
(19p13.2).  
hPrxII protein consists of 198 residues with a molecular weight of ~22 kDa 
(Moore and Shriver, 1994). hPrxII has been found to be the third most abundant 
protein in the erythrocytes and has a cellular concentration of ~5.5 mg/ml 
(Moore et al., 1991). hPrxII is a typical 2-Cys Prx containing two redox active 
cysteines. hPrxII is a functionally dimeric protein with the peroxidatic cysteine 
(CysP) and the resolving cysteine (CysR) being presented to the active site by 
different chains of the dimer (Schroder et al., 2000). 
The PrxII has a wide range of different functions such as the reduction of 
hydrogen peroxide (Peskin et al., 2007) and its ability to act as a molecular 
chaperone. It also has a wide range of functions specific to the erythrocyte. The 
protein is able to activate the Gardos channels in the erythrocytes that help to 
increase the K+ efflux from the red blood cell (Moore et al., 1991).  The protein 
is also known to be an inhibitor of platelet-derived growth factor signalling (Lee 
et al., 2007). 
hPrxII is thought to exist mainly in the reduced state under native conditions due 
to the reductive environment within the erythrocyte. hPrxII is shown to have a 
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high sensitivity to H2O2 and is shown to result in formation of the disulfide 
intermediate (Low et al., 2007). It is believed that the recycling of the disulfide 
intermediate is relatively slow in the erythrocyte due to the relatively low 
amounts of thioredoxin reductase present which can lead to the accumulation of 
disulfide hPrxII. PrxII is thought to be very important in the protection of the 
erythrocyte from H2O2 produced by haemoglobin as mice deficient in PrxII suffer 
from hemolytic anaemia (Low et al., 2008) whereas mice deficient in catalase or 
glutathione peroxidase do not (Johnson et al., 2000; Ho et al., 2004). 
1.5.1.1. The structure of hPrxII 
The crystal structure of the decameric hPrxII was solved to a resolution of 1.7 Å 
at the University of Exeter (Schroder et al., 2000).The monomeric structure can 
be split into two domains. Domain I (residues 2-169) consists of five α helices, 
two 310 helices and an extended seven-stranded β sheet. The second domain is 
the C-terminal arm (residues 170-198) and is made up of one α helix. hPrxII 
contains a thioredoxin fold which consists of four β strands (β3, β4, β6 and β7) 
and four α helices (α1, α2, α4 and α5) (Schroder et al., 2000). 
 
Figure 1.2. Cartoon representation of the monomeric unit from the decameric structure 
of hPrxII from human erythrocytes (PDB: 1QMV). The redox active cysteines are 
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shown in orange sticks with the loop regions shown in green, α helices shown in red 
and β sheets shown in yellow (figure created using PyMol DeLano Scientific). 
hPrxII is thought to be functionally dimeric and the dimer  within the decameric 
structure reveals an active site where the CysP and CysR are brought by 
different members of the homodimer and each dimer contains two redox active 
sites. The dimer has an ellipsoidal shape with dimensions 52 Å x 53 Å x 60 Å. 
The dimer interface buries 2109 Å2 (21 %) of solvent-accessible surface area 
per monomer. The dimer is held together by hydrogen bonds and hydrophobic 
interactions between the C-terminal arm of one monomer and domain I of the 
other monomer. 
 
Figure 1.3. Cartoon representation of the homodimeric structure of hPrxII from human 
erythrocytes (PDB: 1QMV) with one monomer shown in green and the other shown in 
blue. The dimer contains two redox active sites indicated by the numbers 1 and 2. The 
redox active cysteines are shown in orange in stick mode (figure created using PyMol 
DeLano Scientific). 
The crystal structure of hPrxII showed the protein to be in a decameric structure 
where five homodimers join together to form a toroid shape with point group 
symmetry 52 (Schroder et al., 2000) with a maximal diameter of ~130 Å, an 
1 
2 
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inside diameter of ~60 Å and thickness of ~50 Å. In the toroid shape there is an 
overall buried surface area of 2740 Å2 per subunit which is 28% of the surface 
area. The decamer is held together by mainly hydrophobic interactions between 
residues Leu45, Phe47, Thr48, Phe81, Ala85, Val107 and Gly123. The 
decameric structure of this protein had been observed previously using electron 
microscopy (Harris et al., 1969). 
 
Figure 1.4. Cartoon representation of the decameric structure of hPrxII from human 
erythrocytes (PDB: 1QMV) with each individual chain within the 5 homodimers being 
shown in a different colour (figure created using PyMol DeLano Scientific). 
1.5.1.2. The structure of the hPrxII active site 
Within the homodimer there are two active sites. Each active site is made up of 
two redox active cysteines; the CysP is located on the N-terminus of one chain 
and the CysR which is located on the C-terminus of the other chain. In the 
crystal structure presented in Schroder et al., (2000) the CysP is shown to be in 
the hyper-oxidized sulfinic acid form that was thought to leave the protein 
inactive until the discovery of sulfiredoxin (Srx). The CysP is located in a 
hydrophobic pocket made up of residues Tyr43, Pro44, Thr48, Val50, Glu54, 
 Trp86, Arg127, Arg150 and Val
these residues both Thr48 and Arg127 have been confirmed as essential for 
activity through mutagenetic studies 
2002). The Arg127 residue is essential as it will lowe
during the first step of the reaction mechanism 
Figure 1.5. Ribbon and stick representation of the hydrophobic region around the 
active site CysP (CSD51) of hPrxII from human erythrocytes (PDB: 1QMV).
different subunits of the hPrxII homodimer are shown in green and cyan. 
that form this hydrophobic region are 
Arg127, Arg150 and Val171
conserved in all mammalian Prx sequences and the residues in italics are conserved 
only among the 2-Cys mammalian Prxs)
Scientific). 
The CysR (Cys172) is located 
accessibility that could account for why the Cys
oxidation and is preserved in its thiol status. There is a ~10 Å gap between the 
CysP and the CysR which is too far away for an inter
meaning there must be a structural rearrangement that must
two to interact (Schroder 
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171 from the other subunit (figure 1.5) and from 
(Montemartini et al., 1999
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1.5.1.3. The hPrxII catalytic cycle 
The hPrxII catalytic cycle is made up of five different stages. The first step is the 
peroxidation of the CysP which involves the oxidation of the cysteine thiol to a 
cysteine sulfenic acid. The second step is the resolution of the sulfenic acid 
where the CysP and the CysR form an intermolecular disulfide bond. The last 
step of the normal catalytic cycle is the recycling of the intermolecular disulfide 
back to the reduced state with both redox active cysteines in the thiol form. The 
fourth and fifth step represent an abnormal part of the catalytic cycle. The 
second step of the reaction can be thought of as “slow” and the hold at this 
stage can be a factor in the CysP becoming hyper-oxidized to the sulfinic acid 
form (Wood et al., 2003b). This is the fourth step of the cycle. The fifth step of 
the catalytic cycle would involve the reduction of the hyper-oxidized form of the 
protein back to the oxidized form allowing the protein to re-enter the normal 
catalytic cycle (Jeong et al., 2006). 
 
Figure 1.6. The five steps of the hPrxII catalytic cycle. The normal catalytic cycle is 
seen on the left hand side showing the peroxidation (step 1), the resolution (step 2) and 
the recycling (step 3). Hyper-oxidation of the CysP leads to a side catalytic cycle that 
shows the hyper-oxidation (step 4) and reduction of the sulfinic acid (step 5). 
Mechanism adapted from Hall et al., (2009). 
In each reduction step of the catalytic cycle another protein is used to reduce 
hPrxII. Thioredoxin (Trx) is used to reduce the disulfide state back to the fully 
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reduced thiol state (Holmgren, 1985) and in the case of the hyper-oxidized 
sulfinic acid; sulfiredoxin is used to reduce the CysP back to the sulfenic acid 
form which can re-enter the normal catalytic cycle (Jeong et al., 2006). 
1.5.1.4. The hPrxII mechanism 
The mechanism for the 1st step of the catalytic cycle shown above is thought to 
be similar for all classes of PrxII. The CysP is able to form a stable thiolate anion 
due to the active site environment described above which then attacks the 
peroxide forming a cysteine sulfenic acid on CysP and an alcohol molecule is 
released (figure 1.7). 
 
Figure 1.7. The mechanism of the 1st step or peroxidation reaction of hPrxII. Part A 
shows the formation of the thiolate anion that is stabilized by the presence of Arg127. 
Part B shows the attack of the thiolate anion of the peroxide substrate and the 
formation of the alcohol. Part C shows the sulfenic acid and alcohol (or water if the 
peroxide substrate is H2O2) products of the reaction. Mechanism recreated from Wood 
et al., (2003b).  
1.5.1.5. The hyper-oxidation of Peroxiredoxin 
Hyper-oxidation occurs due to a “slow” step in the reaction between the CysP 
and CysR (Wood et al., 2003b). One of the reasons for this is thought to be the 
YF and GGLG structural motif that sits above the active site (figure 1.8). The 
motif sits on a helix in the C-terminus and is thought to limit the ability of the C-
terminus to unfold and allow the formation of the intermolecular disulfide 
(Schroder et al., 2000). This allows the protein to become overwhelmed by the 
peroxide substrate switching the redox state of the CysP (Wood et al., 2003a). 
The cysteine residue becomes hyper-oxidized converting it from the sulfenic 
acid form to the sulfinic acid form (Jacob et al., 2004). This YF structural motif 
contained within the C-terminal arm has been studied by mutagenesis and 
removal or lack of the motif shows a much reduced sensitivity to H2O2 
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role of Prx to regulate redox signaling 
Figure 1.8. Cartoon representation of the GGLG and YF struc
believed to hinder the hPrxII (PDB: 1QMV) ability to allow it to form the disulfide state 
leading to hyper-oxidation of the cysteine residue (figure created using PyMol DeLano 
Scientific).  
1.5.1.6. Oligomerisation of peroxiredoxin II
Although we know the proteins to be homodimeric there was evidence for the 
oligomerisation of the protein to the decameric f
when Torin (now known
showed complexes with tenfold symmetry wh
electron microscopy (TEM) 
form seen in the TEM was confirmed by the crystal structure of hPrxII 
et al., 2000). The decameric form has also been observed for Rat PrxI 
(Matsumura et al., 2008).
dodecameric form and when 
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crystal structure showed dodecamers are interconnected forming a two-ring 
catenane (Cao et al., 2005). 
This oligomerisation of the Prx is thought to be affected by a number of different 
factors.  The oligomeric properties of the Prx have been studied using a number 
of different biophysical techniques such as gel filtration (Logan and Mayhew, 
2000), dynamic light scattering (Wood et al., 2002a) and analytical 
ultracentrifugation (Schroder et al., 2000). The factors shown to affect the 
oligomeric state of the protein are ionic strength (Schroder, 1998), pH 
(Kristensen et al., 1999) and changes in the redox active cysteines (Wood et al., 
2002). It has also been shown that the histidine (his) tag attached and used for 
purification may affect the oligomeric state of the protein. Size exclusion studies 
of the PrxIII protein showed that the presence of the poly histidine tag stabilized 
the formation of the dodecamer and may be a source of bias when working with 
recombinant Prxs (Cao et al., 2007). 
It is believed that the change in oligomeric state of peroxiredoxins can link its 
redox state to its function. A study by Barrano-Medina et al., (2008) shows that 
formation of decameric Prx occurs at a critical concentration (1 – 2 µM) that is 
similar for a range of Prxs. It is believed that this critical concentration is not 
affected by the presence of any poly histidine tag. A study of Prx from pea 
(Bernier-Villamor et al., 2004) and barley (Konig et al., 2002; Konig et al., 2003) 
revealed that the decameric form of the protein is preferred under reducing 
conditions. The decameric form was also preferred when the pH was reduced 
(8.0 – 7.5), suggesting a protonatable amino acid could aid decamer formation 
(Barranco-Medina et al., 2009). The hPrxII decamer has been shown to break 
down at pH >7.8 and in the presence of high concentrations (2.5 M) of urea 
(Kristensen et al., 1999). 
It is postulated in Schroder et al., (2000) that the intermolecular disulfide state 
would find it difficult to form or stay in the decameric structure due to the 
structural rearrangements that would need to take place for the disulfide to 
form.  The interconversion between the oxidized (Matsumura et al., 2008) and 
the disulfide form of the rat PrxI (HBP23) (Hirotsu et al., 1999a) led to a 
breakdown from the decamer to the dimer (Matsumura et al., 2008) respectively 
and it is noted that this could also occur with the hPrxII (Schroder et al., 2000).  
40 
 
A further study by Alphey et al. (2000) postulated that the nucleophilic attack of 
CysR upon CysP would cause the structural rearrangements that break the 
decameric structure during disulfide formation. 
It is believed that the dimer – decamer switch in Prx is dynamic and in vivo 
there is continuous interconversion between the species. Decameric Prxs have 
also been shown to aggregate together to form higher molecular weight forms 
(HMW). A dodecameric form of Prx has been observed and is believed to have 
a chaperone function (Moon et al., 2005) and their presence in the human 
erythrocyte has been postulated (Meissner et al., 2007). 
1.5.1.7. Peroxiredoxin chaperone activity 
A chaperone is a protein that helps to facilitate the correct folding of denatured 
and developing proteins (chaperonins) (Gatenby, 1992). Chaperones can also 
help to maintain proteins in their unfolded state during transportation (molecular 
chaperonins) (Hartl and Martin, 1995) as well as preventing the aggregation of 
certain proteins in vivo (Ellis and Minton, 2006). Many chaperones are 
expressed under cellular stress conditions such as high temperature (Ellis and 
van der Vies, 1991) and repair misfolded proteins. As discussed previously a 
HMW dodecamer of hPrxII was found to be a highly efficient chaperone 
protecting HeLa cells from H2O2 induced apoptosis (Moon et al., 2005). hPrxII is 
found only to be active as a chaperone when the oligomeric switch from 
decamer to dodecamer occurs. This is thought to occur as a response to high 
levels of H2O2 and could help to play a role in protecting the cell from apoptosis 
although the mechanism by which this occurs is not yet fully understood.  
1.5.1.8. Peroxiredoxin cell signalling activity 
One theory put forward to explain the hyper-oxidation of Prx to the sulfinic acid 
state is its ability to take part in cell signaling. It is already known that higher 
eukaryotic organisms are able to use higher concentrations of peroxide in the 
cell to mediate cell signalling (Rhee, 2006). The “floodgate” hypothesis put 
forward suggests that Prx is responsible for removing H2O2 before it is able to 
reach the peroxide sensitive targets. When the H2O2 concentation increases 
and Prx becomes hyperoxidised, the peroxide is able to break through the Prx 
barrier enabling the peroxide to interact with peroxide sensitive targets (Wood et 
al., 2003a). A second hypothesis suggests Prx is used as a measuring tool for 
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the amount of peroxide the cell is exposed to. In this theory hyperoxidised Prx is 
the oxidative stress signal and this signal can be turned off when the sulfinic 
acid is reduced and can be used to signal apoptosis (Jonsson and Lowther, 
2007).  
1.6. Sulfiredoxin 
As part of the mode of action for PrxII the active site CysP can become hyper-
oxidized to the cysteine sulfinic acid as part of the catalytic cycle. This sulfinic 
acid cannot be reduced by biological reductants and was thought to be an end 
point with Prx unable to be reduced (Hamann et al., 2002) until the discovery of 
sulfiredoxin (Srx). The protein was originally identified in Saccharomyces 
cerevisisae and was identified through a screen for hydrogen peroxide-induced 
genes (Biteau et al., 2003). In the Biteau et al. (2003) study it was discovered 
that the Srx mRNA levels were increased >200 fold 15 minutes after treatment 
with peroxide and that deletion of the gene resulted in a decreased tolerance to 
the peroxide treatment. There was also evidence of complex formation between 
yeast peroxiredoxin (Tsa1) and Srx and subsequent removal of the redox active 
cysteine of Srx resulted in loss of activity and complex formation. These 
complexes were also found to be sensitive to dithiothreitol (DTT) suggesting the 
production of a disulfide bond between the two enzymes. This study also 
showed that the reduction of the Prx by Srx requires the conserved cysteine 
residue on the Srx as well as adenosine triphosphate (ATP) and either Mg2+ or 
Mn2+ metal ions. The Srx sequence has been found to be conserved in a 
number of higher eukaryotes with the active site motif (GCHR) containing the 
redox active cysteine residue being highly conserved (Biteau et al., 2003). 
1.6.1. Human sulfiredoxin 
The human Srx (hSrx) has ~34% sequence identity to the original Srx from S. 
cerevisisae. In hSrx the active site motif contains a cysteine residue (Cys99) 
that is thought to be the redox active cysteine (Jeong et al., 2006). hSrx is 136 
amino acids in length and has a molecular weight ~15 kDa. 
1.6.1.1. Structure of hSrx 
The crystal structure of Srx has been studied extensively and has been 
crystallized on its own (Jonsson et al., 2005) as well as in the presence of ATP 
and Mg2+ (Jonsson et al., 2008c), ADP (Jonsson et al., 2005) and PrxI (Jonsson 
 et al., 2008a). In these studies it is a truncated from of the protein (ET
is able to form crystals with the all the residues up to residue 32 removed. This 
is probably due to this region having a high glycine content which is 
unstructured and flexible preventing crystallization
original Srx structure was fou
core of five stranded mixed 
It was found to contain a signature sequence that is able to bind a phosphate 
ion through hydrogen bonds (Phe96
The hSrx has a concave shape that could leave it ideally suited to interacting 
with the convex surface of the hPrxII decamer 
Figure 1.9. Cartoon representation of the crystal structure of hSrx (PDB: 1XW3), the 
five β-sheet strands (yellow) can be seen in the middle surrounded by the three 
helices (red) with the loop regions shown in green (figure created using PyMol DeLano 
Scientific). 
1.6.1.2. hSrx mechanism
The Srx mechanism which has been confirmed by biochemical and structural 
analyses suggests that a structural rearrangement brings the ATP molecule that 
is bound to the nucleotide binding motif of Srx close to the Cys
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et al., 2008c; Jonsson et al., 2008a).The γ-phosphate of ATP is attacked by the 
CysP sulfinic acid generating a phosphoryl ester intermediate. This intermediate 
is then attacked by the thiol on the redox active cysteine residue (Cys-99) to 
form a thiosulfinate bond between the Prx and Srx molecules (figure 1.10) 
(Roussel et al., 2008a; Jonsson et al., 2008d). The disulfide bond can then be 
reduced by another enzyme (glutathione (GSH) or thioredoxin) to allow the 
sulfenic acid form to be reincorporated into the normal hPrxII catalytic cycle 
(Woo et al., 2003).  
 
Figure 1.10. Mechanism of the reduction of the sulfinic acid CysP by hSrx. Step 1 
shows the formation of a sulfinic acid phosphoryl ester intermediate as the ATP 
molecule is attacked. The Cys99 of Srx then attacks this intermediate forming a Prx-
Srx thiosulfinate intermediate (mechanism recreated from Jonsson et al., (2008c). 
1.6.2. The peroxiredoxin – sulfiredoxin interaction 
A number of structural studies have been carried out to look at the interaction 
between the hyper-oxidized Prx and Srx molecules to study the structural 
rearrangements that would need to allow the Srx molecule to access and 
reduce the CysP (Jonsson et al., 2008a; Jonsson et al., 2009a). At the moment 
the structural studies have mainly been limited to PrxI which has a 77% 
sequence identity to PrxII as formation of stable complexes forming crystals 
between PrxII and hSrx have proved unsuccessful (Jonsson et al., 2008a). 
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 The first crystal structure of PrxI in complex with Srx was formed using DTNB to 
form a disulfide bond between the Cys
cysteine of hSrx (Cys99) (figure 1.11).
Figure 1.11. Cartoon and stick representation of the disulfide bond between the Cys
of PrxI (Cys52) and the redox active cy
chain a is shown in green, the PrxI chain b is shown in pale green, the Srx chain is 
shown in blue and the disulfide bond is shown in orange
of this bond we see a simple disulfide bond instead of the thiosulfinate bond we would 
expect to see in the native) 
The complex was found to contain one PrxI dimer and two Srx monomers 
where the Srx was found between the active site of one PrxI chain and 
terminal tail that had unfolded onto the non
(Jonsson et al., 2008a) (figure 1.12).
between the C-terminal arm (residues 172
the Srx molecule. It was suggested that this “embrace” was essential to allow 
the Srx molecule to be held in the correct orientation for catalysi
site interactions would not have been sufficient to hold it.
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(figure created using PyMol DeLano Scientific).
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s as the active 
 Figure 1.12. Cartoon representation of the complex formed between PrxI and Srx 
(PDB: 2RII) shows the C-terminal arm of
catalytic backside of the Srx molecule. The Srx monomers are shown in blue with the 
Prx dimer shown with chain a in green and chain b in light green, the disulfide bonds 
are shown as spheres (figure created using PyMol DeLano Scientific).
From the original hPrxII crystal structure it can be seen that the YF motif seen at 
the C-terminal end of the hPrxII chain must move when binding of the Srx 
molecules occurs, as the two species would try and occupy the same space. 
Unfortunately due to a poor 
PrxI-Srx complex but it must have moved to allow space for the hSrx to bind 
(Schroder et al., 2000; Jonsson 
of the Prx-Srx complex is the GGLG motif tha
binding (Wood et al., 2003b; Jonsson 
The second complex between peroxiredoxin and sulfiredoxin was formed to 
allow the study of the complex in the presence of ATP and Mg
was formed by mutating out all 
needed for the redox reaction (leaving the proteins inactive) and by forming a 
covalent disulfide bond using DTNB, between two
interact in the essential repair embrac
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electron density the YF motif is not observed in the 
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revealed that the C-terminal arm embrace that was seen before provides a 
hydrophobic surface with which Phe50 (PrxI) can bind. This residue binding 
helps to unfold Prx allowing the ATP molecule to attack the hyper-oxidized CysP 
(Jonsson et al., 2009a). As yet there are still no crystal structures of an hPrxII-
Srx complex.  
A second PrxI-ET-Srx structure revealed the position of the co-factors that allow 
the reduction of the sulfenic acid to take place. As mentioned above the 
reduction of the sulfenic acid by sulfiredoxin requires the presence of ATP and 
Mg2+. In the previous crystal structure the intermolecular disulfide formed meant 
that the ATP-Mg2+ was not seen. In this crystal structure the active site Cys 
residues have been mutated out and Cys residue introduced at the “backside” 
interface between hPrxI and ET-Srx. This structure reveals unfolding in the helix 
containing CysP allowing the packing of Phe50 (PrxI) into a hydrophobic pocket 
on Srx. This structural rearrangement positioned an oxygen atom of Asp52 
(PrxI) within 4.3 Å of the γ-phosphate of ATP bound to Srx, which supports the 
phosphorylation of the CysP as the first step in the reaction between the two 
enzymes (Jonsson et al., 2009b). 
 
Figure 1.13. Cartoon representation of the PrxI-ET-Srx (PDB: 3HY2) complex showing 
the position of ATP (yellow stick) and Mg2+ (red sphere). The two subunits of the hPrxI 
homodimer are shown in green and pale green, with the Srx chains shown in blue 
(figure created using PyMol DeLano Scientific). 
 Figure 1.14. Cartoon representation of the ATP
Srx (PDB: 3HY2) complex showing the distance between the Asp52 and the 
phosphate of ATP (yellow stick) and the position of the Phe50 re
subunits of the hPrxI homodimer are shown in green and pale green, the Mg
as a red sphere and the Srx chains shown in blue (figure created using PyMol DeLano 
Scientific). 
1.7. Thioredoxin
Thioredoxin (Trx) is a protein that is ~12 kDa 
residues in a conserved CXXC
in target proteins (Holmgren, 1989)
contain a thioredoxin fold and undergo a dithiol
to catalyze oxidoreductase
characterized role of the Trx enzyme was to reduce the disulfide bond in the 
ribonucleotide reductase enzyme. This reduction took place with Trx forming 
part of a system that moved 
reductase (TrxR) and Trx to reduce the disulfide
The thioredoxin protein has also been found to be used in a number of other 
processes such as transcription factor modulation 
Martin, 1995), protein folding 
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(Gasdaska et al., 1995), cell growth inhibition in pregnancy (Clarke et al., 1991), 
and in the reduction of sulfenic and sulfinic acids (Yoshitake et al., 1994). It is its 
ability to reduce the intermolecular disulfide bond that forms between the CysP 
and the CysR in hPrxII that will be focused on when discussing the structure and 
mechanism. 
1.7.1. Human thioredoxin 
Human thioredoxin (EC 1.8.1.9) is a 105 amino acid protein with a molecular 
weight ~12 kDa. As part of the catalytic cycle of hTrx the reduced form of the 
protein (Trx-(SH)2) will reduce Prx from its intermolecular disulfide state (Prx-S2) 
down to its reduced state (Prx-(SH)2). This leaves hTrx with a disulfide bond 
(Trx-S2) that is then reduced by TrxR which will be discussed later in the 
chapter (figure 1.15) (Holmgren, 1985). 
 
Figure 1.15. The catalytic cycle of hTrx showing the oxidation of the Trx protein as the 
Prx protein is being reduced, followed by the subsequent reduction of the Trx protein 
by TrxR. Mechanism recreated from Holmgren (1995). 
1.7.1.1. hTrx mechanism 
As part of the normal catalytic cycle, Prx will form an intermolecular disulfide 
that must be reduced by thioredoxin back to its reduced state so that it can 
restart its catalytic cycle (Wood et al., 2003b). For this to happen we must first 
have binding occurring between the reduced Trx and Prx molecules which is 
thought to occur via its hydrophobic surface (Holmgren, 1995). The first redox 
active cysteine residue Cys32 is stabilized to form a thiolate ion by the structural 
elements discussed below. This intermolecular disulfide bond between CysP 
and CysR on PrxII then undergoes nucleophilic attack by the Trx thiolate on 
Cys32 resulting in the formation of a mixed disulfide species where the two 
proteins are linked by a disulfide bond. The deprotonated Cys35 then attacks 
the disulfide bond reducing the PrxII protein and leaving Trx with a disulfide 
bond between the two redox active cysteines. 
Prx S2
Prx (SH)2
Trx (SH)2
Trx S2
TrxR
TrxR (Oxidized) 
 
 
TrxR (Reduced) 
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Figure 1.16. The mechanism for the reduction of a target protein by thioredoxin. The 
thiolate anion on Cys32 attacks the disulfide bond in hPrxII forming a disulfide bond 
between the two proteins. This disulfide bond is then attacked by the deprotonated 
Cys35 forming a disulfide bond between the two redox active cysteines on Trx and 
leaving the CysP and CysR residues reduced. Mechanism recreated from Holmgren 
(1995). 
1.7.1.2. hTrx structure 
hTrx has been crystallized and the structure solved for both the reduced and 
oxidized form (Weichsel et al., 1996), as well as NMR solution structures for the 
mutated human protein (Qin et al., 1994). The Trx structure contains a typical 
thioredoxin type fold with five-stranded β-sheets surrounded by four α-helices. 
The conserved active cysteine residues are found to be in the active site motif 
(CGPC) and are located on a loop region of the protein between the second β-
sheet. The second cysteine is located at the start of the second α-helix. 
 Figure 1.17. Cartoon representation of the reduced crystal structure of recombinant 
hTrx (PDB: 1ERT). The picture is coloured according to its secondary structur
five β-sheets (yellow) surrounding four 
in green. The picture also shows the two active site cysteines (Cys32 and Cys35) 
residing between the second 
PyMol DeLano Scientific). 
The crystal structures of oxidized, reduced and mutant forms of thioredoxin all 
show the protein to be in a homodimeric state with a disulfide bond being
formed between the two protomers
showed the same overall structure with differences in the active site (between 
the reduced and oxidized form) and a difference in the formation of the 
homodimer (between the mutant and reduced/oxidized form).
1.7.1.2.1. 
The reduced form showed
active site. In the reduced form the sulfur hydryl groups of the active site 
cysteine residues align which allows for hydrogen bond formation with the 
Cys35 as the proton donor and the Cys32 as the proton
cysteine residues are 3.9 
hydrogen bond to form (figure 1.18). T
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Figure 1.18. Cartoon representation
redox active cysteine residues in the reduced form of human Trx (PDB: 1ERT). The 
distance between the two cysteine atoms is ~3.9 
to secondary structure, showing 
green (figure created using PyMol DeLano Scientific).
Cys32 lies on the surface of the protein whereas Cys35 is almost completely 
buried. This burial would not 
(figure 1.19). It is thought that the pKa of this cysteine residue could be 
increased due to the deprotonation of the Cys32 to a thiolate anion placing a 
negative charge next to Cys35 
the reduced form also rev
the sulfur atom on Cys35 and the nitrogen atom of Ala29 
1996). With a distance of 3.7 
at an appropriate distance and are aligned for hydroge
et al., 1975). 
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Figure 1.19. The surface representations of both the redox active cysteine residues in 
the reduced form of human Trx (PDB: 1ERT). The left picture shows Cys32 on the 
surface of the protein. The right picture shows Cys35 buried under the surface of the 
protein (figure created using PyMol DeLano Scientific). 
1.7.1.2.2. Oxidized hTrx 
The oxidized form of the hTrx protein was also crystallized and the 
conformational changes that allow the formation of the disulfide were studied 
(Weichsel et al., 1996b) (PDB: 1ERU). In general the two structures were very 
similar with a small difference in the positions of the two redox active cysteines 
allowing the formation of the disulfide bond (figure 1.20). The Cys32 is brought 
closer to the Cys35 by movement of the region (Ala29-Cys35) producing a 
disulfide bond with a bond length of 2.0 Å.  
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Figure 1.20. Stick representation of the comparison of the position of the active site 
cysteine residues in both the oxidized and reduced forms of hTrx. The reduced form 
(PDB: 1ERT) is shown in green with the oxidized form (PDB: 1ERU) shown in blue 
(figure created using PyMol DeLano Scientific). 
The oxidized form of Trx also revealed a set of hydrogen bonds that had been 
gained from the reduced form and one that had been lost. Additional hydrogen 
bonds have formed in the oxidized structure between Cys32 and Lys36 and 
Gly33 and Met37 due to the residues coming closer together. The hydrogen 
bond between Cys35 and Ala29 has been lost as the residues have moved 
further apart. It is believed that this hydrogen bond network switch may be one 
of the factors that allow the reduction and oxidation of thioredoxin to be 
reversible (Weichsel et al., 1996). 
1.7.1.2.3. The hTrx dimer 
The four crystal structures for hTrx show the protein to be in a homodimeric 
state with a disulfide bond forming between the Cys73 residues on each 
subunit. The one exception to this is where the Cys73 has been mutated and 
replaced with a serine residue. This Ser73 mutant still forms a homodimer but 
instead forms a hydrogen bond between the two subunits in this position 
(Weichsel et al., 1996). The disulfide bond is maintained and even seen in the 
crystal grown in the presence of 5 mM DTT which was added to keep the active 
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Cys in the SH state. It is hypothesized that this is due to the cysteine’s being at 
the “perfect angle” for disulfide bond formation (Weichsel et al., 1996). As well 
as the bond that forms between the residues at position 73 there are also 
interactions involving a large hydrophobic patch and formation of five hydrogen 
bonds around the Cys73 residue (Weichsel et al., 1996). The hTrx dimeric and 
monomeric forms have both been identified in solution (Ren et al., 1993). The 
Trx is thought to be active as a monomer and the formation of a Trx dimer is 
thought to have regulatory role as the dimeric form has been found to be 
inactive (Holmgren, 1977). 
1.7.1.3. hTrx interaction with hPrxII 
To date there are no structures solved for the complexes between Trx and Prx. 
The interactions are thought to occur due to the hydrophobic nature of the 
reduced form of Trx being able to bind to the Prx protein surface (Holmgren, 
1995). A stable complex has been formed between Trx (HvTrxh2 from barley) 
and barley α-amylase/subtilisin inhibitor (BASI) showing the mixed disulfide 
species (Maeda et al., 2006). The study discovered the interactions that help to 
stabilize the complex were van der Waals contacts and three intermolecular 
hydrogen bonds that were made by three structural motifs. These motifs were 
WCGP (residues 45-48), AMP (residues 87-89) and VGA (residues 104-106) 
(Maeda et al., 2006). A search against the PDB showed similar motifs in the E. 
coli and human reduced forms of the protein as well as a number of other Trx 
and GST enzymes (Maeda et al., 2006). The reduced form of the hTrx protein 
shows a high similarity to the HvTrxh2 enzyme in these regions and therefore 
could bind to hPrxII in a similar way. 
1.8. Thioredoxin reductase 
Thioredoxin reductase (TrxR) (EC 1.8.1.9) is a homodimeric flavo-protein that 
uses NADPH to catalyze the reduction of the disulfide bond between Cys32 and 
Cys35 in Trx (Mustacich and Powis, 2000). The mammalian TrxR enzymes are 
selenocysteine containing enzymes. The selenocysteine is essential for activity 
and forms part of the active site (Arner et al., 1999). Bacteria, plants and 
archaea have a smaller non-selenocysteine protein (Williams et al., 2000). 
There are three different TrxR proteins in mammalian systems (TrxR1-3) that 
differ in sequence, length and sub-cellular location (Sun et al., 2001). The TrxR 
that this project will focus on is TrxR1. 
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1.8.1. Human thioredoxin reductase 1 
TrxR1 is located mainly in the cytosol and is the most common form of human 
thioredoxin reductase (hTrxR). The TrxR1 is a homo-dimeric protein 499 amino 
acids in length and is ~55 kDa in size (Oblong et al., 1993). 
1.8.1.1. Mechanism of hTrxR1 
The TrxR1 has three elements; a selenocysteine, a redox active disulfide, and a 
flavin adenine dinucleotide (FAD) molecule that reduces the disulfide bond in 
Trx. The selenocysteine element is located at the C-terminal end of the protein 
and is the penultimate residue coded for by a UGA codon (Gladyshev et al., 
1996). The selenocysteine (Sec, U) is located in a structural motif (496Gly-Cys-
Sec-Gly499) along with a cysteine residue, with the Cys-Sec thought to form the 
“proper” active site (Zhong and Holmgren, 2000). The second active site has 
two redox active cysteines in a structural motif (59Cys-Val-Asn-Val-Gly-Cys64). 
The two active sites are presented to each other from different chains of the 
homodimer that is arranged in a head to tail fashion (Fritz-Wolf et al., 2007). 
The mechanism reported in Arner et al., (2009) suggests that the first step of 
the reaction involves the reduction of the bound FAD by NADPH. As part of this 
reduction the selenenyl sulfide (Se-S) is converted to a highly reactive 
selenolate anion (Se-). This selenolate anion attacks the disulfide on the Trx 
molecule resulting in a mixed disulfide formed between the two. This mixed 
disulfide is then attacked by the cysteine residue in the active site motif 
(Cys497) to reproduce the selenenylsulfide. This selenenylsulfide is then 
converted to the selenolate anion using the second cysteine from the other 
active site motif (Cys64) starting the cycle once again (Zhong and Holmgren, 
2000) (figure 1.21). 
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Figure 1.21. The proposed mechanism of Trx reduction by TrxR1. The FAD is reduced 
by NADPH forming a selenolate anion that is used to attack the disulfide bond on Trx. 
The enzyme is then recycled by Cys497 reforming the seleneyl sulfide before it is 
reduced by a thiol on the second active site. Mechanism recreated from Zhong and 
Holmgren (2000).  
1.8.1.2. Structure of hTrxR1 
The TrxR1 protein is homodimeric with each chain possessing a FAD and 
NADPH binding site as well as two redox active sites. The NADPH binding site 
is located close to the FAD binding site to allow electron transfer between the 
two molecules. The NADPH molecule binds to the protein through interactions 
between the phosphate groups and three conserved arginine residues (Arg166, 
221 and 226). The FAD binding site lines up the isoalloxazine ring on FAD with 
the nicotinamide ring in parallel positions to allow for the electron transfer as 
seen in a number of other enzymes. 
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 Figure 1.22. Cartoon representation of the structure of TrxR1 (PDB: 2J3N). The 
different subunits are shown in green and light green. The cy
in sphere mode and the FAD (orange) and NA
(figure created using PyMol DeLano Scientific).
The redox centre containing the selenocysteine is located on the C
of the protein which was 
different states. These different states show a side chain specific switch 
between the reduced and oxidized form of the second redox active centre 
(497CC498). The switch brings about a change in the 
active centre with the cysteine groups in the oxidized state
would not allow for electron transfer with the Trx. The cysteine groups in the 
reduced form will face outward allowing them to interact with the Trx molecule. 
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Figure 1.22. Cartoon representation of the structure of the active site residues in both 
the oxidized (left) and reduced (right) form of TrxR1. The subunits of TrxR1 are shown 
in green and light green. The Cys residues and the cofactors FAD (orange) and 
NADPH (blue) are shown in stick mode (figure created using PyMol DeLano Scientific). 
1.9. Reconstitution of the Peroxiredoxin system 
To form an activity assay for Prx all the enzymes in the normal catalytic cycle 
must be brought together. The enzymatic activity of hPrxII can be measured by 
coupling hTrx and TrxR1 in the presence of NADPH. In a typical Prx assay the 
enzymes in the system are mixed together in µM concentrations and the 
reaction is initiated by the addition of H2O2. The activity is calculated by 
measuring the decrease in A340nm over a set time frame (usually 3-5 min) and by 
using the initial rate of reaction expressed in the amount of NADPH oxidized per 
minute (Kim et al., 2005; Cao et al., 2007).  
1.10. Aims of the project 
The aims of this project are: 
• The over-expression and purification of stable hPrxII. This will be used 
along with Trx and TrxR to form a working Prx assay, and also for 
complex formation and structural studies. 
• The over-expression and purification of hPrxII in the disulfide form and 
subsequent crystallization and structural analysis. 
• The formation of a complex between PrxII and Srx. The complex will then 
be studied using size exclusion chromatography and surface plasmon 
resonance, and crystallization attempted to obtain a 3D structure. 
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• The formation of a complex between PrxII and Trx. The complex will then 
be studied using size exclusion chromatography and surface plasmon 
resonance, and crystallization attempted to obtain a 3D structure. 
• Cloning, over-expression and purification of an active TrxR. This will be 
used with PrxII and Trx to form a working Prx assay. 
  
60 
 
2. Cloning, expression and purification of Human 
Peroxiredoxin II from red blood cells and the effect of 
a fourth residue mutation 
2.1. Introduction 
In order to study hPrxII it was essential to have a recombinant protein which 
could be expressed and purified to high homogeneity. This would negate the 
need to work with human blood in order to obtain the levels of proteins required 
for this study.  A clone of the hPrxII gene in the pET28a expression vector was 
obtained from Dr Kirsty Line (University of Exeter). Original attempts to purify 
the enzyme proved problematic, the recombinant enzyme aggregated very 
easily during purification, dialysis and concentration. The recombinant protein 
was also predominantly produced in a different oligomeric state to that of the 
native enzyme. Native hPrxII is seen mainly in the decameric form with a small 
amount in the dimeric form, but the opposite was observed for the hPrxII clone. 
When the sequence information was re-assessed it was noticed that there was 
a point mutation in the DNA sequence, which resulted in a change of the fourth 
amino acid of the protein from glycine to valine. Glycine is the smallest amino 
acid and is very flexible whereas valine is much larger and hydrophobic.   
 
Figure 2.1. Comparison of the Protein sequences for hPrxII (4Gcorrect) and hPrxII 
(4Vincorrect). 
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Figure 2.2. Comparison of the first 200 bp of the DNA sequences for hPrxII (4Gcorrect) 
and hPrxII (4Vincorrect).  
In view of the problem with aggregation of the recombinant Prx the decision was 
taken to re-clone the hPrxII gene. This chapter discusses the re-cloning, 
expression and purification of the hPrxII gene and the resulting effects on the 
solubility and oligomeric state of the protein. 
2.2. Materials and Methods 
2.2.1. Cloning of hPrxII 
PCR was used to generate a DNA fragment which encoded the hPrxII gene and 
the restriction sites Nde I and Not I. These were incorporated onto the 5’ end of 
the forward and the reverse primer sequences, respectively. 
hPrxIIF 5’ – AACATATGGCCTCCGGTAACGCGCGCATCG – 3’  
hPrxIIR 5’ – AAGCGGCCGCTAATTGTGTTTGGA – 3’  
The PCR was performed in a total volume of 50 µl containing 200 ng of 
template DNA, 100 ng of each primer, 200 µM of each dNTP, 2 U Deep Vent 
Polymerase (New England Biolabs, Beverley, MA), 1 x Deep Vent Buffer and 
nuclease free water to adjust to the final volume. The PCR cycle consisted of 3 
min at 94oC followed by 40 consecutive cycles of denaturation (1 min at 94oC), 
annealing (1 min at 65oC) and polymerisation (1 min at 72oC). There was also a 
final extension time of 5 min at 72oC. The DNA was treated with Red Taq 
Polymerase (Sigma Aldrich) to produce an A overhang (20 min, 72oC) and then 
separated on a 1% agarose gel. The DNA on the gel was visualized using 
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ethidium bromide staining and DNA bands visualised by UV. The PCR product 
of the expected size (747 bp) was purified using a gel extraction kit (Qiagen) 
according to the manufacturer’s instructions. The A overhang was used to ligate 
the gene into the TOPO TA Cloning vector pCR2.1-TOPO (Invitrogen). The 
hPrxII gene insert was excised from the cloning vector using the restriction 
enzymes NdeI and NotI and ligated into pET28a (Novagen) that had been 
predigested with the previously mentioned restriction enzymes. A 20 µl aliquot 
of the ligation mixture was transformed (as in methods 2.2.2) into the E. coli 
Nova Blue cell line (Novagen). The E. coli cells were plated onto Luria Bertani 
(LB) agar plates containing 50 µg/ml kanamycin. The transformants were 
verified to contain the hPrxII by plasmid DNA isolation, digestion and agarose 
gel electrophoresis. The recombinant plasmid containing the hPrxII gene was 
sequenced by Eurofins MWG Operon (Ebsberg, Germany). 
 
 
 
 Figure 2.3. The strategy for the cloning of 
followed by subsequent cloning into pET
(figure modified from TOPO Kit manual Invitrogen).
2.2.2. Transformation of hPrxII into an expression cell line
hPrxII DNA was used to transform chemically competent 
2 (Novagen) cells by addition of 1 
were thawed on ice. The reaction was incubated on ice for 30 min followed by 
heat shock at 42oC for 45 sec. The reaction was cooled on ice for 2 min before 
the addition of 200 µl of sterile LB medium, followed by incubation in a shaking 
incubator at 37oC for 1 h before being plated out on a LB agar plate containing 
kanamycin (50 µg/ml), 
µg/ml). Colonies were picked, glycerol stocked and the presence of the gene 
confirmed by DNA sequencing (Geneservice, Oxford).
 
 
63 
hPrxII into the pCR2.1
28a to allow for the expression of the protein 
  
E. coli  
µl DNA to ~50 µl of Rosetta Gami 2 cells that 
tetracycline (37.5 µg/ml) and chloroamphenicol (12.5 
 
 
-TOPO vector, 
 
Rosetta Gami 
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2.2.3. Expression of recombinant hPrxII 
The hPrxII gene was cloned incorporating an N-terminal His-tag and expressed 
under the control of the T7 promoter. The recombinant hPrxII gene was 
transformed into the E. coli Rosetta Gami 2 expression cell line and cells (from 
glycerol stock) containing the pET28a/hPrxII construct were used to inoculate 
100 ml LB containing kanamycin (50 µg/ml) tetracycline (37.5 µg/ml) and 
chloroamphenicol (12.5 µg/ml). This starter culture was grown under agitation at 
200 rpm overnight at 37oC and 20 ml were used to inoculate 1 L fresh LB 
medium containing the appropriate antibiotics for selection, and was grown with 
agitation at 37oC until the optical density OD600nm was approximately 0.8, when 
isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration 
of 1.0 mM and the culture incubated for a further four hours at 37oC. The E. coli 
cells were harvested by centrifugation (20,000 x g, 20 min, 4oC) using a 
Beckman JA-25.50 rotor. The cell pellet was stored at -20oC until further use. 
2.2.4. Purification of Recombinant hPrxII 
2.2.4.1. Cell lysis 
Cell paste was re-suspended at 10% w/v in 100 mM Tris-HCl, pH 7.5, 0.5 M 
NaCl, 20 mM imidazole. Cells were disrupted by sonication at 10 microns 
(Soniprep 150, Sanyo) on a program; 30 sec on, 1 min off (x 6 cycles) and the 
cell debris removed by centrifugation at 20,000 x g, 20 min and 4oC using a 
Beckman JA-25.50 rotor. 
2.2.4.2. Purification buffers 
Buffer A – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 20 mM imidazole 
Buffer B – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 M imidazole 
Buffer C – 100mM Tris-HCl, pH 7.5, 0.1 M NaCl 
2.2.4.3. Nickel affinity chromatography 
A HiLoad (GE Healthcare) column containing 50 ml metal chelating cellulose 
charged with Ni2+ (Bioline) was equilibrated with three column volumes of buffer 
A at a flow rate of 3 ml/min. The sample was then applied to the column via an 
injection “super loop” (GE Healthcare). Any unbound sample was removed by 
applying three column volumes of buffer A. Then a six column volume gradient 
to 100% buffer B was applied to the column, followed by a further two column 
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volumes of 100% buffer B. Fractions were collected throughout the entire 
protocol and the absorbance measured at 280 nm. Fractions were analyzed 
using SDS-PAGE. All columns were run on an ÄKTA Purifier (GE Healthcare). 
2.2.4.4. Gel filtration chromatography  
A Superdex 200 HiLoad 16/60 (GE Healthcare) gel filtration column (column 
volume 120 ml) was equilibrated with one column volume of buffer C at a flow 
rate of 1 ml/min. The sample was loaded and fractions were collected over the 
elution volume of one column volume and the absorbance measured at 280 nm. 
Fractions corresponding to protein peaks were analyzed using SDS-PAGE. 
The Superdex 200 gel filtration column was calibrated with the protein 
standards ferritin (440 kDa), β-amylase (200 kDa), alcohol dehydrogenase (158 
kDa), albumin (67 kDa), carbonic anhydrase (29 kDa) and cytochrome c (12.4 
kDa). These standard proteins were applied to the column pre-equilibrated with 
10 mM Tris-HCl, pH 8.0 and eluted with the same buffer. The void volume was 
determined using the protein standard Blue Dextran (2000 kDa). The elution 
profile (Appendix 7.1) was used to determine an approximate native molecular 
mass for the proteins using the calculations below. 
 
Kav	= 
Ve-Vo
Vt-Vo
 
Equation 2.1. Calculation of Kav. Ve = elution volume of the protein, Vo = void volume of 
the column (44 ml), Vt = total volume of the column (122 ml). 
A rearrangement of the equation of the line from the calibration is used to 
calculate the log molecule weight from the Kav value. 
log MW	= 
1.0185-Kav
0.3457
 
Equation 2.2. Calculation of the log of the molecular weight.  
2.2.4.5. Protein concentration 
The protein was concentrated using an Amicon Ultrafiltration centrifugal 
concentrator (10 kDa cut-off PES membrane, Millipore, Cork, Ireland) at 4,000 x 
g and 4oC. 
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2.2.4.6. SDS-PAGE 
Protein was analyzed by SDS-PAGE following a modification of the method of 
(Laemmli, 1970). A gel containing a 6% stacking gel and a 12.5% separating 
gel was made and run using a Mini Protean II system (BioRad Labaratories Ltd)  
2.2.4.6.1. Stock solutions 
10 x SDS PAGE running buffer:- 36 g Tris-HCl, pH 8.8 
 12 g SDS 
 172.8 g Glycine 
 Made up to 2 L with ddH2O 
Solution A:- Acrylamide (30 %) Bisacrylamide (0.8 %) 
Solution 
Solution B (Separating gel buffer):- 1.5 M Tris-HCl, pH 8.8 
Solution C (Stacking gel buffer):- 0.5 M Tris-HCl, pH 6.8 
Solution D:- SDS 10 % w/v 
SDS PAGE loading buffer:- 100 mM Tris-HCl, pH 8.0 
 2 % β-mercaptoethanol 
 4 % SDS w/v 
 0.2 % Bromophenol blue w/v 
 20 % Glycerol v/v 
SDS PAGE non-denaturing loading 
buffer:- 
100 mM Tris-HCl, pH 8.0 
 0.2 % Bromophenol blue w/v 
 20 % Glycerol v/v  
SDS-PAGE Microwave Stain:- 1 g Coomassie Brilliant Blue (G250) 
 1 L Methanol 
 800 ml ddH2O 
 200 ml Glacial acetic acid 
2.2.4.6.2. Preparation of gels 
Separating Gels (12.5 %):- 4.2 ml A 
 2.5 ml B 
 1 ml D 
 2.3 ml ddH2O 
Stacking Gel (6%):- 2.0 ml A 
 2.5 ml B 
 1 ml D 
 4.5 ml ddH2O 
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100 µl ammonium persulfate (APS) (10% w/v) and 10 µl N,N,N’,N’,-
tetramethylethylenediamine (TEMED) was added to each gel mixture to initiate 
polymerisation before pouring between the glass plates. 
The gel apparatus was assembled according to the manufacturer’s instructions. 
Glass plates were placed in the gel casting apparatus separated by 1 mm 
spacers. The separating gel was poured between the glass plates to a depth of 
~2/3rds and covered with water-saturated isobutanol. Once the gel had 
polymerized the isobutanol was removed, the gel washed with ddH2O and 
blotted dry with filter paper. The stacking gel was then poured on the top of the 
polymerized separating gel to the top of the glass plates and a comb placed into 
the top forming the sample wells and the gel was left to polymerize. 
2.2.4.6.3. Sample preparation 
2 x SDS-PAGE loading buffer was mixed with the protein samples. The SDS 
buffer denatures the proteins and also adds a negative charge to the protein 
molecules that is proportional to mass. The loading buffer also contained β-
mercaptoethanol to reduce any disulfide bridges within the proteins. The 
mixture was heated at 100oC for 5 min to ensure the protein was fully denatured 
before being loaded onto the gel stacking layer. Once fully denatured the 
protein was capable of travelling through the gel at a distance proportional to its 
individual subunit molecular weight allowing for determination of molecular 
weight. 
2.2.4.6.4. Sample preparation using non-reducing buffer 
2 x non-reducing SDS-PAGE loading buffer was mixed with the protein sample. 
In this case, the buffer contained no reducing agents and was not heated 
therefore leaving any disulfide bonds intact. The mixture was left for 5 min at 
room temperature. The protein was then loaded onto the gel stacking layer.  
2.2.4.6.5. SDS-PAGE running 
The prepared samples were loaded into the gel wells using a 20 µl Hamilton 
syringe (Hamilton) additionally 5 µl of a molecular weight marker (Precision Plus 
Protein Standard 15 – 250 kDa, BioRad Laboratories, Appendix 7.2) was 
loaded as a molecular weight marker. The gel was run at 200 V for 50 min. 
68 
 
2.2.4.6.6. Gel staining procedure 
The SDS-PAGE gel was removed from the gel tank apparatus and placed in the 
microwave stain solution and heated in the microwave on full power for 3 min. 
The gel was transferred to 1 L of ddH2O and heated on full power for 20 min to 
destain. 
2.2.4.7. Protein concentration determination using A280 
The protein concentration was calculated by measuring the absorbance at 280 
nm. A 200 µl aliquot of the protein solution was placed in a quartz cuvette with a 
1 cm path length. The A280 measurement was taken in a Biotech UV1101 
Photometer (Schimadzu), blanked against a cuvette containing all buffers and 
reagents apart from the protein. The protein’s extinction coefficient was 
calculated using the protein sequence and the Protparam online bioinformatics 
tool (Wilkins et al., 1999) (www.expasy.ch/tools/protparam.html). The protein 
concentration was then calculated using Beer-Lambert Law (equation 2.3).  
A = Ɛ l c 
Equation 2.3. Beer-Lambert Law: A is the Absorbance at 280 nm, ε is the 
extinction coefficient of the protein, l is the path length and c is the 
concentration.  
2.2.5. Purification of native hPrxII 
The method used to isolate and purify the native protein was reproduced from 
Schroder et al., 1998. The purification of native hPrxII was achieved from out of 
date blood packs obtained through the Peninsula Medical School (Exeter).  
2.2.5.1. Haemolysis and purification buffers 
Haemolysis buffer:- 0.625 mM Tris-HCl pH 7.5 
 5 mM EDTA 
 20 µM Benzamidine (BAM) 
 10 µM Phenylmethanesulfonylfluoride (PMSF) 
Native hPrxII Purification Buffer 
A:- 
20 mM Tris-HCl pH 7.5 
 5 mM EDTA 
 20 µM BAM 
 10 µM PMSF 
Native hPrxII Purification Buffer 20 mM Tris-HCl pH 7.5 
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B:- 
 5 mM EDTA 
 20 µM BAM 
 10 µM PMSF 
 2 M NaCl 
Native hPrxII Purification Buffer 
C:- 
25 mM Tris-HCl pH 7.5 
 1 mM EDTA 
 20 µM BAM 
 10 µM PMSF 
 0.1 M NaCl 
2.2.5.2. Preparation and haemolysis of erythrocytes 
A 200 ml volume of blood was measured and centrifuged at 1,000 x g, 40 min 
and 4oC in a Beckman JA-25.50 rotor to separate the plasma from the red blood 
cells. The red blood cell layer (bottom) was centrifuged again at 1,000 x g, 40 
min and 4oC in a Beckman JA-25.50 rotor to completely remove all the sera 
before haemolysis. The pellet was then suspended in 200 ml of haemolysis 
buffer and left over night at 4oC. The haemolysate was centrifuged to remove 
cell debris at 13,700 x g, 90 min, and 4oC in a Beckman JA-25.50 rotor.  
2.2.5.3. Ion exchange chromatography of native hPrxII 
A HiLoad column containing 250 ml of Fast Flow Q Sepharose media (FFQ) 
(GE Healthcare) was equilibrated with three column volumes of buffer A at a 
flow rate of 3 ml/min. The sample was loaded onto the column under gravity 
and unbound sample was eluted with buffer A until the flow through ran clear. 
The column was then connected to an ÄKTA purifier (GE Healthcare) and an 
elution was carried out over a six column volume linear gradient of 0–50% 
buffer B. Fractions were collected throughout the entire protocol and the 
absorbance measured at 280 nm. Fractions were analyzed using SDS-PAGE. 
2.2.5.4. Size exclusion chromatography of native hPrxII 
A Superdex 200 HiLoad 16/60 (GE Healthcare) gel filtration column (column 
volume 120 ml) was equilibrated with one column volume of buffer C at a flow 
rate of 1 ml/min. The sample was loaded and fractions were collected over the 
elution volume of one column volume and the absorbance measured at 280 nm. 
Fractions were analyzed using SDS-PAGE. 
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2.3. Results 
2.3.1. Cloning of hPrxII gene 
Plasmid DNA encoding hPrxII (V4Incorrect) was used as template DNA for PCR 
and the cloning of hPrxII was carried out as described in methods 2.2.1. The 
amplification of hPrxII resulted in a DNA band of the expected size (figure 2.4), 
which was successfully cloned into the expression vector pET28a. DNA 
sequencing results showed that the correct wild type hPrxII sequence had been 
obtained. 
 
Figure 2.4. 1% agarose gel showing the PCR amplification of the hPrxII gene. Lane 1, 
Marker (Hyperladder 1, BIOLINE (Appendix 7.3)); Lane 2, hPrxII PCR band at ~600 bp. 
2.3.2. Expression of recombinant hPrxII 
The pET28a/hPrxII construct was transformed into the E. coli strain Rosetta 
Gami 2. Rosetta Gami 2 was chosen as it aids disulfide bond formation through 
mutations in the thioredoxin B (trxB) and glutathione oxidoreductase (gor) 
genes. As the hPrxII protein contains an intra-molecular disulfide bond in its 
reaction mechanism, it was thought that the promotion of this oxidation state 
might aid protein stability. hPrxII protein expression was under the control of the 
T7 promoter and was induced by IPTG. The over-expression of hPrxII was 
investigated by induction studies to obtain the best conditions for over-
expression. The optimal over-expression was achieved by addition of a final 
concentration of 1 mM IPTG when the cells had reached an OD600nm of 0.8 with 
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further incubation for 4 hours at 37oC. The over-expression of hPrxII resulted in 
soluble protein being produced at the expected size (~24 kDa).  
2.3.3. Purification of recombinant hPrxII 
One litre of culture produced 2.1 g of cell paste and after cell lysis and 
centrifugation (as described previously see section 2.2.4.1) the supernatant was 
purified using nickel affinity chromatography and gel filtration chromatography 
as described in methods 2.2.4.3 and 2.2.4.4.  
2.3.3.1. Nickel Affinity Chromatography 
The clarified cell extract was applied to a nickel column as described in 
methods 2.2.4.3 (figure 2.5). The fractions were analyzed using SDS-PAGE as 
described in methods 2.2.4.6 (figure 2.6 and 2.7). The fractions containing 
hPrxII were pooled and concentrated (methods 2.2.4.5) for gel filtration 
chromatography. 
 
Figure 2.5. Elution profile of hPrxII (4Gcorrect) (red line) and (4Vincorrect) (green line) 
from nickel affinity chromatography. 10 ml fractions were collected throughout the 
entire elution. The blue line shows the % imidazole concentration. The fractions that 
showed a band of the correct size on SDS-PAGE (figure 2.6) are indicated by a red 
bar. 
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Figure 2.6. SDS-PAGE analysis of the hPrxII (4Vincorrect) nickel affinity column 
elution. Lane 1, molecular weight marker; Lane 2, sample loaded  on to the column; 
Lane 3, sample from 20 ml; Lane 4, sample from 160 ml; Lane 5, sample from 170 ml; 
Lane 6, sample from 180 ml; Lane 7, sample from 210 ml; Lane 8, sample from 220 ml. 
 
Figure 2.7. SDS-PAGE analysis of the hPrxII (4Gcorrect). Lane 1, molecular weight 
marker; Lane 2, sample from 160 ml; Lane 3, sample from 170 ml. 
 
 
PrxII (~ 24 kDa) 
PrxII (~ 24 kDa) 
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2.3.3.2. Gel filtration chromatography 
Gel filtration chromatography was used as a final step of the purification and as 
a tool for the estimation of the molecular weight of the protein. The concentrated 
protein sample was loaded onto an equilibrated HiLoad 16/60 Superdex 200 
and run as described in methods 2.2.4.4. The elution profiles for both hPrxII 
(4Vincorrect and 4Gcorrect) are shown in figure 2.8. The peak fractions were 
analyzed by SDS-PAGE and those that contained hPrxII were pooled and 
concentrated. 
 
 
Figure 2.8. The elution profile from the Superdex 200 gel filtration column for hPrxII 
(4Gcorrect) (red line), hPrxII (4Vincorrect) (green line) and native hPrxII (blue line). 
Fractions were collected at 1 ml intervals throughout the elution volume. Peak A1 and 
B1 (~38 ml) correspond to the void volume; Peak C1, A2 and B2 (~58 ml) correspond to 
the decameric form of hPrxII; Peak A3, B3 and C2 (~76 ml) correspond to the dimeric 
form of hPrxII. The oligomeric state was determined using a calibrated Superdex 200 
column (Appendix 7.1). 
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Figure 2.9. SDS-PAGE analysis of peaks from gel filtration chromatography of hPrxII 
(4Gcorrent), hPrxII (4Vincorrect) and native hPrxII. Lane 1, molecular weight marker; 
Lane 2, sample from peak A2; Lane 3, sample from peak B2; Lane 4, sample from peak 
C1; Lane 5, sample from peak C2; Lane 6, sample from peak A3; Lane 7, sample from 
peak B3. 
2.3.3.3. Overview of purification of hPrxII (4Gcorrect) and 
hPrxII (4Vincorrect) 
The purification of both hPrxII proteins was successfully achieved using nickel 
affinity and gel filtration column chromatography (Superdex 200), however, 
these proteins showed different properties during purification as well as 
exhibiting different oligomeric states.  
The molecular weight of the hPrxII monomer is known to be ~24 kDa. It was 
seen that hPrxII (4Vincorrect) is produced mainly in the dimeric form with a 
small percentage of it being produced in the decameric form, whereas hPrxII 
(4Gcorrect) is produced mainly in the decameric form with a small percentage 
of it being produced in the dimeric form. The elution profile for hPrxII 
(4Gcorrect) is similar to that seen during the purification of the native protein 
obtained from blood (as seen in figure 2.12). 
Both proteins were very different during the purification in terms of stability. 
hPrxII (4Vincorrect) was very unstable during the purification. The protein would 
aggregate very quickly between purification steps; this aggregation meant that it 
was not possible to be concentrate the protein. Ammonium sulfate precipitation 
PrxII (~ 24 kDa) 
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and storage at -20oC would also result in aggregation. hPrxII (4Gcorrect) was 
much more stable during purification. The protein could be stored at 4oC for 4 
days and -20oC for up to a month without aggregation or degradation 
(confirmed by gel filtration chromatography and SDS-PAGE (data not shown)). 
The protein was amenable to concentrations in excess of 20 mg/ml. 
2.3.4. Purification of native hPrxII 
2.3.4.1. Ion exchange chromatography of native hPrxII 
The haemolysate was applied to a FFQ column as described in methods 2.2.5.3 
producing the trace seen in figure 2.10. The fractions were analyzed using 
SDS-PAGE as described in methods 2.2.4.6 (figure 2.11). 
 
Figure 2.10. Elution profile of native hPrxII (blue line) from ion exchange 
chromatography. 10 ml fractions were collected throughout the entire elution. The red 
line shows the NaCl concentration. The fractions that showed a band of the correct size 
on SDS-PAGE are indicated by the red bar. The second peak showed protein but not 
hPrxII (SDS-PAGE result not shown). 
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Figure 2.11. SDS-PAGE analysis of peaks from the ion exchange chromatography of 
native hPrxII. Lane 1, molecular weight marker; Lane 2, sample from column elution 
(300 ml); Lane 3, sample from column elution (340 ml); Lane 4, sample from column 
elution (360 ml); Lane 5, sample from column elution (380 ml); Lane 6, sample from 
column elution (400 ml);. 
2.3.4.2. Gel filtration chromatography of native hPrxII 
Gel filtration chromatography was used as a final step of the purification and as 
a tool for estimation of the oligomeric state of the protein. A concentrated 
protein sample was loaded onto an equilibrated HiLoad 16/60 Superdex 200 
(GE Healthcare) and run as described in methods 2.2.4.4. 
PrxII (~ 24 kDa) 
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Figure 2.12. The elution profile for native hPrxII from gel filtration chromatography. 
Peak 1 (36 ml) corresponds to the void volume of the column; Peak 2 (62 ml) 
corresponds to the decameric form of the protein (~250 kDa); Peak 3 (78 ml) 
corresponds to the dimeric form of the protein (~48 kDa). 
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Figure 2.13. SDS-PAGE analysis of the peaks from gel filtration chromatography. Lane 
1, molecular weight marker; Lane 2, sample from peak 2 (62 ml); Lane 3, sample from 
peak 3 (78 ml). 
2.3.4.3. Overview of purification of native hPrxII 
The purification of native hPrxII was successfully achieved using FFQ 
Sepharose and gel filtration chromatography. The trace from FFQ 
chromatography produced two peaks with the first containing the native hPrxII 
protein. The calibrated gel filtration column showed the protein to be mainly 
produced in the decameric form. Using this method ~20 mg of protein was 
purified from 500 ml of blood. 
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2.4. Discussion 
During the early studies on recombinant hPrxII a number of difficulties were 
encountered during purification and concentration. It was discovered that there 
was a point mutation in the DNA sequence and consequentially the fourth 
amino acid in the protein sequence was a valine residue rather than a glycine 
residue as found in the native enzyme. Glycine is the simplest and smallest 
amino acid with only a hydrogen atom as the side chain, whereas valine is a 
branched-chain amino acid with hydrophobic properties. Looking at the two 
residues it was observed that this mutation might affect the some local 
properties of the protein chain but the broader changes to solubility and 
oligomeric state were not predicted. A valine insertion is known to affect the 
properties of some proteins due to its hydrophobic nature, for example the 
substitution of a glutamic acid for a valine in haemoglobin is the cause of sickle 
cell disease (Blouin et al., 2000). 
 
Figure 2.14. Comparison of the structure and the van der Waals surface of glycine and 
valine. 
 
The mutation was first investigated using the MUpro software (Cheng et al., 
2006) which can help predict protein stability changes based on single amino 
acid mutations using the sequence information. Although the MUpro software 
predicted an increase in stability due to this amino acid change, the software 
only looks at a single monomer of the protein and not at the active oligomer.  
To look at the effects that this mutation might have on the oligomerisation of the 
protein the 3D structure of the protein (PDB: 1QMV) was analyzed using the 
Glycine Valine 
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program PyMol (Delano Scientific). The amino acid was changed from a glycine 
to a valine using the PyMol mutagenesis wizard (Figure 2.15 and Figure 2.16). 
 
Figure 2.15. Cartoon representation of the location of the fourth residue glycine in 
relation to helix α4 (of the same subunit) in the native hPrxII and hPrxII (4Gcorrect) 
enzyme. The fourth residue glycine is shown in stick mode (left hand side) and sphere 
mode (right hand side) along with 4 residues on helix α4 and the loop associated with 
it. The glycine residue is ~3.5 – 5 Å away and due to its lack of a side chain will not 
interact with helix α4. (PDB: 1QMV) (Figure created using PyMol DeLano Scientific). 
 
Figure 2.16. Cartoon representation of the location of the fourth residue valine in 
relation to helix α4 (of the same subunit) in the native hPrxII and hPrxII (4Vincorrect) 
enzyme. The fourth residue glycine is shown in stick mode (left hand side) and sphere 
 mode (right hand side) mode along with 4 residues on helix 
with it. The valine residue can be seen interfering w
subunit), (PDB: 1QMV) (Figure created using PyMol 
 
The fourth residue valine is shown interacting with helix 
associated with it. The larger valine molecule is now much closer to the loop 
and helices and could cause a conformational change pushing the helices 
further away. 
The dimer-dimer interface in the peroxiredoxin decamer has mainly hydrophobic 
interactions with some water
that interact to hold the dimers in place are Phe47, Phe81, Thr82, Val107, 
Arg109 and Asp121 (Figure 2.17) 
  
Figure 2.17. Cartoon representation of the interface between two dimers in the native 
hPrxII decameric structure. The residues in stick mode 
involved in the interactions between dimers
DeLano Scientific). 
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 Looking at the quaternary structure of the protein, it is seen that the mutated 
fourth residue is located on a loop regio
hypothesized that when the mutation from the small glycine to the bulkier 
hydrophobic valine is present there is no longer enough space for the relatively 
larger valine residue to fit in the natural position. Th
position of helix α4 and the attached 
hydrophobic interactions between the dimer:dimer interface residues (Figure 
2.18). This theory could be used to explain why the mutant protein pr
mainly in the dimeric form instead of the decameric form, as this conformational 
change, caused by the mutation, could easily disrupt the dimer:dimer interface 
while leaving the monomer
Figure 2.18. Cartoon representa
the mutation in the protein sequence to Val4 (sphere mode). The molecule is coloured 
according to chain and shows the Arg109 (stick) residues involved in the dimer:dimer 
interface. The arrow represents t
(PDB: 1QMV). (Figure created in PyMol 
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It is hypothesized that the fourth residue valine could cause a movement of α4 
in the direction of the dimer:dimer inteface (direction shown by an arrow in 
figure 2.18). If this conformational change was to occur it could cause a 
disruption in the dimer:dimer interface at Arg109. This disruption in the 
dimer:dimer interface could cause the breakup of the decameric structure to 
dimers. 
The conversion of this valine residue back to a glycine caused a change in the 
protein’s behavior during purification. The protein was over-expressed and 
purified mainly in the decameric form and the protein was able to be 
concentrated to the concentrations required for crystallization. 
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3. Crystallization and structure determination of the 
disulfide state of hPrxII 
3.1. Introduction 
The crystal structure of a decameric form of hPrxII from erythrocytes was 
previously determined to 1.7 Å resolution at the University of Exeter (Schroder 
et al., 2000). The structure revealed that hPrxII is a toroid formed from five 
dimer units. As part of the mechanism of this enzyme, the peroxidatic cysteine 
(Cys51) forms an intermolecular disulfide bond with the resolving cysteine 
(Cys172) from another monomer (Wood et al., 2003b). In the crystal structure of 
hPrxII the peroxidatic cysteine is found in the hyper-oxidized sulfinic acid form. 
In this sulfinic acid form the peroxidatic and resolving cysteine are found to be 
~10 Å apart. In order for the intermolecular disulfide to be formed there would 
have to be some structural movement to allow them to be close enough for the 
bond to form. 
3.1.1. hPrxII disulfide state  
The disulfide decamer has been seen in the native protein from both out of date 
blood packs and fresh blood (Line et al., 2009, manuscript in preparation). The 
oligomeric state of the hPrxII enzymes has been proposed to alternate between 
the decameric and dimeric forms depending on the oxidation state of the 
peroxidatic cysteine (Wood et al., 2002b). It was hypothesized when looking at 
the crystal form of the native hPrxII from human erythrocytes that the formation 
of the disulfide state could result in a breakdown of the dimer-dimer interface 
(Schroder et al., 2000). This would mean that when the disulfide state was 
formed the hPrxII decamer would break down producing five homodimers. 
3.1.2. Producing the protein in the disulfide state 
One strategy for the production of proteins in the disulfide state was to place the 
plasmid in the Rosetta-gami 2 pLysS (DE3) (Novagen) cell line. This cell line is 
designed to aid disulfide bond formation through mutations in the thioredoxin 
reductase (trxB) and glutathione reductase (gor) genes. These mutations 
prevent the production of thioredoxin B and the glutathione reductase enzymes 
which are responsible for the reduction of disulfide bonds. A way to induce 
recombinant enzymes to produce an intermolecular disulfide bond is the 
addition of the reagent diamide (figure 3.1) to convert the thiol thiolate sulfhydryl 
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group (XSH) to a disulfide (XSSX) (Kosower et al., 1969; Kosower et al., 1995). 
Diamide has also previously been used to form the oxidized disulfide form of the 
hTrx protein (Andersen et al., 1997). 
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Figure 3.1. The structure of the thiol oxidizing agent diamide. 
3.1.3. Protein crystallography 
The production of protein crystals can be achieved by allowing the protein to 
reach a state of super-saturation when being brought out of solution by addition 
of a precipitant. This can be achieved by the variation of conditions including 
protein concentration, precipitant concentration and pH. The most common 
precipitants are ammonium sulfate and polyethylene glycol (PEG). 
Crystallization can be further explained by looking at the phase diagram (see 
figure 3.2). The phase diagram shows the solubility of the protein as a function 
of the crystallization conditions. This consists of an under-saturated zone in 
which crystal growth will not occur as the protein is fully dissolved. In the 
metastable zone crystal growth is most likely and crystals grown are usually 
stable. The nucleation zone is a zone of lower super-saturation and the zone in 
which crystals are also known to grow. Proteins going above this zone will 
precipitate out although crystal growth in this zone is not impossible (Asherie, 
2004). As the protein crystal grows the protein concentration in solution will 
decrease bringing the phase diagram back into the metastable zone. 
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Figure 3.2. The phase diagram showing the solubility of the protein as the precipitant 
concentration changes. At point A the protein will stay under-saturated. At point B the 
protein will crystallize and the concentration of the protein in solution drops to 
saturation as the crystal grows. At point C the protein will precipitate out but crystals 
may still grow. Figure adapted from Asherie (2004). 
There are several different methods of crystallization such as microbatch and 
vapour-phase diffusion. Microbatch experiments are where the protein and 
precipitant are mixed directly under oil. In the true microbatch method there is 
little to no diffusion as H2O cannot travel through the paraffin oil placed on top of 
the droplet (Chayen et al., 1992; Brumshtein et al., 2008). In this method protein 
crystallization requires that the precipitant concentration is correct for crystal 
formation. Microbatch crystallization using Al’s oil (50/50 paraffin/silicon oil mix) 
shows some diffusion increasing the concentration of precipitant and protein 
and is similar in this way to vapor diffusion. 
 
 
Figure 3.3. The microbatch crystallization setup in a 96 well plate with 1 µl of protein 
and 1 µl of precipitant mixed directly under oil. 
Vapor diffusion consists of a reservoir which contains the precipitating condition 
that is separated from the protein droplet mixed with a small volume of 
Oil 
Protein 1 µl Precipitant 1 µl 
Undersaturation 
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precipitant. Water will diffuse from the droplet to the reservoir bringing about 
equilibrium with the precipitant in the reservoir. This increase in precipitant and 
protein concentration within the drop can bring the protein into the super-
saturation state. As protein crystals begin to grow the solution is brought into 
the metastable crystal growth zone. 
3.1.4. X-ray crystallography 
X-rays can be used to determine the 3D structure of a protein. Typically X-rays 
with a wavelength between 0.5 and 1.6 Å are used as these wavelengths are 
comparable to the interatomic distances in protein crystals. They also should 
suitably penetrate and should be scattered strongly enough by the crystals. The 
X-rays are “shot” onto the crystal and a diffraction pattern is produced according 
to the different properties of the crystal. The diffraction patterns are used to 
determine the three dimensional structure of the proteins. 
A typical crystal is made up of a regular repeating array of unit cells that amplify 
the X-ray diffraction patterns. The unit cell is defined by three lengths (a, b, and 
c) and its three angles (alpha, beta, gamma) and the more unit cells that are 
present within the crystal the stronger the resulting diffraction. The crystal can 
be thought of as being divided into a number of planes that run through the unit 
cell. These planes have various orientations and spacing between them. The 
diffraction pattern is made up of a number of individual reflections (spots); the 
spots correspond to the diffraction from the crystal planes. 
Bragg’s law (Bragg, 1913) helps us to understand the relationship between the 
diffraction pattern and the spacing of the crystal planes.  Bragg’s law describes 
the relationship between the reflection angle (θ), the distance between the 
planes (d) and the wavelength (λ) shown in equation 3.1.  
nλ=2dsinθ 
Equation 3.1. Bragg’s law: n is an integer, λ is the wavelength of the radiation, d is the 
spacing between the lattice planes and θ is the angle of incidence of the X-ray beam. 
Bragg’s law treats all the planes that run through the crystal as mirrors that can 
reflect the X-rays and these reflections give rise to the reflection spots.  The X-
rays will add up constructively if they start in phase and arrive at the crystal 
plane in phase. Constructive diffraction will occur according to Bragg’s law 
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within a crystal with two planes separated by distance (d) if the difference in 
path length (2dsinθ) between the waves is equal to the integer number of 
wavelengths (figure 3.4). 
 
Figure 3.4. Conditions that satisfy Bragg’s law. Figure adapted from Asherie (2004). 
From this we can observe that the shorter the spacing between the crystal 
planes then the greater the angle of diffraction. The various lattice planes that 
divide the crystal across its three dimensions (a, b and c) are described by a set 
of Miller indices (h, k, and l). A value of the reflection angle (θ) can be calculated 
using simple trigonometry and from this the spacing (dhkl) can be calculated. 
This spacing will allow the dimensions of the unit cell to be calculated. 
During data collection the crystals were rotated because for a stationary crystal 
only a limited number of the crystal planes will satisfy Bragg’s law and therefore 
produce a diffraction pattern. Rotating the crystal should allow data to be 
collected from all the crystal planes. This is better explained by the Ewald’s 
sphere, which describes Bragg’s law in three dimensions. Ewald’s sphere 
places the crystal at the centre and has a radius of 1/λ. Each reciprocal lattice 
point has a position relative to its family of crystal planes, which are located at a 
vector from the crystal with a length that is inversely proportional to the d 
spacing. A diffraction spot is produced if the lattice point lies on the surface of 
the sphere (figure 3.5). When the crystal is rotated so are the reciprocal lattice 
points. This changes the points that lie on the sphere’s surface and this should 
produce all the required reflections. 
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Figure 3.5. Ewald’s Sphere. Figure adapted from Dauter (1999) 
The X-ray diffraction data is used to calculate the electron density throughout 
the unit cell.  The intensity of each spot is proportional to the amplitude of the 
diffracted X-ray waves.  Phase information is recalculated using other methods, 
as it is lost during data collection. By combining the amplitude (|Fh|) and phase 
(iαh) of the reflections a structure factor (F) can be obtained. The total structure 
factor (equation 3.2) can be described by all the atomic structure factors (fj) 
described by their Miller indices. The structure factor is related to the electron 
density resulting from the diffracted X-rays by a mathematical Fourier 
transformation. 
 = 	││expℎ = 	

2πi(hx + ky + lz!) 
Equation 3.2. The structure function equation. 
Using the inverse Fourier transform of all the structure factors from each of the 
Miller indices the electron density for all the positions in the unit cell ρ(x,y,z) can 
be calculated (equation 3.3). 
ρ(, $, %) = 1'F)*+	exp−2πi	(hx + 	ky	 + 	lz)
 
Equation 3.3. Calculation of the electron density in a crystal. 
The phase information that is lost during data collection can be determined in a 
number of different ways. One of these is molecular replacement where a 
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model is used that typically has a sequence homology of 25% or greater to that 
of the unknown structure. This model is then used to make estimations about 
the initial phases. Molecular replacement is based upon properties of the 
Patterson map, which is a Fourier transform of the squared amplitudes with the 
phases set to zero. Patterson maps are calculated for both the model and the 
unknown structure. A rotation function is then calculated by rotating the map for 
the model and scoring for a fit to the map calculated from the diffraction pattern 
(Crowther and Blow, 1967). The highest score occurs when the structures are in 
a similar orientation. Next a translation function is used where the model is 
positioned at all the possible positions within the unit cell of the unknown 
structure and a statistical correlation of the Patterson functions is calculated for 
each translational movement.  Positions that possess a high correlation are 
output as positional coordinates (Evans and McCoy, 2008). 
If the molecular replacement method is not available then another method must 
be used to solve the phase problem. Heavy atoms can be bound to specific 
sites within the molecule that can significantly alter the scattering and the 
structure factors. The amplitudes of reflections are calculated for the crystals 
with and without the heavy atom and the differences between the Patterson 
functions allow calculation of the phases. This technique is known as single or 
multiple isomorphous replacement.  
Multi-wavelength anomalous dispersion (MAD) and single-wavelength 
anomalous dispersion (SAD) are techniques that typically involve a heavy atom 
within the crystal. A typical example involves the replacement of the methionine 
residues with selenomethionine and the phases calculated from the same 
crystal using multiple data sets collected at different wavelength (MAD) or a 
single wavelength (SAD).  The phases are calculated by using changes in the 
structure factor amplitudes which are used to locate the heavy atoms.  
Once the electron density map has been calculated from the observed 
amplitudes and the calculated phases, the building of the amino acid chain into 
the map can begin. A map is created that minimises the bias of the structure 
factors calculated for the model by subtracting the calculated structure factors 
from a multiple of the observed amplitudes. This map is referred to as the 2Fo-
Fc map (equation 3.4). 
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Equation 3.4. The electron density 2Fo-Fc map summation. 
The Fo-Fc map is used to highlight regions in which electron density has been 
observed but has not been accounted for in the model and where the model has 
been built but no electron density has been observed. These maps allow the 
protein chain to be built followed by a refinement process. The refinement 
process involves the structure being adjusted to give the best fit to the data  
followed by new phase calculation; the phase calculated should improve if the 
atoms have been placed correctly. This refinement involves the adjustment of 
the positional coordinates for each atom that is not hydrogen together with their 
temperature B-factor and their occupancy. The refinement procedure has set 
bond distances, planarity and angles of groups such as peptide linkages and 
aromatic rings that allow appropriate models to be built. The accuracy of the 
model is confirmed by the calculation of R factor. The R factor compares the 
amplitudes calculated from the model (Fcalc) with the amplitudes observed from 
the model (Fobs) over a group of reflections (h) (equation 3.5). An Rfree factor is 
also calculated using a test set of reflections (typically 2-5%) which are not used 
in the refinement process. 
4 = ∑ ∣∣ 678 ∣ −∣ 9:9 ∣∣∑ ∣ 678 ∣  
Equation 3.5. The R factor equation. 
Refinement is stopped when you cannot make the model more consistent with 
the data in a meaningful way. The structure is then validated using parameters 
such as bond length and angles as well as stereochemical parameters. The 
structure is thought to be correct if the parameters fall within expected values 
(Tronrud, 2007). 
This chapter describes the over-expression and purification of the protein in the 
disulfide decameric state (hPrxII(S-S)), as well as its crystallization and 
subsequent X-ray structural analysis. 
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3.2. Materials and methods 
3.2.1. Expression of protein in the disulfide state 
The recombinant hPrxII gene was transformed into the BL21 DE3 (Novagen) 
cell line as described in 2.2.1 and plated onto an LB agar plate containing 
kanamycin (50 µg/ml). Induction studies were conducted to find the optimal 
conditions for producing hPrxII completely in the disulfide state. The BL21 DE3 
cells containing the pET28a/hPrxII construct were used to inoculate 100 ml of 
LB containing kanamycin (50 µg/ml). This starter culture was grown under 
agitation overnight at 37oC. 20 ml of the starter culture was used to inoculate 1 
L LB containing the appropriate selection, and was grown with agitation at 37oC 
until the OD600nm was approximately 1.0. Induction of hPrxII was carried out 
using IPTG added to a final concentration of 1.0 mM and addition of diamide to 
a final concentration of 250 µM. The culture was incubated overnight at 37oC. 
The cells were then harvested by centrifugation (20,000 x g, 20 mins, 4oC) 
using a Beckman JA-25.50 rotor. The cell pellet was stored at -20oC until further 
use. 
3.2.2. Protein purification of hPrxII(S-S) 
3.2.2.1. Cell lysis 
The cell paste was re-suspended to 10% w/v in 100 mM Tris-HCl, pH 7.5, 0.5 M 
NaCl, 20 mM imidazole, 250 µM diamide. Cells were disrupted by sonication as 
described in section 2.2.4.1. 
3.2.2.2. Purification buffers 
Buffer A – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 20 mM imidazole, 10 µM 
diamide 
Buffer B – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 M imidazole, 10 µM diamide 
Buffer C – 100 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 10 µM diamide 
3.2.2.3. Nickel affinity and gel filtration chromatography 
The nickel affinity chromatography was performed as in methods 2.2.4.3 using 
a six column volume gradient to 100% buffer B. The fractions from the column 
elution were analyzed using SDS-PAGE. Size exclusion chromatography was 
carried out as in methods 2.2.4.4 with fractions collected over one column 
volume. Fractions containing protein were analyzed using SDS-PAGE (as in 
93 
 
methods 2.2.4.6). The presence of the disulfide state of hPrxII was confirmed 
using SDS-PAGE analysis loading the protein on to a 12.5 % SDS gel using 
non-reducing loading buffer. hPrxII(S-S) showed a band ~48 kDa which was 
double the size of hPrxII (~24 kDa) using reducing buffer.  
3.2.3. Western blot analysis 
Samples were separated on a 12.5% SDS gel, and the gels were set up to 
allow the transfer of proteins from the gel onto a nitrocellulose membrane for 
immunodetection. The blotting apparatus was set up as follows: three layers of 
3 mm blotting paper, one layer of nitrocellulose membrane, SDS gel and 
another three layers of blotting paper. The blotting paper and membrane were 
presoaked in 1 x transfer buffer (25 mM Tris-HCl pH 7.5, 20 mM glycine). The 
proteins were transferred from the gel to the membrane at 60 mA for 30 min. 
The filter membrane was then soaked in 10 – 20 % dried milk diluted in a 1 x 
wash buffer for 60 min with agitation.  
5 x Wash buffer    
1 M Tris-HCl pH 7.6 50 ml/L 
NaCl 146 g/L 
Tween 20 2.5 ml/L 
 
The filter was then washed for 2 x 5 min in a large volume of 1 x wash buffer 
prior to incubation with rotation overnight at 4oC with the primary antibody for 
hPrxII (5 µl diluted in 5 ml of 1 x wash buffer). The filter was then washed twice 
rapidly, followed by a 1 x 15 min wash, then followed by a 2 x 5 min washes in 
larger volumes of 1 x wash buffer. The filter was incubated with the secondary 
antibody (1 µl diluted in 5 ml of 1 x wash buffer) with rotation at room 
temperature for 1 hour. The filter was washed as above and left in buffer until it 
was developed. The ECL™ Western Blotting System (GE Healthcare) was used 
to detect the over expressed hPrxII. The prepared filter membrane was drained 
on blotting paper and soaked briefly in the detection reagent. 4.5 ml of ECL™ 
detection mix (2.25 ml of solution I plus 2.25 ml of solution II prepared 
immediately before use) was added and the filter was left to incubate for one 
minute with agitation in a plastic folder, which was then transferred to a film 
development box for visualization by autoradiography in a dark room. 
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3.2.4. Crystallization of hPrxII(S-S) 
3.2.4.1. Preparation of proteins 
After size exclusion chromatography the fractions containing purified hPrxII(S-
S) were concentrated to ~15 mg/ml as in methods 2.2.4.5. The samples were 
centrifuged at 15,000 x g at 4oC for 10 min before being used in crystallization 
trials to remove any precipitated protein. 
3.2.4.2. Initial crystal trials 
Microbatch crystallization trials were set up in a Hampton 96 well plate using an 
Oryx 6 crystallization robot (Douglas Instruments, UK). A range of different 
commercial screens were used for the microbatch trials including the screens 
MDL1 and MDL2 (Molecular Dimension Laboratories) (Appendix 7.4), Sigma 
8007, Sigma 70437 (Sigma Aldrich) (Appendix 7.5) and JCSG (Molecular 
Dimensions Laboratories) (Appendix 7.6). The final droplet volume was varied 
between 1 µl and 2 µl depending on the amount of protein solution available. 
The droplet contained a 50:50 ratio of protein solution to screen ratio. The 
droplet was covered with Al’s oil (50:50 mix of silicon oil and paraffin). The 
plates were stored at 18oC and regularly checked for growth of crystals using a 
light microscope. 
3.2.4.3. Optimization of crystal trails 
For any conditions that produced crystals optimization was carried out using the 
X-step optimization software (Douglas Instruments, UK). The X-step software 
varies the precipitant concentrations, protein concentrations, additive 
concentrations and pH by +/-30 %. The microbatch method was once again 
used on the Oryx 6 crystallization robot (Douglas Instruments, UK). The droplet 
was covered with Al’s oil (50:50 mix of silicon oil and paraffin). The plates were 
stored at 18oC and regularly checked for crystals using a light microscope. 
3.2.4.4. Preparing crystals for data collection 
Crystals were frozen using a cryo-protectant (0.1 M HEPES Na salt, pH 7.5, 
20% PEG 200, 10% PEG 8000, 25% Glycerol). The crystals were removed 
from the droplet and placed in the cryo-protectant before being frozen directly in 
liquid nitrogen. 
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3.2.5. X-Ray data collection 
Data were collected on IO3 at the Diamond Synchrotron light source (Oxford, 
UK) using an ADSC Q315 CCD detector. Data were collected under cryo 
cooled conditions (100 K in a stream of gaseous nitrogen). 
A high resolution dataset was collected at a wavelength of 0.98 Å at a distance 
of 460.5 mm. 360 frames were collected at an oscillation of 0.5o for each frame. 
3.2.6. Structure Determination 
3.2.6.1. Data processing 
Data was processed using MOSFLM (CCP4) (Evans, 2006), SCALA (CCP4) 
(Weiss and Hilgenfeld, 1997) and Xia2 (CCP4). 
3.2.6.2. Phase determination 
Phases were determined using the molecular replacement method performed in 
MOLREP (Vagin and Teplyakov, 2010). 
3.2.6.3. Model building and refinement 
Electron density maps were calculated and the structure was fitted to give the 
best fit to both the 2Fo-Fc and Fo-Fc maps. Maximum likelihood refinement was 
performed using REFMAC 5.2 (Murshudov et al., 1997) after each session of 
model building performed in COOT (Emsley and Cowtan, 2004). No solvent 
molecules were added to the final PDB due to the low resolution. 
3.2.6.4. Structure validation 
After refinement the quality of the model was checked using the program 
PROCHECK (Laskowski et al., 1993). 
3.3. Results 
3.3.1. Expression of the protein in the disulfide state 
The hPrxII gene in the pET28a vector was transformed into the E. coli 
expression strain BL21 DE3. hPrxII protein expression was under the control of 
the T7 promoter and was induced using IPTG. The over-expression of hPrxII in 
the disulfide state was investigated by induction studies to obtain the conditions 
not only for over-expression but to have the protein completely in the disulfide 
state. The optimal conditions for this were addition of a final concentration of 1 
mM IPTG and 250 µM diamide when the cells had reached an OD600nm of 1.0 
with further incubation overnight at 37oC. The over-expression of hPrxII resulted 
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in soluble protein being produced at the expected size (~24 kDa). The presence 
of the disulfide state was confirmed with a band on SDS-PAGE using native 
buffer at ~48 kDa. 
3.3.2. Protein purification of hPrxII(S-S) 
One litre of culture produced 3.0 g of cell paste and after cell lysis (as in 
methods 2.2.4.1) and centrifugation the supernatant was purified using nickel 
affinity and gel filtration chromatography as described in methods 2.2.4.3 and 
2.2.4.4. 
3.3.2.1. Nickel affinity and gel filtration chromatography of 
hPrxII(S-S) 
The clarified cell extract was applied to a nickel column as described in 
methods 2.2.4.3 producing the trace seen in figure 3.6. The fractions were 
analyzed using SDS-PAGE (see figure 3.8) as described in methods 2.2.3.6. 
The fractions containing hPrxII were pooled and concentrated for gel filtration 
chromatography. Gel filtration chromatography was used as a final step of the 
purification process and as a tool for the estimation of the molecular weight of 
the protein. The concentrated protein was loaded on to an equilibrated gel 
filtration column as in methods 2.2.4.4 (figure 3.7). The peak fractions were 
analyzed by SDS-PAGE and those that contained hPrxII were pooled and 
concentrated. The presence that the disulfide had formed was confirmed by 
SDS-PAGE using non-reducing buffer (figure 3.8). The disulfide form was also 
confirmed by the use of Western blot analysis (methods 3.2.3) (figure 3.9) as 
the hPrxII primary antibody will bind to both protein bands on SDS-PAGE ran 
with native buffer. 
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Figure 3.6. Elution profile of hPrxII(S-S) (blue line) from nickel affinity chromatography. 
10 ml fractions were collected throughout the entire elution. The red line shows the % 
imidazole concentration. The fractions that showed a band of the correct size on SDS-
PAGE are indicated by the red bar. 
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Figure 3.7. Elution profile from the gel filtration column for hPrxII(S-S) (blue line). 1 ml 
fractions were collected throughout the elution volume. Peak 1 (~42 ml) corresponds to 
the void volume of the column; Peak 2 (~58 ml) corresponds to the decameric form of 
hPrxII (250 kDa). The oligomeric state was determined using a calibrated Superdex 
200 column (Appendix 7.1.) 
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Figure 3.8. SDS-PAGE analysis of the elution from the hPrxII(S-S) gel filtration 
column. Lane 1, molecular weight marker; Lane 2, sample from peak 2 run on SDS-
PAGE using non-reducing buffer; Lane 3, sample from peak 2 run on SDS-PAGE using 
reducing buffer. 
 
Figure 3.9. Western blotting analysis of hPrxII using non-reducing SDS buffer to show 
the presence of the intermolecular disulfide bond. Lane 1, analysis of hPrxII from 
Rosetta-gami 2 pLysS (DE3) cells; Lane 2, analysis of hPrxII from BL21 (DE3) cells; 
Lane 3, analysis of hPrxII from BL21 (DE3) cells with diamide present at cell lysis; Lane 
4, analysis of hPrxII from BL21(DE3) cells with diamide present at induction and in all 
purification and cell lysis buffers. The molecular weight is predicted based on the 
marker run on the SDS-PAGE (Marker not shown). 
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After gel filtration pure hPrxII(S-S) protein was obtained and eluted at ~58 ml 
from the calibrated gel filtration corresponding to a molecular weight of ~250 
kDa suggesting it was present as a decamer. 
3.3.3. Crystallization of hPrxII(S-S) 
The purified enzyme was concentrated to ~15 mg/ml and microbatch 
crystallization experiments were carried out using commercial crystal screens 
(as in methods 3.2.4). Initial results gave crystals produced in 0.1 M HEPES Na 
Salt pH 7.5, 8% ethylene glycol, 10% PEG 8000 (figure 3.10). 
 
Figure 3.10. hPrxII(S-S) crystals obtained from 0.1 M HEPES Na Salt pH 7.5, 8% 
ethylene glycol, 10% PEG 8000. 
Optimization experiments were carried out around these conditions (as in 
methods 3.2.4.3) but they failed to yield any crystals and the original crystals 
were frozen using a cryo-protectant (as in methods 3.2.4.4) and taken to the 
Diamond Light Source (Oxford, UK) 
3.3.4. Structure determination 
3.3.4.1. X-ray data collection 
Data were collected at the Diamond Light Source (Oxford, UK) as described in 
methods 3.2.5. Indexing and scaling revealed the crystal belongs to the 
monoclinic space group P31 2 1 or P32 2 1. The statistics for the data 
processing are shown in table 3.1. 
 
 
0.5 mm 
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Crystal hPrxII(S-S) 
Resolution range (Å) 140-3.3 (3.38 – 3.30) 
Space group P31 2 1 
Cell parameters 
a=b= 211.2, c=217.5 Å 
α =β=90°, γ = 120° 
Solvent content (%) 
VM (Å3 Da-1) 
82.7 
7.11 
No. protomers in asymmetric unit 10 
No. measured reflections 929861 
No. unique reflections 84379 
Completeness (%) 100 (100) 
Redundancy 11.02 (11.24) 
(I)/σ (I) 9.8 (1.8) 
Rsym† (%) 0.23 (1.36) 
Table 3.1. Data processing statistics for the hPrxII(S-S). Values in parentheses are 
given for the outer resolution shell. 
Rsym=ΣhΣJ|<Ih>-I J(h) |/ΣhΣJI(h), where I(h) is the intensity of reflection h. Σh is the sum 
over all reflections and ΣJ is the sum over J measurements of the reflection. 
3.3.4.2. Structure solution 
Molecular replacement studies were carried out with the program MOLREP 
(Vagin and Teplyakov, 2010) using the original decameric structure of the PrxII 
(PDB: 1QMV). The solution was found with the full model, however, significant 
clashes were observed.  Residues 165-198 were removed from each model 
subunit and molecular replacement was successfully performed on the modified 
decameric model. This work was carried out in collaboration with Dr. M. Isupov 
at Exeter. 
The cross-rotation function was calculated for the decamer with a radius of 60 Å 
and a resolution range of 40-3.5 Å. The rotation solution had a peak at 12 σ with 
a noise peak no greater than 3 σ.  The translation function was calculated in 
both possible enantiomorphs of the space group, (P31 2 1 and P32 2 1). The 
solution was found in the P31 2 1 enantiomorph with a correlation of 50.3% and 
an R-factor of 46.6% with a background correlation of 32.9%. The highest 
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correlation for the other enantiomorph of the space group was calculated at 
27%. 
3.3.4.3. Model building and validation 
Ten fold electron density averaging was carried out on the solution from 
molecular replacement and was subsequently refined using REFMAC 
(Murshudov et al., 1997) and rebuilt in COOT (Emsley and Cowtan, 2004) using 
the averaged maps. The LOCAL NCS option of REFMAC (Murshudov et al., 
1997) was used for further refinement, allowing individual B factors to be 
assigned to all atoms. Final rounds of model building were done independently 
for each subunit using the 2Fo-Fc maps. Statistics for the final model are 
displayed in table 3.2. The Ramachandran plot for the structure is displayed in 
appendix 7.7. 
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Crystal hPrxII(S-S) 
Resolution range (Å) 50-3.30 
Overall R factor (%) 19.4 
Rfree (5% total data) 21.3 
No. protein residues 1705 
Residues modeled 
Residues 
(A,B 1 -174), (C,D,G,J 1 – 172), 
(E,F,H 1 – 175), I (1 – 173). 
S-S BONDS 
Cys 172 (E) – Cys 51 (F), Cys 51 (E) – Cys 172 (F) 
Cys 51 (G) – Cys 172 (H), Cys 172 (A) – Cys 51 (B) 
Cys 51 (C) – Cys 172 (D), Cys 172 (I) – Cys 51 (J) 
Cys 172 (C) – Cys 51 (D) 
No. solvent molecules (water) 0 
No. substrate/cofactor molecules 16 (SO4) 
RMSD bond length  (Å) 0.012 (0.022) 
RMSD bond angles (o) 1.43 (1.99) 
Wilson B factor (Å2) 73.83 
Average B factor  
        Protein (Å2) 78.0 
REFMAC RMS error (Å) 0.29 
Ramachandran analysis (% of 
residues) 
 
Most favoured 87.7 
Additionally allowed 9.8 
Generously allowed 1.9 
Disallowed 0.5 
G factor  0  
Table 3.2. The final X-ray refinement statistics for hPrxII(S-S) structure. Target values 
are given in parenthesis. 
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3.4. Discussion 
3.4.1. Expression of the protein in the disulfide state  
Over-expression of the protein in the disulfide state was attempted in a number 
of different ways. The protein was originally transformed into the chemically 
competent Rosetta-gami 2 pLysS (DE3) E. coli cell line as it is known to 
enhance disulfide bond formation in the cytoplasm. The enhanced disulfide 
bond formation is caused by this strain of E. coli having mutations in the trxB 
and gor genes. These mutations prevent the production of thioredoxin B and the 
glutathione reductase enzymes which are responsible for the reduction of 
disulfide bonds. The purified protein from Rosetta-gami 2 pLysS (DE3) was 
found to be a mixed species with the protein being expressed in both the 
disulfide and a non-disulfide state (figure 3.9). hPrxII was then transformed into 
the BL21 (DE3) cell line and diamide was introduced at cell lysis and at 
induction and the composition of the purified sample was studied using SDS-
PAGE and Western blotting (figure 3.8 and figure 3.9). It was shown that in the 
BL21 (DE3) cell line without diamide, the protein was expressed in greater 
levels than in the Rosetta-gami 2 pLysS (DE3), but was still expressed equally 
in the disulfide and non-disulfide state. When diamide was introduced in the 
purification and cell lysis buffers, the amount of protein being produced in the 
disulfide state was greatly improved but to obtain protein crystals suitable for X-
ray diffraction data the protein had to be in a completely homogenous state. By 
introducing diamide at induction and then keeping it present in the cell lysis and 
all the purification buffers, the protein was produced completely in the disulfide 
state.  
3.4.2. Crystal structure of hPrxII(S-S) 
3.4.2.1. Monomer unit 
The monomer of the disulfide hPrxII within the decameric structure consists of 
domain I (residues 1-169) as previously described in the hyperoxidised/thiol 
form of the enzyme (Schroder et al., 2000). Residues 176-202 were not built in 
the current structure due to poorly defined electron density. The thioredoxin fold 
is made up of four β strands (β3, β4, β6 and β7) and by four flanking α helices 
(α1, α2, α4 and α5) as found in the original hPrxII structure. The overall 
secondary structure of the disulfide Prx monomer is shown in figure 3.11. 
 
 Figure 3.11. Cartoon representation of the overall secondary structure fold of the 
hPrxII monomer within the decameric structure with the 
shown as spheres. The figure is 
residues are shown as sphere
3.4.2.2. Dimer
The dimer highlighting the formation of the dis
3.12. The C-terminal region was believed to play
interface based on the
structure.   Rearrangements of the N and C terminal regions which al
formation of the disulfide and a comparison to the hyper
the enzyme are described in section 3.4.2.5
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 Figure 3.12. Cartoon representation of the hPrxII dimer 
highlighting the disulfide as 
homodimer are shown in cyan and green with the disulfides shown in sphere mode 
(Figure produced using PyMol DeLano scientific).
3.4.2.3. Decamer
The disulfide structure of the hPrxII revealed a decam
Although not all dimers were shown to be in the disulfide state due to poorly 
defined electron density, this structure still suggests the disulfide state of the 
enzyme does exist in a decameric form. Figure 3.13
disulfide bonds on neighbouring dimer subunits. It was originally hypothesized 
that the disulfide state might only exist
breakdown in the dimer:
disulfide formation.  This disulfide structure however provides evidence that the 
disulfide state exists in the decamer
interface is largely hydrophobic with the interface formed between αH3, its 
preceding loop region, and the loop region
on each neighbouring subunit. In particular Phe47 from one subunit is involved 
in a hydrophobic cluster with Phe47, Phe81 and Ala85 from the neighbouring 
dimer as described for the original hPrxII structure. A comparison of
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dimer 
-α4 and β3-α1 
 the 
 dimer:dimer interface between this disulfi
hyperoxidised/thiol state is discussed in section 3.4.2.5
  
Figure 3.13. Cartoon representation of the decameric structure of hPrxII highlighting 
the position of the disulfide bonds shown in spheres mode (Figure produced using 
PyMol DeLano scientific). 
3.4.2.4. The active site
The 2Fo-Fc and Fo-Fc electron density maps revealed the pre
disulfide bond in the subunits as described in table 3.2
did not allow the other disulfides to be described). Electron density for the 
disulfide bond is shown in figure 3
highlighted in reference 
active site and Cys binding pockets is discussed in section 
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.14. The disulfide and residues within 5 
to the hPrxII dimer in figure 3.15. A comparison of the 
3.4.2.5
sence of the 
Å are 
. 
 (A)                                                          (B)
Figure 3.14. A) The 2Fo-
residues. B) The Fo-Fc omit map calculated in the absence of the shown residues. 
Figure 3.15. Stereo cartoon representation
surrounding residues in reference to the dimer.
coloured in blue and light blue with the disulfide and surrounding residues shown in 
stick mode (Figure produced using PyMol DeLano scientific).
3.4.2.5. Structural comparison between hPrxII hyper
oxidized/thiol
The hPrxII disulfide structure was compared to the previously known form of the 
structure (PDB: 1QMV) in whic
thiol states respectively. The overall composition of the secondary structure of 
the disulfide form of the enzyme is unchanged. A comparison of the two 
structures highlights structural changes which occur in loop regions consisting 
of residues 47-54 and 170
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Fc electron density map for the disulfide and surrounding 
 of the hPrxII disulfide bond and 
 The two subunits of the homodimer are 
 
 and hPrxII(S-S) crystal structure. 
h Cys51 and Cys172 are in hyper
-202 as well as at the C terminal region,
 
 
 
-
-oxidized and 
 which occur 
 to allow for disulfide bon
shown in figure 3.16. In the previously known structure it was reported that 
there was a 10 Å distance
the neighbouring subunits of the dimer and a 13 
atoms of the two redox active cysteines. 
Figure 3.16. Stereo diagram 
and the hPrxII(S-S) (blue) forms. Cysteines are shown as spheres.
using PyMol DeLano scientific).
It was reported previously 
Val50, Glu54, Trp86, Arg127 and Arg150 and Val171 from the neighbouring 
subunit. The disulfide structure reveals an overall movement of the loop 
consisting of residues 47
the side chains of Val50 and Phe49 are displaced from the dimer interface 
resulting in a 6 Å movement of Cys51 towards the neighbouring subunit. The 
positions of Tyr43, Pro44, Thr48, Glu54, Trp86,
relatively unchanged.  
In the neighbouring subunit Cys172 was previously described in the thiol state 
positioned within a hydrophobic pocket consisting of residues Ala161, Tyr164 
and Trp176 and Val148 from the neighbouring subunit. I
large structural movements of the region consisting of residues 170
observed to allow for the formation of this bond. In the thiol state this loop 
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 between the Cα positions of Cys51 and Cys172 from 
Å gap between the sulfur 
 
comparison of the original hyper-oxidized
 (Figure produced 
 
that Cys51 is buried by residues Tyr43, Pro44, Thr48, 
-54 towards the neighbouring monomer. In particular 
 Arg127 and Arg150 are 
n the disulfide structure 
 
/thiol Prx (red) 
-202 are 
 region folds in towards the neighbouring subunit. However
structure the loop adopts a dramatically different conformation which moves the 
Cα of Cys172 10 Å. This results in residues 170
displacing the C terminal αH6 in the 
completely different conformation allowing disulfide bond formation. The 
displaced αH6 C terminal region has not been able to be mode
disulfide structure due to poorly defined electron density. The previously 
described binding pocket of Cys172 in 
The new conformation of both subunits results in potential hydrogen bonds 
between the two subunits
Phe49 of one subunit to the main chain nitrogen atom of Cys172 of the 
neighbouring subunit and between the main chain oxygen atom of Glu170 to 
the main chain nitrogen atom of Val150.
Overall these structural changes allow the cysteine
bond on the surface of the dimer which would allow future reduction by T
(The C-terminal region has not been defined in the disulfide structure; however 
there is plenty of room available to suggest this region would not shield the 
disulfide bond).  
Figure 3.17. Stereo diagram 
for the disulfide bond formation. The original hyper
displayed in red and light red corresponding to the two subunits of the homodimer. The 
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 disulfide Prx is displayed in blue and light blue corresponding t
homodimer (Figure produced using PyMol DeLano scientific)
Figure 3.18. Stereo diagram highlighting the differences and similarities for the active 
site pocket residues around Cys51 and Cys172. The original hyper
structure is displayed in red and light red corresponding to the two subunits of the 
homodimer. The disulfide Prx is displayed in blue and light blue corresponding to the 
two subunits of the homodimer 
Comparisons of the dimer:dimer interface reveal there are few changes at this 
interface, apart from the
similarities in the dimer:dimer interface. The only noticeable difference is the 
position of Phe49 howev
clash with the neighbour
the active site Cys51-
responsible for the dimer:dimer interaction which exp
form of hPrxII can exist in the decameric state. 
Heme-binding protein 23 (HBP23) (PDB: 1QQ2) is
peroxiredoxin that was found to be in the intermolecular disulfide state wi
disulfide bond between Cys52 a
homology with hPrxII (Hirotsu 
revealed only the dimer. Based on differences observed between the disulfide 
HBP23 enzyme and the original hyperoxidised
111 
o the two subunits of the 
. 
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 un-modeled C terminus. Figure 3.19
er, the position adopted in the disulfide state does not 
ing dimer. Therefore the changes which occur around 
Cys172 bond do not affect the original residues 
lains how the disulfide 
 
 a mammalian two
nd Cys173 and shares 77% sequence 
et al., 1999). The structure of the HBP23 protein 
/thiol hPrxII enzyme it was 
 
Prx 
. 
 highlights the 
 cysteine 
th a 
 hypothesized that changes at the dimer: dimer interface upon disulfide 
formation would cause the breakdown of the decamer.
It was originally suggested in the hPrxII enzyme (based on the disulfide HDP23 
structure) that partial unwindin
change in the position of the side
cause a steric clash with the Phe81 from the neighbouring dimer i
structure. Figure 3.19 clearly shows there is no movem
residues in the disulfide decamer interface. It was also suggested movements in 
residue Trp86 would result in a clash with Ala85 from the neighbouring subunit. 
(This corresponds to the position of Trp87 obse
3.19 shows there is no movement of these residues between the two different 
hPrxII states. The only change observed at the dimer:dimer interface is in the 
position of Phe49, however
would not cause a breakdown of
Figure 3.19. Cartoon representation of the dimer:dimer interface f
in orange and the original hyperoxidize
at the dimer interface are shown as lines 
scientific). 
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4. Study of the complexes formed between hPrxII and 
the proteins it interacts with in the Prx antioxidant 
system. 
4.1. Introduction 
4.1.1. The interaction between hPrxII and Srx 
During the normal catalytic cycle hPrxII will undergo oxidation converting the 
peroxidatic cysteine sulfur hydryl group (-SH) to a sulfenic acid (-SOH). Once 
the sulfenic acid group has been produced the resolving cysteine is thought to 
reduce the peroxidatic cysteine to its natural state. The attack of the resolving 
cysteine is thought to be potentially slow due to the distance between the 
peroxidatic and resolving cysteines, as well as interference from the GGLG and 
YF motifs restricts access to the peroxidatic cysteine (Wood et al., 2003a). This 
slow mechanism allows the sulfenic acid to become hyper-oxidized to the 
sulfinic acid form (-SOOH). This form was once thought to be “un-repairable” 
and was believed to leave the protein inactivated (Chae et al., 1994). It has also 
been suggested that this over-oxidized state is a signal for apoptosis (Zhao et 
al., 2009). A protein was discovered in S. cerevisae that was found to repair the 
hyper-oxidized sulfinic acid form of a yeast peroxiredoxin (Biteau et al., 2003a). 
The protein was found to have a human homologue. The human 
oxidoreductase hSrx is 14.2 kDa in size and requires both ATP and Mg2+ to 
function. 
The structure of the peroxiredoxin-sulfiredoxin complex has been studied using 
a disulfide link between PrxI and hSrx to mimic the proposed thiosulfinate 
intermediate (Jonsson et al., 2008b) but a complex was unable to be formed 
between the decameric form of either PrxI or PrxII. 
The crystal structure of hPrxII reveals the structure of the hyper-oxidized form to 
be a stable decameric structure with buried active sites that would provide 
difficulty for Srx to access the sulfinic acid (Schroder et al., 2000). The crystal 
structure of the hSrx reveals a concave shape to the active site that is 
hypothesized to be ideally suited to interacting with the convex shape of the 
PrxII decamer (Jonsson et al., 2005). The interaction between decameric PrxII 
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and hSrx has been studied using molecular modelling (Lee et al., 2006), but as 
yet there is little data on the complex and the stoichiometry of Srx binding.  
4.1.2. The interaction between hPrxII and Trx 
As part of the normal catalytic cycle of hPrxII an intermolecular disulfide is 
formed in the reduction of the peroxidatic cysteine. This intermolecular disulfide 
is then reduced by thioredoxin. The disulfide bond undergoes nucleophilic 
attack by the thiolate of Cys32 forming a covalently linked mixed disulfide. The 
second catalytic cysteine (Cys35) then attacks the mixed disulfide leaving the 
hPrxII reduced and an intermolecular disulfide between the catalytic cysteine 
residues on Trx (Holmgren, 1995).  
4.1.3. Site-directed ligase independent mutagenesis (SLIM) of Srx 
to ET-Srx 
Previous work on the crystallization and the complex formation of Prx and Srx 
showed that Srx contains a glycine-rich region (35%; 13 of 37 residues) 
(Jonsson et al., 2005; Jonsson et al 2008b). In both studies it was an 
engineered truncated Srx (ET-Srx) with the first 31 residues removed that 
produced the best crystals. 
The optimal way to produce the ET-Srx involved mutating out the undesired 
residues by using SLIM on the original Srx clone. SLIM is a method for 
producing mutations in a DNA sequence using PCR (figure 4.1). PCR is 
performed using four primers, two short primers and two long tailed primers. It is 
the two tailed primers that contain the desired mutation on complementary 
overhangs. The PCR reaction will produce four products. Products one and two 
are identical except for the positions of the tails which are found at opposite 
ends of the sequence. Product three contains the tail sections on both ends and 
product four does not possess the tailed portion (therefore no sequence 
deletion).  The PCR product is then denatured and re-annealed forming a stable 
heteroduplex generated from one strand of product one and one strand of 
product two. This heteroduplex is stable as the generated strand will form with 
complementary 5’ and 3’ overhangs at opposite ends which can form circular 
DNA.  The circular DNA is then transformed into a cloning E. coli cell line. SLIM 
was chosen to create ET-Srx as it can be done in a single tube in a short time 
frame and has shown to be >95% efficient (Chiu et al., 2004). 
115 
 
 
Figure 4.1. The SLIM method for the production of ET-Srx. Inverse PCR is performed 
to remove the DNA region corresponding to the first 31 amino acids. The PCR will 
produce four products. On denaturation and annealing a heteroduplex will be formed 
from one strand of product one and one strand of product two. This heteroduplex will 
have complementary 5’ and 3’ overhangs that can form stable circular DNA that can 
then be transformed into chemically competent E. coli cells. Figure adapted from Chiu 
et al., (2004). 
4.1.4. Site directed mutagenesis 
4.1.4.1. Site directed mutagenesis of hPrxII to mPrxII 
In order to produce the complex between hPrxII and ET-Srx it was necessary to 
produce a disulfide linkage using a chemical method. In order to produce the 
disulfide link between the peroxidatic cysteine (Cys51) and the cysteine on Srx 
it was necessary to remove the resolving cysteine (Cys172) and the remaining 
cysteine residue (Cys70).  
4.1.4.2. Site directed mutagenesis of Trx to mTrx 
In order to produce the complex between mPrxII and Trx the same chemical 
conjugation reaction was used. In order to recreate the reaction between the 
 peroxidatic cysteine (Cys51) and Cys32 on Trx it was necessary to remove the 
second catalytic cysteine residue (Cys35). Trx contains four other cysteine 
residues but only one of these 
appears on the surface of the protein and so is the 
would react with the chemical conjugating agent.
4.1.5. Chemical conjugation of the proteins
4.1.5.1. Chemical conjugation of mPrxII to ET
To form stable complexes
a disulfide bond that mimic
al., 2008). In the first part of this p
(DTNB) was added to the mPrxII, this r
leaving TNB. TNB can then be attacked by the cysteine residue on Srx forming 
the disulfide linkage between the two and resulting in the release of TNB (figure 
4.2). The release of TNB can be followed by monitoring the A
Figure 4.2. The mechanism of conjugation between mPrxII and ET
Step one shows the reaction between mPrxII and DTNB forming a link to the 
peroxidatic cysteine. Step two shows the ET
complex and releasing the TNB which can be followed at A
4.1.5.2. Chemical conjugation of mPrxII and Trx
In this case DTNB was used to form the mixed disulfide between the peroxidatic 
cysteine (Cys51) and the first catalytic cysteine residue on Trx (Cys32). The 
step is the same as the above mechanism 
the peroxidatic cysteine. In this second step the available cysteine residue from 
Trx replaces the TNB molecule which can be monitored by following the A
(figure 4.3). 
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Figure 4.3. The second step of the conjugation reaction with the cysteine residue on 
Trx replacing the TNB molecule attached to the peroxidatic cysteine of mPrxII. The 
release of TNB can be monitored by following the A412nm. 
4.1.6. Potential interaction with PDCL3 
This work was performed in collaboration with Professor Keith Willison (Institute 
of Cancer Research) and Heather Rada (Institute of Cancer Research). 
Phosducin-like protein 2 (PLP2) is an ATP-elutable binding partner for the yeast 
chaperonin-containing TCP-1 (CCT) (McCormack et al., 2009). PLP2 has been 
shown to interact with CCT to help to promote actin folding, with a 30% increase 
in actin folding with PLP2 compared to without PLP2 (McCormack et al., 2009). 
PDCL3 is the human orthologue of yeast phosducin-like protein 2 (PLP2) 
(Stirling et al., 2007) and a potential interaction with PDCL3 was first identified 
using electro spray ionization mass spectrometry (ESI-MS). PDCL3 from human 
colorectal cancer cell extracts and potential binding partners were analyzed by 
ESI-MS with a very strong signal being shown with PrxI.  
4.1.7. Surface plasmon resonance 
Surface plasmon resonance (SPR) can be used to measure bimolecular 
interactions (Homola et al., 1999). In this technique polarized light is shone 
through a prism on to the sensor chip. This sensor chip has a thin layer of gold 
that acts as a mirror reflecting the light. The angle of incidence of the polarized 
light is changed and the intensity measured and the intensity passes through a 
minimum at which point the light will excite surface plasmons. The intensity of 
the optical field in the waves coming off the surface will decay exponentially with 
distance from the surface. This will happen at a distance of over 100 nm and 
means that the SPR angle will change depending on the refractive index (RI) of 
anything adjacent to the surface (Kooyman, 2008). 
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An SPR gold chip can have a protein (ligand) covalently linked to the surface 
and a buffer containing the other protein (analyte) will flow over the chip and the 
change in RI at the surface can be measured. If the two partner proteins bind or 
interact with each other there will be a change in the RI and therefore a change 
in the SPR angle can be observed. SPR is now frequently used to look at 
protein-protein interactions. 
 
Figure 4.4. The set up of the SPR assay with the prism reflecting light on to the sensor 
chip gold film surface and the immobilized ligand bound to it interacting with the 
analyte. Figure modified from Cullen et al., (1987). 
 
The typical means of immobilization of the protein to the surface is via amide 
coupling which consists of three stages: activation, pre-concentration and 
deactivation. The gold chip is supplied with a layer of carboxylic acids on the 
surface. During activation of the surface the carboxylic acid group reacts with 1-
Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) and is then reacted with N-
hydroxysulfosuccinimide (Sulfo-NHS) to form a reactive NHS-ester. 
Preconcentration is done immediately after activation: the proteins are injected 
in a condition below their pI so they are positively charged and attracted to the 
negatively charged surface. Lysine residues containing primary amines will form 
a stable amide bond to the surface. Unreacted activated carboxyl groups are 
deactivated in the final step by ethanolamine. Ethanolamine will also remove 
ligands that are bound electrostatically and not covalently to the surface. 
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Figure 4.5. The 3 steps for ligand immobilization to the surface of a carboxylic acid 
coated gold chip. Figure recreated from Kooyman (2008).  
 
There are four steps to an SPR assay that allow reliable results to be obtained. 
The first step is to achieve a suitable baseline. The sensor surface should be 
conditioned with a suitable buffer solution to produce a repeatable baseline to 
which other steps can be compared. In the second step injection of the analyte 
begins and a shift in RI can be measured that should respond to the association 
of the analyte to the ligand. This association step should allow the calculation of 
adsorption kinetics in real time. After a suitable time period injection is switched 
to a buffer solution that does not contain the analyte and dissociation of the 
ligand and analyte will occur. Once again in this region dissociation kinetic data 
should be obtained in real time. The surface is then regenerated for the use in 
another assay as a solution is injected that will break the specific interaction 
between the ligand and the analyte while still leaving the ligand covalently 
bound to the chip surface. A typical cycle will end with buffer injected to 
reestablish the baseline ensuring no analyte remains bound to the surface of 
the sensor.  
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Figure 4.6. A sensogram showing the steps of an SPR assay. Step one shows the 
baseline; Step two shows association; Step three shows disassociation; after this buffer 
is injected to re-establish the baseline and check all the analyte has been removed. 
Figure recreated from Cullen et al. (1987). 
 
This chapter will discuss the cloning and over-expression of mPrxII and ET-Srx, 
as well as the chemical conjugation to produce an mPrxII-ET-Srx complex in 
order to fully investigate the interactions between hSrx and the decameric form 
of PrxII. The complex stoichiometry was analyzed using a calibrated gel 
filtration column and the produced complex was placed into crystallization trials. 
A potential interaction with PDCL3 was analyzed by native gel electrophoresis 
and sucrose gradients. Surface plasmon resonance was also attempted to 
obtain kinetic data on the interactions between the proteins. 
4.2. Materials and Methods 
4.2.1. Cloning of ET-Srx 
The original Srx clone was supplied by Dr Kirsty Line, University of Exeter. 
4.2.1.1. Primer design 
The PCR reaction amplified the entire vector with the deletion incorporated into 
the oligonucleotide primers. Four primers were designed for this technique. 
SRXETF 5’ ATCCACTCGGGCCGCATCGC 3’ 
SRXETFT 5’ CCGCGCGCATATG ATCCACTCGGGCCGCATCGC 3’ 
SRXETR 5’ CACCAGGCCGCTGCTGTGATGATGATGATGATG 3’ 
1 
2 
3 
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SRXETRT 
5’CATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGATG
ATG 3’ 
4.2.1.2. SLIM PCR amplification  
PCR was carried out to amplify hSrx and the expression vector pET28a minus 
the deletion set by the primers. The PCR was performed in a total volume of 25 
µl containing 2.5 µl of 10 x Pfx buffer (Invitrogen, California, USA), 200 µM each 
dNTP, 1 mM MgSO4, 100 mM betaine, 10 pmol of each primer, 100 pg of the 
template hSrx, 0.5 U Taq DNA polymerase (New England Biolabs, 
Massachusetts, USA), 0.25 U Platinum Pfx DNA polymerase (Invitrogen, 
California, USA) and nuclease free water to adjust to the final volume. The 
reaction was hot started by heating to 98oC for 2 min, then cooling to 85oC at 
which point the DNA polymerase mixture was added. The PCR cycle consisted 
of 30 consecutive cycles of denaturation (15 s at 95oC), annealing (20 s at 
50oC) and polymerization (3.5 min at 68oC). The reaction was then subjected to 
a final extension step of seven minutes at 68oC. 
4.2.1.3. SLIM hybridization 
The conditions for the hybridization reaction were adapted from Chiu et al., 
(2004). The PCR mixture was diluted in 5 µl of fast enzyme buffer (Fermentas) 
and mixed with 5 U Dpn I. The mixture was incubated for 10 min at 37oC and 
then denatured by incubating at 99oC for 3 min. Hybridization was performed 
using two cycles of 65oC for 5 min and 30oC for 15 min. An aliquot of 20 µl from 
the PCR reaction was used to transform chemically competent E. coli One shot 
TOP10 (Invitrogen, California, USA). The mutation was confirmed by DNA 
sequencing (Geneservice, Oxford, UK). 
4.2.2. Site directed mutagenesis of hPrxII to mPrxII and Trx to mTrx 
4.2.2.1. Primer design 
Primers were designed using the www.bioinformatics.org/primerx tool. The 
primers were designed to be between 25-45 base pairs in length, have a 
melting temperature (TM) between 75-85oC and GC content between 40-60%. 
mPrxII Mutation C172S 
mPrxIIFC172S 5’ CATGGGGAAGTTAGTCCCGCTGGCTG 3’ 
mPrxIIRC172S 5’ CAGCCAGCGGGACTAACTTCCCCATG 3’ 
mPrxII Mutation C70S 
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mPrxIIFC70S 5’ CGCAAGCTGGGCAGTGAAGTGCTGG 3’ 
mPrxIIRC70S 5’ CCAGCACTTCACCTGCCCAGCTTGCG 3’ 
mTrx Mutation C35S 
mTrxFC35S 5’ CGTGGTGTGGGCCTAGCAAAATGATCAAG 3’ 
mTrxRC35S 5’ CTTGATCATTTTTGCTAGGCCCACACCACG 3’ 
mTrx Mutation C73S 
mTrxFC73S 5’ GAGTGTGAAGTCAAAAGCATGCCAACATTCC 3’ 
mTrxRC73S 5’ GGAATGTTGGCATGCTTTTGACTTCACACTC 3’ 
4.2.2.2. Site directed mutagenesis 
The Trx DNA was supplied by Dr Kamal Hamidi (University of Exeter). The 
hPrxII and Trx DNA was prepared using a mini prep kit (Fermentas) and carried 
out according to the manufacturer’s instructions. The mutagenesis was carried 
out following the manufacturer’s instructions using a QuikChange lightning site-
directed mutagenesis kit (Stratagene). The mutant DNA was then used to 
transform chemically competent E. coli XL10-Gold ultra-competent cells 
(Stratagene). The transformation mixtures were spread on LB agar plates 
containing the appropriate antibiotic selection and incubated at 37oC overnight. 
A single colony from the mutagenesis reaction was selected and grown 
overnight in 10 ml LB medium containing the appropriate antibiotic selection 
and the DNA was extracted and sent for sequencing to confirm the mutation 
(Geneservice, Oxford, United Kingdom). 
4.2.3. Expression of ET-Srx 
The ET-Srx/pET28a construct encoded for an N-terminal His-tag and was 
expressed under the control of the T7 promoter. The recombinant ET-Srx gene 
was transformed into the E. coli BL21 (DE3) (Merck Biosciences) expression 
cell line and these cells were used to inoculate 100 ml LB containing the 
appropriate antibiotic for selection. The starter culture was grown under 
agitation at 200 rpm overnight at 37oC and 10 ml used to inoculate fresh 1 L LB 
medium containing the appropriate antibiotic for selection, and was grown with 
agitation at 37oC until the OD600nm reached 0.6. IPTG was added to a final 
concentration of 1.0 mM and the culture incubated for a further 4 hours at 37oC. 
The E. coli cells were harvested by centrifugation (20,000 x g, 20 min, 4oC) 
using a Beckman JA-25.50 rotor. The cell pellet was stored at -20oC until further 
use. 
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4.2.4. Expression of mTrx 
The mTrx in pET30 Xa/LIC vector encoded for an N-terminal His-tag and was 
expressed under the control of the T7 promoter. The recombinant mTrx gene 
was transformed into the E. coli BL21 (DE3) (Merck Biosciences) expression 
cell line and these cells were used to inoculate 100 ml LB containing the 
appropriate antibiotic for selection. The starter culture was grown under 
agitation at 200 rpm overnight at 37oC and 10 ml was used to inoculate fresh 1 
L LB medium containing the appropriate antibiotic for selection, and was grown 
under agitation at 37oC until the OD600nm reached 0.8. IPTG was added to a final 
concentration of 1.0 mM and the culture incubated overnight at 37oC. The E. 
coli cells were harvested by centrifugation (20,000 x g, 20 min, 4oC) using a 
Beckman JA-25.50 rotor. The cell pellet was stored at -20oC until further use. 
4.2.5. Expression of mPrxII 
The mPrxII/pET28a construct encodes for an N-terminal His-tag and was 
expressed under the control of the T7 promoter. The expression was carried out 
as in methods 2.2.3 and the pellet stored at -20oC until further use. 
4.2.6. Protein purification of ET-Srx and mTrx 
4.2.6.1. Cell lysis 
The cell paste was re-suspended at 10% w/v in 50 mM Tris-HCl, pH 7.5, 0.5 M 
NaCl, 20 mM imidazole. Cells were disrupted by sonication as described in 
2.2.4.1. 
4.2.6.2. Purification buffers 
Buffer A – 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 20 mM imidazole 
Buffer B – 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 M imidazole 
Buffer C – 50 mM Tris-HCl, pH 7.5, 1 M NaCl 
4.2.6.3. Nickel affinity chromatography 
The nickel affinity chromatography was performed as in methods 2.2.4.3 using 
a six column volume gradient to 100% buffer B. The fractions containing protein 
were analyzed using SDS-PAGE as in methods 2.2.4.6. 
4.2.6.4. Gel filtration chromatography 
The protein fractions were pooled together and concentrated to a 2 ml sample 
to be loaded onto the GF column using the method described in 2.2.4.5. The 
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Superdex 200 HiLoad 16/60 (GE Healthcare) was equilibrated with one column 
volume of buffer C at a flow rate of 1 ml/min. The sample was loaded and 
fractions were collected over the elution volume (one column volume) and the 
absorbance measured at 280 nm. The fractions were analyzed using SDS-
PAGE as in methods 2.2.4.6. 
4.2.7. Protein purification of mPrxII 
4.2.7.1. Cell lysis  
Cell paste was re-suspended at 10% w/v in 100 mM Tris-HCl, pH 7.5, 0.5 M 
NaCl, 20 mM imidazole and cell lysis was carried out as in methods 2.2.4.1. 
4.2.7.2. Purification buffers 
Buffer A – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 20 mM imidazole 
Buffer B – 100 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 M imidazole 
Buffer C – 100 mM Tris-HCl, pH 7.5, 1 M NaCl 
4.2.7.3. Nickel affinity and gel filtration chromatography 
The nickel affinity chromatography was performed as in methods 2.2.4.3 using 
a six column volume gradient to 100% buffer B. The fractions containing protein 
were analyzed using SDS-PAGE as in methods 2.2.4.6. The fractions 
containing protein were pooled together and concentrated to a 2 ml sample to 
be loaded on to the GF column using the method described in 2.2.4.5. The 
fractions were analyzed using SDS-PAGE as in methods 2.2.4.6. 
4.2.8. Conjugation of the mPrxII to both mTrx and ET-Srx 
The conjugation of mPrxII to ET-Srx was adapted from Jonsson et al., (2008b). 
A similar method has also been used to study the mixed disulfide complexes of 
Trx (Maeda et al., 2006). Once mPrxII had been purified as described above the 
fractions from GF containing the protein of interest were pooled together and 
500 µM 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) added. The protein was run 
down a GF Superdex 200 column to remove excess DTNB and generated TNB. 
Purified ET-Srx or mTrx was then titrated into the mPrxII solution until no further 
release of TNB was observed at A412nm. The new complex was then run down a 
GF Superdex 200 column to remove produced TNB and excess ET-Srx or 
mTrx. 
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4.2.9. Crystallization of both complexes 
Microbatch crystallization trials were set up in a Hampton 96 well plate using an 
Oryx 6 crystallization robot (Douglas Instruments, UK). A range of different 
commercial screens were used for the microbatch trials (as in methods 3.2.4.2). 
The final droplet volume was varied between 1 µl and 2 µl dependent on the 
amount of protein solution available. The droplet contained a 50:50 ratio of 
protein solution to screen ratio. The droplet was covered with Al’s oil (50:50 mix 
of silicon oil and paraffin). The plates were stored at 18oC and regularly 
checked for crystals using a light microscope. 
4.2.10. Interaction with PDCL3 
4.2.10.1. Probing the interaction via native gel electrophoresis 
Reactions were set up between hPrxII and PDCL3 and between hPrxII and 
fluorescent labelled PDCL3 (PDCL3*568). Reactions were set up in a 1:1 ratio (1 
µg:1 µg) and a 3:1 ratio (3 µg:1 µg) and made up to an overall reaction volume 
of 10 µl with buffer (20 mM HEPES, 50 mM KCl, pH 8.0). A second round of 
reactions also took place that contained 1 mM TCEP (reducing agent). The gel 
was visualized for fluorescence using a Typhoon (Ex-532 nm, Em-610BP30) 
(Amersham Biosciences) and then Coomassie blue stain. 
4.2.10.2. Native SDS-PAGE 
The gel was made with a 6% resolving gel and a 3.3% stacking gel. 
 
Resolving Gel 7.5 ml Acrylamide (40%)  
 3.7 ml Bis-acrylamide (2 %) 
 18.55 ml 1 M Tris (pH8.8) 
 25 µl TEMED 
 10 µl APS 
 
Stacking Gel 4.0 ml Acrylamide (40%) 
 3.0 ml Bis-acrylamide (2 %) 
 1 M Tris-HCl pH 8.8 
 50 µl TEMED 
 15 µl APS 
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The gels were run using Electrophoresis Buffer (1x): 0.6 g Tris, 2.9 g glycine 
and ddH2O to 200 ml. A 10% volume of sample buffer (190 µl Tris-HCl pH 8.8, 
1.26 ml glycerol and 50 µl ddH2O + Bromophenol blue to colour) was added to 
the sample before running at 90-110 V at 4oC in a Hoeffer Mini-gel system. 
4.2.10.3. Probing the interaction via sucrose gradients 
Sucrose gradients were prepared as below and PDCL3*568, incubated with 
PrxII (1:1 ratio, 50 µg: 50 µg), was applied to the sucrose gradient. The sucrose 
gradient was made using two buffers.  
Buffer A – 20 mM HEPES, pH 8.0, 150 mM KCl, 0.01% LDAO, 15% glycerol, 1 
mM TCEP.  
Buffer B – 20 mM HEPES, pH 8.0, 150 mM KCl, 0.01% LDAO, 15% glycerol, 1 
mM TCEP, 40% sucrose. 
10 – 40% sucrose gradient solutions were made in 2.5% steps and stored at -
20oC. Gradients were poured into Beckman Ultra-Clear (13 x 51 mm) centrifuge 
tubes (Beckman) using 0.4 ml of each solution starting with 40% and 
decreasing the sucrose solution percentage at each level. Each layer is frozen 
before the next layer was added and the gradient had a total volume of 5.2 ml. 
The gradients were centrifuged after addition of 50 µl of sample and tubes spun 
at 48,000 rpm using a Beckman Coulter Optima L-100 XP ultracentrifuge 
(Beckman) with an SW55 Ti rotor at 4oC for 18-19 hours. 600 µl fractions were 
collected by piercing the bottom of the tubes and collecting drop-wise. This was 
repeated using three truncations of PDCL3 (1-211, 90-end and 90-226). 
4.2.10.4. Identification of potential binding partners for hPrxII 
4.2.10.4.1. Confirmation of binding to a Zymo His-Affinity 
column 
First the binding of the PrxII protein to a Zymo His-Affinity column was 
confirmed. An aliquot of 200 µl fully mixed Zymo His-Affinity gel was placed into 
two Zymo columns and the columns pulse spun for 5 sec (13,000 rpm max). 50 
µl of hPrxII was then added to the top of each column along with 250 µl His-
binding buffer (50 mM Na2HPO4/ NaH2PO4), 300 mM NaCl, 10 mM imidazole, 
0.03% Triton-X-100, pH 7.7) to one column and 250 µl E. coli post spin lysate to 
the other. The columns were resuspended and allowed to incubate for ~5 min 
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followed by a pulse spin for 7 sec (13,000 rpm max). A sample of the 
flowthrough was taken for SDS-PAGE analysis before being washed three 
times with 250 µl His-binding buffer followed by a pulse spin for 5 sec (13,000 
rpm max). A sample of the first wash was taken for SDS-PAGE analysis. The 
protein was then eluted from the columns by resuspension with 100 µl His-
Elution buffer (50 mM Na2HPO4/ NaH2PO4, 300 mM NaCl, 250 mM imidazole, 
pH 7.7) for 1 min followed by a pulse spin for 7 sec (13,000 rpm max) and a 
sample taken for SDS-PAGE analysis. 
4.2.10.4.2. Identification of binding partners using the Zymo 
His-Affinity column 
Adherent human colon carcinoma cells (BE) cell lysate was prepared from six 
175 cm2 flasks of cells lysed in 2 ml HARMS buffer (250 mM sucrose, 10 mM 
triethanolamine, 10 mM acetic acid, 1 mM EDTA pH 7.45 + complete mini 
EDTA-free protease inhibitor mix (Roche) with bug buster. The lysate was spun 
down and the soluble fractions aliquoted into 200 µl samples and snap frozen in 
liquid nitrogen and stored at -80oC until further use. 
A 100 µl Zymo-His column was run with the addition of 15 µl purified hPrxII 
diluted with 200 µl of 20 mM HEPES, 50 mM KCl, pH 8.0 buffer and incubated 
for seven min with mixing. The flowthrough was separated by pulse spin for 
seven sec (13,000 rpm max). The resin was then resuspended with 100 µl BE 
cell lysate diluted with 400 µl 20 mM HEPES, 50mM KCl, pH 8.0 buffer and 
mixed on a roller mixer at 4oC for 45 min. The flowthrough was then separated 
by a pulse spin for 10 sec (13,000 rpm max). Three washes were then carried 
out using 250 µl His-binding buffers and a pulse spin was carried out for five 
sec. Elution was then carried out by resuspending the resin with 80 µl of His-
Elution buffer for two min and the elution sample separated by a pulse spin for 
seven sec (13,000 rpm max). Samples of the BE cell lysate and the elution from 
the column were analyzed by SDS-PAGE and the elution sample was sent for 
analysis by mass spectrometry. 
4.2.11. Surface plasmon resonance assay 
This work was undertaken in collaboration with Dr Robert Parker (University of 
Exeter) and run on a SensiQ® Discovery SPR machine. For these experiments 
a COOH1 (2D surface) chip was used. A second round of experiments was also 
undertaken using a ProteOn XPR36 (BIORAD) machine in collaboration with 
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BIORAD and Dr Kamal Hamidi (University of Exeter). For these experiments a 
GLC (alginate) sensor chip was used.  
In all experiments amide coupling immobilization was achieved using EDC and 
Sulfo-NHS, and capping (or deactivation) was achieved by the injection of 
ethanolamine. The experiments were designed as below. The proteins were 
prepared as before (as described in methods 2.2.4) except the final proteins 
were buffer exchanged into 50 mM Na2PO4/ NaH2PO4, 0.1 M NaCl, pH 7.5. 
4.2.11.1. Interactions between hyperoxidised hPrxII and Srx 
Ligand: Srx 
Analyte: Prx (SOOH) 
Buffer: 50 mM Na2PO4/ NaH2PO4, 0.1 M NaCl, 1 mM ATP, 1 mM MgCl2, pH 7.5 
The ligand was bound to the surface by the injection of 30 µg/ml of ligand. A 
concentration between 0.1 µM, 75 nm, 50 nM, 25 nM and 10 nM of analyte was 
injected to test for an interaction between the proteins. 
4.2.11.2. Interaction between disulfide hPrxII and Trx 
Ligand: Trx 
Analyte: Prx (S-S) 
Buffer: 50 mM Na2PO4/ NaH2PO4, 0.1 M NaCl, pH 7.5  
The ligand was bound to the surface by the injection of 30 µg/ml of ligand. A 
concentration between 0.1 µM, 75 nm, 50 nM, 25 nM and 10 nM of analyte was 
injected to test for an interaction between the proteins. 
4.3. Results 
4.3.1. Cloning of ET-Srx 
Plasmid DNA encoding the hSrx gene was used as a template for the SLIM 
reaction. The SLIM PCR amplification of the entire vector minus the deletion set 
by the primers was carried out as in methods 4.2.1.2. The PCR product 
underwent hybridization as in methods 4.2.1.3 creating products with 
complementary 5’ and 3’ overhangs at opposite termini. These overhangs 
allowed the DNA to form circular DNA that can then be transformed into 
chemically competent E. coli cells. The transformation yielded eight colonies of 
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which seven contained the desired mutation. Presence of the mutation was 
confirmed by DNA sequencing (APPENDIX 7.8) (Geneservice, Oxford, UK). 
4.3.2. Site directed mutagenesis of hPrxII to mPrxII 
The site-directed mutagenesis of hPrxII to mPrxII was carried out as described 
in methods 4.2.2.2. The DNA was then transformed into the E.coli expression 
cell line BL21 (DE3) (Merck Biosciences). DNA sequencing (APPENDIX 7.9) 
(Geneservice, Oxford, UK) was used to confirm the mutation of the cysteine 
residues at position 172 and position 70 to a serine residue. 
4.3.3. Expression of ET-Srx 
The pET28a/ET-Srx construct was transformed into the E. coli expression strain 
BL21 (DE3) (Merck Biosciences). ET-Srx protein expression was under the 
control of the T7 promoter and was induced by IPTG. The over-expression of 
ET-Srx was investigated by induction studies to obtain the best conditions for 
over-expression. The optimal over-expression was achieved as described in 
methods 4.2.3 and the over-expression resulted in soluble protein being 
produced at the expected size (~13 KDa). 
4.3.4. Expression of mTrx 
The pET30 Xa/LIC/mTrx construct was transformed into the E. coli expression 
strain BL21 (DE3) (Merck Biosciences). The mTrx protein expression was under 
the control of the T7 promoter and was induced by IPTG. The over-expression 
of mTrx was investigated by induction studies to obtain the best conditions for 
over-expression. The optimal over expression was achieved as described in 
methods 4.2.4 and the over-expression resulted in soluble protein being 
produced at the expected size (~12 KDa).  
4.3.5. Expression of mPrxII 
The pET28a/mPrxII construct was transformed into the E. coli expression strain 
BL21 (DE3) (Merck Biosciences). The mPrxII protein expression was under the 
control of the T7 promoter and was induced by IPTG. The over-expression of 
mPrxII was investigated by induction studies to obtain the best conditions for 
over-expression. The optimal over-expression was achieved as described in 
methods 4.2.4 and the over-expression resulted in soluble protein being 
produced at the expected size (~24 KDa).  
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4.3.6. Purification of ET-Srx and mTrx 
One litre of ET-Srx culture produced 1.6 g of cell paste and one litre of mTrx 
culture produced 2.8 g of cell paste. After cell lysis and centrifugation (as 
described in methods 2.2.4.1) the supernatant was purified using nickel affinity 
chromatography and gel filtration chromatography (as described in sections 
4.2.5.3 and 4.2.5.4.) 
4.3.6.1. ET-Srx nickel affinity chromatography 
The clarified cell extract was applied to a nickel column as described in 
methods 4.2.6.3 producing the trace seen in figure 4.7. The fractions were 
analyzed using SDS-PAGE as described in methods 2.2.3.6 (figure 4.8). The 
fractions containing ET-Srx were pooled together and concentrated for gel 
filtration chromatography (as in methods 4.2.6.4). 
 
Figure 4.7. Elution profile of ET-Srx (blue line) from nickel affinity chromatography. 10 
ml fractions were collected throughout the entire elution. The green line shows the % 
imidazole concentration. The fractions that showed a band of the correct size on SDS-
PAGE are indicated by a red bar. 
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Figure 4.8. SDS-PAGE analysis of the ET-Srx nickel affinity chromatography elution. 
Lane 1, molecular weight marker; Lane 2, sample from fraction at 270 ml (middle of the 
elution peak). 
4.3.6.2. mTrx nickel affinity chromatography 
The clarified cell extract was applied to a nickel column as described in 
methods 4.2.6.3 producing the trace seen in figure 4.9. The fractions were 
analyzed using SDS-PAGE as described in methods 2.2.3.6 (figure 4.10). The 
fractions containing mTrx were pooled together and concentrated for gel 
filtration chromatography. 
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Figure 4.9. Elution profile of mTrx (red line) from nickel affinity chromatography. 10 ml 
fractions were collected throughout the entire elution. The green line shows the % 
imidazole concentration. The fractions that showed a band at the correct size on SDS-
PAGE are indicated by a red bar. 
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Figure 4.10. SDS-PAGE analysis of the mTrx nickel affinity chromatography elution. 
Lane 1, molecular weight marker; Lane 2, sample from middle of peak from nickel 
affinity chromatography (~290 ml). 
4.3.6.3. ET-Srx gel filtration chromatography 
Gel filtration chromatography was used as a final step of the purification and as 
a tool for the estimation of the oligomeric state of the protein. The concentrated 
protein sample was loaded onto a Superdex 200 column and run as described 
in methods 4.2.6.4, the elution profile of which can be seen in figure 4.11. The 
peak fractions were analyzed by SDS-PAGE (figure 4.12) and those that 
contained ET-Srx were pooled and concentrated. Pure ET-Srx protein was 
obtained and eluted at ~93 ml from the calibrated gel filtration corresponding to 
a molecular weight of ~13 kDa suggesting it was present as a monomer. 
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Figure 4.11. Elution profile from the gel filtration column for ET-Srx (red line). 1 ml 
fractions were collected throughout the elution volume. Peak 1 (92 ml) corresponds to 
the monomeric ET-Srx (~13 kDa). The molecular weight was determined using a 
calibrated Superdex 200 column (Appendix 7.1). 
 
Figure 4.12. SDS-PAGE analysis of the elution from the ET-Srx gel filtration column. 
Lane 1, molecular weight marker; Lane 2, sample from peak 1 (~93 ml). 
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4.3.6.4. mTrx gel filtration chromatography 
Gel filtration chromatography was used as a final step of the purification and as 
a tool for the estimation of the oligomeric state of the protein. During the first gel 
filtration run the protein eluted at 86 ml which corresponds to a MW of ~24 kDa 
suggesting it was present as a dimer whereas Trx is functionally active as a 
monomer (as discussed in section 1.7). The protein was then incubated with a 
final concentration of 5 mM DTT to break any potential disulfide bonds between 
monomeric units and then loaded onto a Superdex 200 column and run as 
described in methods 4.2.6.4. The elution profile can be seen in figure 4.13. The 
peak fractions were analyzed by SDS-PAGE (figure 4.14) and those that 
contained mTrx were pooled and concentrated. After treatment with DTT pure 
Trx protein was obtained and the protein eluted at ~93 ml, corresponding to a 
molecular weight of ~12 kDa, suggesting it was present as a monomer. 
 
Figure 4.13. Elution profile of mTrx (blue line) from gel filtration chromatography. 
Fractions were collected at 1 ml intervals throughout the elution volume. Peak 1 (~44 
ml) corresponds to the void volume; Peak 2 (~93 ml) corresponds to the monomeric 
Trx (12 kDa); Peak 3 (~125 ml) corresponds to the DTT used to separate the Trx 
dimer. 
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Figure 4.14. SDS-PAGE analysis of the mTrx gel filtration chromatography elution. 
Lane 1, molecular weight marker; Lane 2, sample from peak 2 (~93 ml) corresponding 
to a MW of ~12 kDa. 
4.3.7. Purification of mPrxII 
One litre of culture produced 2.2 g of cell paste and after cell lysis and 
centrifugation (as described in methods 2.2.4.1) the supernatant was purified 
using nickel affinity chromatography and gel filtration chromatography (as 
described in sections 4.2.6.3). 
4.3.7.1. Nickel affinity and gel filtration chromatography 
The clarified cell extract was applied to a nickel column as described in 
methods 4.2.7.3 producing the trace seen in figure 4.15. The fractions were 
analyzed using SDS-PAGE as described in methods 2.2.3.6 (figure 4.16). The 
fractions containing ET-Srx were pooled together and concentrated for gel 
filtration chromatography and the column ran as in methods 4.2.7.3 producing 
the trace seen in figure 4.17. The fractions were analyzed using SDS-PAGE as 
described in methods 2.2.3.6 (figure 4.18). Pure mPrxII protein was obtained 
and eluted at ~58 ml from the calibrated gel filtration corresponding to a 
molecular weight of ~250 kDa suggesting it was present as a decamer.  
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Figure 4.15. Elution profile of mPrxII from nickel affinity chromatography (blue line). 
Fractions were collected at 10 ml intervals throughout the entire elution. The green line 
shows the % imidazole concentration. The fractions that showed a band of the correct 
size on SDS-PAGE are indicated by a red bar. 
 
Figure 4.16. SDS-PAGE analysis of peak fractions from mPrxII nickel column. Lane 1, 
molecular weight marker; Lane 2, sample from the middle of the peak from the nickel 
chromatography elution (~460 ml) 
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Figure 4.17. Elution profile of mPrxII from gel filtration chromatography. Peak 1 
corresponds to the void volume (~44 ml); Peak 2 corresponds to the decameric form 
(~250 kDa) of the protein (~56 ml). 
 
Figure 4.18. SDS-PAGE analysis of peak fraction from mPrxII gel filtration column. 
Lane 1, molecular weight marker; Lane 2, sample from peak 2 (~56 ml). 
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4.3.8. Conjugation of mPrxII to ET-Srx 
Conjugation of mPrxII to ET-Srx was carried out as in methods 4.2.8. In the first 
step the free peroxidatic cysteine on mPrxII was reacted with DTNB. The 
formation of the mPrxII-TNB complex was confirmed by the addition of 
dithiothreitol and monitoring the release of TNB by measuring A412nm. After this 
step the protein-DTNB mix was run down the GF column to remove excess 
DTNB before the addition of ET-Srx. The second step was to react the mPrxII-
TNB with ET-Srx. As the ET-Srx has a higher affinity to the peroxidatic cysteine 
the complex was formed replacing the TNB. This was confirmed by watching 
the release of the TNB at A412nm. After each step the proteins were run down a 
Superdex 200 column as in methods 4.2.6.4 the trace of which can be seen in 
figure 4.19. 
 
Figure 4.19. The elution profile from the gel filtration column for mPrxII-ET-Srx (red 
line). Peak 1 corresponds to the void volume (~44 ml); Peak 2 corresponds to the 
mPrxII-ET-Srx complex (~56 ml); Peak 3 corresponds to Srx (~92 ml); Peak 4 
corresponds to TNB produced in the conjugation reaction. 
 
The gel filtration elution of ET-Srx produced a peak at ~92 ml. The molecular 
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Superdex 200 column (appendix 7.1). This estimates the molecular weight at 
~13 kDa which corresponds to the monomeric truncated protein. The gel 
filtration elution of mPrxII produced a peak at ~58 ml. The molecular weight is 
estimated at ~245 kDa which corresponds to the decameric form of mPrxII. 
Once this protein had been reacted with DTNB the elution volume decreased to 
~56 ml and the molecular weight was estimated at slightly above that expected 
for the decameric protein. A small peak was also seen at the very end of the 
column corresponding to un-reacted DTNB and produced TNB. This complex 
was then reacted with ET-Srx and the elution volume increased to ~55 ml. The 
molecular weight was estimated at ~300 kDa. SDS-PAGE analysis of the peak 
at ~56 ml showed the presence of both mPrxII and ET-Srx (figure 4.20). 
 
Figure 4.20. SDS-PAGE analysis of peak 2 from the gel filtration column elution of 
mPrxII-Et-Srx. Lane 1 molecular weight marker; Lane 2, sample from peak 2, this 
shows a band at the size of mPrxII (~25 kDa) and a band at the size of ET-Srx (~13 
kDa). 
 
Using the calibration curve from the gel filtration column the presence of the 
decameric form of the protein (~245 kDa) it is evident that there is ~65 kDa of 
ET-Srx attached to the mPrxII. This would indicate that we are seeing five 
molecules of ET-Srx reacting with one mPrxII decamer. 
mPrxII 
ET-Srx 
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4.3.9. Conjugation of mPrxII to mTrx 
Conjugation of mPrxII to mTrx was carried out as in methods 4.2.8. In the first 
step the free peroxidatic cysteine on mPrxII was reacted with DTNB. The 
formation of the mPrxII-TNB complex was confirmed by the addition of 
dithiothreitol and monitoring the release of TNB by meaduring A412nm. The 
second step was to react the mPrxII-TNB with mTrx. As the mTrx has a higher 
affinity to the peroxidatic cysteine the complex was formed replacing the TNB. 
This was confirmed by watching the release of TNB at A412nm. After each step 
the proteins were run down a Superdex 200 column as in methods 4.2.6.4, the 
trace of which can be seen in figure 4.21. 
 
Figure 4.21. The elution profile from the gel filtration column for mPrxII-mTrx (blue 
line). Peak 1 corresponds to the mPrxII-mTrx complex (~54 ml); Peak 2 corresponds to 
un-reacted mTrx (~93 ml). Peak 3 corresponds to TNB released as part of the reaction 
(~110 ml). 
 
The gel filtration elution of the mTrx produced a peak at ~93 ml. The molecular 
weight of this peak is estimated at ~12 kDa which corresponds to the 
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monomeric form of the Trx protein. The gel filtration elution of mPrxII produced 
a peak at ~58 ml. The molecular weight is estimated at ~250 kDa which 
corresponds to the decameric form of mPrxII. Once this protein had been 
reacted with DTNB the elution volume decreased to ~55 ml and the molecular 
weight was estimated at slightly above that expected for the decameric protein. 
A small peak was also seen at the very end of the column corresponding to un-
reacted DTNB and produced TNB. This complex was then reacted with mTrx 
and the elution volume decreased to ~54 ml. The molecular weight was 
estimated at ~367 kDa. SDS-PAGE analysis of the peak at ~54 ml showed the 
presence of both mPrxII and mTrx (figure 4.22.). 
 
Figure 4.22. SDS-PAGE analysis of peak 2 from the gel filtration column elution of 
mPrxII-mTrx. Lane 1 molecular weight marker (Spectra™ multicolour broad range 
protein ladder (Fermentas) (appendix 7.10); Lane 2, sample from peak 2, showing a 
band at the size of mPrxII (~25 kDa) and a band at the size of mTrx (~12 kDa). 
 
Using the calibration curve from the gel filtration column and the presence of the 
decameric form of the protein (~245 kDa) it is evident that there is ~120 kDa of 
mTrx attached to the mPrxII. This would indicate that we are seeing 10 
molecules of mTrx reacting with one mPrxII decamer. 
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4.3.10. Interaction with PDCL3 
4.3.10.1. Probing the interaction via native gel electrophoresis 
The hPrxII was run on a native gel with PDCL3 and PDCL3*568 as in methods 
4.2.10.1 (figure 4.23). The hPrxII was also run on a native gel in the presence of 
a reducing agent (TCEP) with PDCL3 and PDCL3*568 as in methods 4.2.10.1 
and the fractions analyzed using SDS-PAGE (gel not shown). The gels were 
also visualized on a Typhoon (Ex-532nm, Em-610BP30) (figure 4.24). 
 
Figure 4.23. Native gel analysis of complex formation between hPrxII and PDCL3. 
Lane 1, 1 µg PrxII; Lane 2, 3 µg PrxII Lane 3, 1 µg PDCL3; Lane 4, 1 µg PDCL3*568; 
Lane 5, 1 µg PrxII + 1 µg PDCL3; Lane 6, 1 µg PrxII + 1 µg PDCL3*568; Lane 7, 3 µg 
PrxII + 1 µg PDCL3*568. 
 
PDCL3 
hPrxII 
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Figure 4.24. Fluorescence image of complex formation between hPrxII and PDCL3. 
Lane 1, 1 µg PrxII; Lane 2, 3 µg PrxII Lane 3, 1 µg PDCL3; Lane 4, 1 µg PDCL3*568; 
Lane 5, 1 µg PrxII + 1 µg PDCL3; Lane 6, 1 µg PrxII + 1 µg PDCL3*568; Lane 7, 3 µg 
PrxII + 1 µg PDCL3*568. 
 
It was confirmed that hPrxII ran well on a native gel with a sharp band obtained 
with both with a fresh and samples after snap freezing in liquid nitrogen and 
stored at -80oC overnight. Addition of TCEP did affect the running of hPrxII 
showing some slight smearing, but this did not break down the hPrxII decamer. 
No shifting was seen in any of the lanes containing both hPrxII and either 
PDCL3 and PDCL3*568.    
4.3.10.2. Probing the interaction via sucrose gradients 
The interaction between hPrxII and PDCL3 was best analysed using sucrose 
gradients rather than the slightly dissociative conditions of the native gel 
system. An interaction was observed between hPrxII and PDCL3 in fractions 6 
and 7 from the sucrose gradient (Figures 4.25 and 4.26). The complex was 
estimated to migrate at ~ 200 – 300 kDa. This estimates the binding ratio to be 
10:1 (PDCL3: hPrxII(decamer)). When the sucrose gradients were run with the 
three truncated forms of the PDCL3 (1-211, 90-end and 90-226) no interaction 
was seen between the two protein fragments that start at residue 90 suggesting 
the interaction site was located on the N-terminus. 
PDCL3 
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Figure 4.25. SDS-PAGE analysis of hPrxII interacting with PDCL3 on a sucrose 
gradient. M is the Sigma SDS 7 molecular weight marker (Appendix 7.12) and the 
numbers correspond to the fraction collected from sucrose gradient (as in methods 
4.2.10.3). The gel on the left is PDCL3 run without hPrxII, the gel on the right is run 
with hPrxII. 
 
Figure 4.26. Fluorescence image hPrxII interacting with PDCL3*568 on a sucrose 
gradient with only PDCL3*568 being visualised. The numbers correspond to the fraction 
collected from the sucrose gradient (as in methods 4.2.10.3). The gel on the left is 
PDCL3 run without hPrxII, the gel on the right is run with hPrxII.  
4.3.10.3. Identification of potential binding partners for hPrxII 
4.3.10.3.1. Confirmation of binding to a Zymo His-Affinity 
column 
The hPrxII binding to the Zymo His-Affinity was confirmed as in methods 
(4.2.10.4.1) and the fractions analyzed by SDS-PAGE (figure 4.27). Both 
proteins (PrxII and PrxII + E.coli lysate) behaved identically on the Zymo 
columns, binding without any problem. 
Complex 
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Figure 4.27. SDS-PAGE analysis of hPrxII binding to the Zymo His-Affinity column. 
Lane 1, Sigma SDS 7 molecular weight marker (Sigma)(Appendix 7.12); Lane 2, post 
resin lysate (-); Lane 3, post resin lysate (+); Lane 4, wash 1 (-); Lane 5, wash 1 (+); 
Lane 6, elution (-); Lane 7, elution (+). (-) is without E. coli lysate added, (+) is with E. 
coli lysate added. 
4.3.10.3.2. Identification of binding partners using the Zymo 
His-Affinity column 
The hPrxII was bound to the Zymo His-Affinity column and the BE cell lysate 
was run over it as in methods 4.2.10.4.2. SDS-PAGE analysis of the elution 
confirmed that some proteins had been pulled down by the hPrxII attached to 
the column (figure 4.28). The elution sample was sent for mass spectrometry 
sequencing to identify the proteins content using trypsin digestion and 
comparison of the fragment pattern against known protein fingerprints. These 
results are still awaiting analysis. 
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Figure 4.28. SDS-PAGE analysis of hPrxII pull down from the BE cell lysate from the 
Zymo His-Affinity column. Lane 1, Sigma SDS 7 molecular weight marker (Sigma) 
(Appendix 7.12); Lane 2, BE cell lysate; Lane 3, elution 1 sample. 
4.3.11. Surface plasmon resonance assay results 
In all assays (both BIORAD and “in house”) the ligand was found to bind to the 
surface of the chip in varying amounts but within the amounts needed to allow 
for data to be collected (figure 4.29). No results were obtained for these assays 
due to non specific binding (figure 4.30) dominating the signal or due to a lack 
of an interaction being observed between the ligand and the analyte (data not 
shown). Potential reasons for this are discussed below. 
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Figure 4.29. Typical sensogram for the immobilization of the ligand to the carboxylic 
acid surface of the gold chip. 
 
Figure 4.30. Typical sensogram showing non-specific binding in the assay between the 
ligand with injection of the analyte (association) followed by injection of buffer 
(disassociation) and the typical sensogram of the reference channel. 
4.4. Discussion 
Both sets of complex formation binding stoichiometry results are based upon 
the elution volumes from a calibrated Superdex 200 gel filtration column 
(Appendix 7.1). Size-exclusion chromatography separates a protein based on 
its Stokes radius (Irvine, 2001), which is based on the molecular weight and 
shape. Prx has been seen to elute at the volume expected for the mass of the 
decameric state of the protein despite its toroidal shape. The binding of Trx and 
Srx to the decameric hPrxII is assumed to not affect the overall shape on 
complex formation. 
4.4.1. The mPrxII-ET-Srx Complex 
Both proteins were purified in a state required to form the complex. The hPrxII 
was over-expressed and purified in the decameric form and remained in the 
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decameric form throughout complex formation and Srx was over-expressed and 
purified as its functionally active monomer. 
The Prx/Srx complex has been studied previously by both crystallography and 
molecular modelling. To date only the crystal structure of hPrxI-Srx complex 
(PDB: 2RII) has been described (Jonsson et al., 2008; Jonsson et al., 2009). 
This complex was achieved with hPrxI in its homodimeric form and the complex 
contained one PrxI dimer and two Srx monomers. From this structure it would 
be easy to postulate that the PrxII decamer would be able to accommodate 10 
Srx proteins around it. 
The SDS PAGE results described in this chapter show that the second peak on 
the gel filtration column ~56 ml contains both the mPrxII and ET-Srx protein. 
Using a calibration curve for the Superdex 200 column the size of the complex 
was estimated to be ~310 kDa taking into account both the ~245 kDa size of the 
decameric mPrxII protein and the ~65 kDa of ET-Srx attached to it this is 
assuming that the stokes radius does not change too much. This would equate 
to five ET-Srx proteins attached to hPrxII suggesting that in this form and under 
these conditions, each individual dimer in the decamer is able to bind one ET-
Srx molecule. 
The crystal structure of the decameric form of the protein previously studied in 
Exeter (PDB: 1QMV) shows the protein has two active sites per homodimer and 
that the CysP in all of the active sites of the decamer is present in the sulfinic 
acid form. Previous work on modelling of the hPrxII decamer in complex with 
the Srx protein had suggested that the hPrxII was able to form an interaction 
with Srx at each of the active sites resulting in a 10:1 ratio of Srx to PrxII 
(decamer). The model shows Srx bound to all 10 potential sites in the PrxII 
molecule because there should be no steric reason why the PrxII molecule 
should not be able to be reduced by 10 Srx molecules at once. The model 
however does not take into account any potential allosteric effects that might be 
caused by the interaction of the two proteins. The complex formation as seen 
from the results in this chapter suggests that out of the ten available sites on 
mPrxII only five show an interaction with Srx. 
150 
 
 
Figure 4.31. The axial (left) and side (right) view of the surface of the model produced 
in Lee et al., (2006). The Prx monomers are shown in light blue and dark blue while the 
Srx monomers are shown in purple and orange. The model shows no contact between 
the Srx monomers suggesting that all available sites could show an interaction. 
 
The first crystal structure reporting the interactions between a Prx and Srx 
(PDB: 2RII) (Jonsson et al., 2008b) shows a large movement in the C-terminal 
of Prx, which could potentially be the cause of the “closing off” of one of the 
active sites. The structure was analyzed by aligning five copies of the dimeric 
complex (PDB: 2RII) to the five dimers in the decameric hPrxII structure (PDB: 
1QMV) and the differing residues mutated in PyMol Delano Scientific.  
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Figure 4.32. The axial (left) and side (right) view of the surface of the complex between 
hPrxI and Srx (PDB: 2RII) superimposed on to the decameric structure of hPrxII (PDB: 
1QMV). Srx molecules are shown in red and blue with the individual monomers of the 
hPrx shown in cyan and magenta. The “backside” interaction can be seen between the 
hPrxI monomer and a Srx molecule (figure created using PyMol DeLano Scientific). 
 
Looking at the surface view of this model it is possible that the surface of an Srx 
protein attached to one homodimer can interfere with the surface of a Prx of the 
neighbouring homodimer within the decamer. One explanation for the binding 
ratio could be that to stop the surface interference between the Srx and the Prxs 
on adjacent homodimers only one active site at each homodimer allows an Srx 
protein to bind. This could also help to explain why no X-ray diffracting crystals 
have been produced from this complex if different active sites are used. If this 
were the case it would be difficult to produce a protein complex of sufficient 
homogeneity required to obtain X-ray quality crystals. 
4.4.2. The mPrxII-mTrx Complex 
Both proteins were purified in a state required to form the complex. The hPrxII 
was over-expressed and purified in the decameric form and remained in the 
decameric form throughout complex formation (as mentioned previously). The 
mTrx originally formed a previously reported homodimer (Weichsel et al., 1996) 
even though it lacked the Cys73 required to form the disulfide usually 
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accountable for this. The previous structure paper (Weichsel et al., 1996) shows 
that the Trx molecule forms hydrogen bonds between the mutated Ser73 
residues. In the study reported here this interaction was broken and did not re-
form when the protein was stored for 3 months at -20oC (data not shown). 
Looking at the results from gel filtration chromatography the complex between 
mPrxII and mTrx has an estimated molecular mass of ~370 kDa. The mPrxII 
decamer is ~250 kDa in size leaving ~120 kDa unaccounted for. This would 
indicate that there are 10 molecules of mTrx interacting with one mPrxII 
decamer. To better understand this potential interaction, the way in which Trx 
binds to the PrxII is discussed to give a better understanding into why a 10:1 
ratio is seen where a potential 5:1 ratio was observed with Srx. 
The interaction between thioredoxin and its target proteins has been researched 
before in three major studies. The first two were NMR structural determinations 
of two disulfide bonded complexes between a mutant form of the hTrx and 
some short synthetic peptide fragments derived from the transcription factors 
NF-kB and Ref-1 (Qin et al., 1995; Qin et al., 1996) and the third was a crystal 
structure of a mutant HvTrxh2 from barley and one of its protein substrates, 
barley α-amylase/subtilisin inhibitor (BASI) (Maeda et al., 2006). 
It is understood from the early work on the Trx structure that there is a switch in 
the hydrophobic surface of the protein around the redox active cysteine 
residues between the oxidized and reduced form of the protein (Qin et al., 
1994). The Prx molecule could bind to the hydrophobic region around the 
oxidized Trx cysteines and this suggests a mechanism for recognition of the 
oxidized form over the reduced form. The crystal structure of the BASI/Trx 
complex revealed three regions that make up specific loops that can then bind 
via hydrophobic interactions and hydrogen bonds, to the outside of the 
substrate molecule. These three regions were 45WCGP48, 87AMP89 and 
104VGA106. These structural loop regions are highly conserved in the Trx 
proteins and correspond well to three regions in hTrx (PDB: 1ERT), 45WCGP48, 
87CMP89 and 104SGA106 (residues in bold differ from the BASI/Trx complex). 
The crystal structure of the disulfide state of hPrxII that was determined in 
Chapter 3 was used to model the interaction between hPrxII and Trx, using the 
ClusPro2 Server (Comeau et al., 2004). The obtained model revealed a slight 
 rearrangement of the residues around the disulfide bond that allowed a bond to 
be formed between Cy
molecule. This rearrangement was localized to the disulfide area and did not 
cause any major structural 
The model does suggest that the Trx molecule will interact with both subunits in 
a hPrxII dimer but not interact near the dimer: dimer interface. The model 
suggests that the mixed disulfide complex is held together by hydro
interactions in the binding motifs mentioned above as well as hydrogen bonds 
between Trp31 and Arg91 (Subunit 1), Gly33 and Phe49 (Subunit 1), Cys73 
and Gly175 (Subunit 2), Met74 and Thr53 (Subunit 1), Ser90 and Tyr164 
(Subunit 2), and Ala92 and Val
Figure 4.33. Cartoon representation of the 
and Trx (Cys32) (shown in 
reduced Trx (PDB: 1ERT) structures. The binding motif residues are 
with interacting residues from the two hPrxII subunits shown in blue and red
respectively (figure created using PyMol DeLano Scientific). 
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s35 of the Trx molecule and Cys52 of the hPrxII 
movements in the rest of the protein.  
171 (Subunit 2). 
potential disulfide between hPrxII (Cys51) 
yellow) from the model created from the hPrxII(S
 
phobic 
 
-S) and 
shown in green 
, 
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The interaction of Trx from the model suggests that the 10 Trx molecules would 
be able to interact with the decameric form of the protein at once without 
interfering with either the dimer:dimer interactions or with each other. This 
agrees with the 10:1 ratio that can be seen in the covalent complex of 
mPrxII/mTrx. The fact that all 10 Trx molecules are seen bound to the PrxII 
enzyme in the covalent complex does not necessarily mean that in the real 
cellular situation this would occur.  
 
Figure 4.34. Surface representation of the model of Trx interacting at all 10 active sites 
of decameric form of hPrxII S-S. The hPrxII subunits are shown in blue and light blue 
with Trx molecules shown in red (figure created using PyMol DeLano Scientific). 
 
It is possible that Trx molecules would associate and dissociate, with the actual 
number interacting with PrxII at any one time relating to the oxidative pressures 
within the cell. This oxidative pressure would govern how many PrxII active 
sites are being oxidized at any one time and control the rate of oxidation. 
4.4.3. Interaction with PDCL3 
The native gel electrophoresis studies of the complexes were unable to yield 
any results even though a potential interaction had been flagged during the ESI-
MS studies (Professor Keith Willison, Personal Communication). It is possible 
that the native gels were unable to yield any results as the complexes were too 
transient to be analyzed on the gel. The complex was then analyzed using a 
sucrose gradient, a much “softer” technique which showed a positive result. The 
PDCL3*568 was shown to interact with hPrxII forming a complex ~ 250 – 300 
kDa in size. This would suggest that the ratio of binding would be 10:1 (PDCL3: 
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hPrxII(decamer)). The sucrose gradients run with the two truncations of PDCL3 
missing the first 90 residues showed no interaction suggesting the binding site 
is on the N-terminus. The third truncation (1-211) was shown to be prone to 
aggregation and it was shown that hPrxII may prefer binding to the aggregates 
over the monomeric form (Professor Keith Willison, Personal Communication). 
This interaction is under further investigation although it is believed that hPrxII 
may have a chaperone type function in its interaction with PDCL3. 
4.4.4. Surface plasmon resonance  
4.4.4.1. Interactions between hyperoxidised hPrxII and Srx 
The immobilized Srx and Trx proteins were inactive and did not show any 
interaction with the hPrxII. It is suggested that the loss of activity was due to the 
immobilization process. 
The hPrxII enzymes were checked to be in the correct oxidation state for the 
reaction to occur before injected into the SPR machine. The hPrxII interacting 
with Trx was shown to be solely in the disulfide state and was prepared in 
exactly the same manner as the hPrxIIS-S that was crystallized. The hPrxII 
interacting with Srx was reduced with DTT and hyperoxidised with H2O2 and 
confirmed to contain no disulfide bonds using SDS-PAGE. The Srx and Trx 
were checked to be in their functional monomeric state and were reduced with 
DTT prior to the assay. 
The proteins could have been bound to the gold surface restricting access to 
their active site. Both Trx and Srx were analysed to determine the position of 
their lysine residues (Pymol DeLano Scientific). Trx has six surface accessible 
lysine residues that would preferentially bind with the activated carboxylic acid 
surface but none of these are located at the active site or in the previosuly 
postulated binding domains between Trx and its target protein (Maeda et al., 
2006). Srx has four surface accessible lysine residues so would bind to the 
surface of the chip. The recent structure of the essential repair embrace 
(Jonsson et al., 2008) that occurs in the hPrxI-ET-Srx complex shows the C-
terminal arm of hPrxI interacting with ET-Srx along the site of these surface 
lysine residues. If the protein was bound to the SPR chip by these residues the 
C-terminal arm of PrxII would not be able to interact with the Srx and could 
result in the complex not being observed. One way to solve this could be to 
mutate those residues and introduce some other lysine residues on the surface 
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of Srx that do not show any interaction with the hPrxII. Another solution could 
be to tag the proteins with a biotin tag or His-tag and immobilize the proteins via 
this interaction instead of amide coupling. As both of the proteins are His-
tagged, one of the proteins would have to have its tag removed or be cloned 
without a His-tag. The problem of non-specific binding needs to be addressed 
and could possibly be due to the denaturation of the protein during amide 
coupling. Another explanation for the non-specific binding could be electrostatic 
interaction with the chip surface as it was partially removed upon the addition of 
NaCl. 
  
157 
 
5. The cloning and over-expression of an active human 
thioredoxin reductase 
5.1. Introduction 
5.1.1. Thioredoxin reductase 
Thioredoxin reductase is part of a family of homodimeric flavoproteins that are 
known to reduce thioredoxin as part of the peroxiredoxin peroxide scavenging 
system. Thioredoxin reductase 1 (TrxR1) is the major form of thioredoxin 
reductase and is found mainly in the cytoplasm. TrxR1 is a selenoprotein 
containing a selenocysteine which is essential for the activity of the enzyme. 
The selenocysteine forms part of the TrxR1 active site at the C-terminal end in a 
Cys-Sec-Gly-COOH motif (Arner, 2009). 
5.1.2. Selenocysteine and selenocysteine incorporation 
Selenocysteine is the 21st amino acid and has the same structure as cysteine 
except the sulfur group has been replaced by selenium (figure 5.1) to form a 
selenol group. Selenocysteine has a lower pKa and a higher reducing potential 
complared to cysteine (Stadtman, 1996).  
HNH2
CH2
SH
COOH
HNH2
CH2
SeH
COOH
Cysteine Selenocysteine  
Figure 5.1. The chemical structure of the amino acids cysteine and selenocysteine. 
Selenocysteine has the sulfur atom replaced by a selenium atom. 
Selenocysteine containing proteins are difficult to reproduce in an E. coli 
expression system as secondary structural elements and genes that aide 
selenocysteine incorporation are missing.  
5.1.2.1. Selenocysteine insertion sequence 
A selenocysteine insertion sequence (SECIS) is required to incorporate a 
selenocysteine in place of the stop codon UGA. The SECIS used in this project 
is a minimal SECIS and is an mRNA element that forms a stem-loop structure. 
It was adapted from the SECIS found in the E. coli selenoprotein formate 
 dehydrogenase (Jormakka 
nucleotides which form the mini upper
must be located 11 nucleotides away from the UGA codon that will encode for 
the selenocysteine (Liu et al
Figure 5.2. The structure and sequence of the minimal SECIS developed from 
formate dehydrogenase. The UGA codon that will encode for the selenocysteine is 
located 11 nucleotides away from the 17 nucleotide upper
The SECIS aids incorporation of the selenocysteine at the UGA codon as the 
stem-loop region will bind to the selenocysteine specific elongation factor (SelB) 
protein. The SelB protein binds to the 
selenocysteine-specific tRNA
a seryl residue but is converted to selenocysteinyl by selenocysteine synthase, 
an oligomer of the selA
elements in the incorporation of a selenocysteine residu
5.1.2.2. Co-expression with the 
the use of a double stop codon
As well as the SECIS it has been shown that the co
proteins with the selA, selB
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et al., 2003). The minimal SECIS is made up of 17 
-stem-loop structure; these nucleotides 
., 1998) (figure 5.2).  
 
-stem-loop structure.
selC gene product which is the 
 (tRNASec). The tRNASec is originally charged with 
 gene product. The selABC genes are important 
e (Arner et al
selA, selB and selC
 
-expression of the 
 and selC genes greatly increases 
E. coli 
 
., 1999). 
 genes and 
hTrxR 
the amount of 
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selenocysteine inserted and therefore the activity of the protein (Arner et al., 
1999). The pSUABC plasmid contains all three genes in a specially designed 
pSU vector supplying the relevant tRNA, tRNA synthase and the recognition 
factor for translation of the UGA SeCys codon (Cao et al., 2007). A double stop 
codon is also incorporated on the 3’ end of the TrxR1 open reading frame as it 
has been shown to promote a higher level of SeCys incorporation in 
recombinant TrxR1 (Arner et al., 1999). 
5.2. Materials and Methods 
5.2.1. Cloning of hTrxR1 
TrxR1 was cloned using the ligation-independent cloning (LIC) vector system 
(Merck Biosciences). PCR was used to amplify the gene with vector specific 
overhangs. The vector specific overhangs were created by pre-treating the 
vector with T4 DNA polymerase and dGTP. The gene with the overhangs 
attached was then annealed to the vector allowing the vector plus insert to be 
transformed into an E. coli expression cell line for protein expression and 
purification (see figure 5.3). 
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Figure 5.3. The strategy for the cloning of TrxR1 gene into the pET30 Xa/LIC vector to 
allow for expression of the protein (adapted from LIC Manual, Novagen). 
5.2.1.1. Primer sequences 
TrxR1F 5’ GGTATTGAGGGTCGCATGAACGGCCCTGAAGATC 3’ 
TrxR1R 
5’AGAGGAGAGTTAGAGCCGGTGCAGACCTGCAACCGATTATTAACCTCAGC
AGCCAGC 3’ 
Underlined are the vector specific overhangs for the pET30 Xa/LIC vector. The 
SECIS sequence is shown in red. 
5.2.1.2. PCR of hTrxR1 
An image clone was purchased from Open Biosystems which contained Homo 
sapiens TrxR1 in the pCMV-SPORT6 vector and was used as the template for 
the PCR reaction. The PCR was performed in a total volume of 50 µl containing 
200 ng of template DNA, 100 ng of each primer, 200 µM dNTP solution mix, 1 U 
Deep Vent Polymerase (New England Biolabs, Beverley, MA), 1x Deep Vent 
Buffer and nuclease free water to adjust to the final volume. The PCR cycle 
consisted of an initial denaturation step of 5 min at 95oC and 30 consecutive 
Reverse primer with 
SECIS and vector specific 
overhangs 
Forward primer with 
vector specific overhangs 
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cycles of denaturation (30 sec at 95oC), annealing (30 sec at 65oC) and 
polymerisation (1.5 min at 72oC). There was also a final extension time of five 
min at 72oC. A 1% agarose gel was run to confirm a DNA product of the correct 
size and the PCR product was purified using a gel extraction kit (Qiagen) 
according to the manufacturer’s instructions. The purified PCR product was 
eluted using TlowE® buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0). 
5.2.1.3. T4 DNA polymerase treatment of the hTrxR1 insert 
The purified PCR product was treated with T4 DNA Polymerase to generate the 
vector compatible overhangs. The reaction was performed in a total volume of 
20 µl containing 0.2 pmol of the purified PCR product in TlowE® buffer, 1x T4 
DNA polymerase buffer, 2.5 mM dGTP, 5 mM DTT, 1 U T4 DNA Polymerase 
(LIC qualified, Merck Biosciences) and nuclease free water to adjust to the final 
volume. The reaction was incubated at 22oC for 30 min followed by enzyme 
inactivation by incubation at 75oC for 20 min. The prepared insert was then 
stored at -20oC before the annealing reaction took place. 
5.2.1.4. Annealing the vector and prepared insert 
The annealing reaction takes place in a final volume of 4 µl containing 1 µl 
pET30 Xa/LIC vector, 2 µl T4 DNA Polymerase treated hTxrR1 insert (0.02 
pmol) this was then incubated at 22oC for five min before addition of 1 µl EDTA 
(6.25 mM) and further incubation at 22oC for 5 min. 1 µl of the annealing 
reaction was used to transform chemically competent E. coli NovaBlue cell line 
(as described in methods 2.2.2) (Merck Biosciences). The E. coli cells were 
plated onto LB agar plates containing the appropriate antibiotic for selection. 
The transformants were verified to contain hTrxR1 gene by plasmid DNA 
isolation, digestion and agarose gel electrophoresis. The recombinant plasmid 
containing the hTrxR1 gene was sequenced by Geneservice (Oxford, United 
Kingdom). 
5.2.2. Expression of recombinant hTrxR1 
The TrxR1 DNA was used to transform the chemically competent expression 
cell line BL21 (DE3)-pLysS (Invitrogen) as previously described in methods 
2.2.2. The pET30 Xa/LIC vector encodes for an N-terminal poly histidine tag 
and features a T7lac promoter to control expression of the target protein. 
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Expression trials on the TrxR1 protein showed poor expression and production 
of insoluble protein under conditions previously used for expression of proteins 
(as in methods 2.2.3), so new conditions based on previous work on expressing 
thioredoxin reductases were used (Cao et al., 2007). The protein was 
expressed in a new modified rich LB media (recipe shown below).  
Modified rich LB media:- 0.5 % w/v NaCl 
 1.2 % w/v Bactotryptone 
 2.4 % w/v Yeast extract 
 4 % v/v Glycerol 
 0.5 % w/v K2HPO4 
 0.0142 % w/v Na2SO4 
BL21 (DE3)-pLysS cells containing the TrxR1 plasmid were used to inoculate 
100 ml of modified rich LB media containing the appropriate antibiotic for 
selection. This starter culture was grown under agitation at 200 rpm overnight at 
37oC and 10 ml was used to inoculate 1 L fresh modified rich LB media 
containing the appropriate antibiotic selection, and grown under agitation at 
37oC until the OD600nm reached 0.6. At this point the temperature was reduced 
to 15oC and left for 30 min before the addition of 0.3 mM IPTG and 1 µM 
sodium selenite and the culture incubated for a further 18 hours at 15oC. The 
cells were then harvested by centrifugation (20,000 x g, 20 min, 4oC) using a 
Beckman JA-10 rotor. The cell pellet was stored at -20oC until further use. 
5.2.2.1. Co-expression with pSUABC 
The protein was also co-expressed with the selA, selB and selC genes that 
were kindly donated in one plasmid (pSUABC) by Professor Elias Arner 
(Department of Medical Biochemistry and Biophysics, Karolinska Institute). The 
pSUABC component was placed into the pLysS cell line and used to inoculate 
100 ml modified rich LB media containing chloroamphenicol and kanamycin. 
The starter culture was grown under agitation at 200 rpm overnight at 37oC. 10 
ml was then used to inoculate 1 L of fresh modified rich LB media that was then 
also inoculated by 10 ml of TrxR1 starter culture. The rest of the over-
expression procedure was carried out as described previously (see methods 
5.2.2). 
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5.2.3. Purification of recombinant TrxR1 
Cell lysis was carried out as described in methods 2.2.4.1.  
5.2.3.1. Purification buffers 
Buffer A – 20 mM HEPES, pH 8.0, 0.5 M NaCl, 20 mM imidazole 
Buffer B – 20mM HEPES, pH 8.0, 0.5 M NaCl, 1 M imidazole 
Buffer C – 20mM HEPES, pH 8.0, 0.1 M NaCl 
5.2.3.2. Nickel affinity and gel chromatography 
The nickel affinity chromatography was performed as in methods 2.2.4.3 using 
a six column volume gradient to 100 % buffer B with the fractions containing 
protein analyzed using SDS-PAGE as described in methods 2.2.4.6. The 
protein was loaded on a Superdex 200 column (GE Healthcare) using the 
method described in 2.2.4.5. The Superdex 200 column was equilibrated with 
one column volume at a flow rate of 1 ml/min. The sample was loaded and 
fractions collected over one column volume and the fractions were analyzed 
using SDS-PAGE as in methods 2.2.4.6. 
5.2.4. TrxR1 DTNB assay 
The activity of TrxR1 was determined by measuring the DTNB reductase 
activity. The assay was performed at 25oC in a final volume of 2 ml containing 1 
µg TrxR1 and 1.5 mM DTNB and made up to volume with 100 mM Tris-HCl, pH 
7.5, 2 mM EDTA. The reaction was started by the addition of 0.2 mM NADPH 
and the change in A412nm was measured over 10 min. The activity of the protein 
was expressed as µmol/min/mg of protein and was calculated using the formula 
below. 
Activity (µmol/min) = (∆A412 x 1000)/ 13.6 /min 
Equation 5.1. The activity of the protein in µmol/min is determined by measuring the 
∆A412 over the 10 min time period and using the equation above. 13.6 is the extinction 
coefficient of TNB.   
5.2.5. Reconstitution of the PrxII pathway 
An assay to measure the activity of the hPrxII pathway was performed at 25oC 
in a final volume of 1 ml containing 100 µM NADPH, 2 µM hTrx, 1 µM TrxR1 
and 0.5 µM hPrxII and made up to volume with 50 mM Tris-HCl, pH 7.5. The 
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reaction was started by the addition of 0.1 mM H2O2 and the change in A340nm 
was measured over 180 seconds.  
5.3. Results 
5.3.1. Cloning of TrxR1 
An IMAGE clone was purchased from Open Biosystems encoding for the TrxR1 
gene and was used as a template for PCR, which was carried out as described 
in methods 5.2.1. The amplification of the TrxR1 gene resulted in a DNA band 
of the correct size (~1.5 kbp) which was successfully cloned into the expression 
vector pET30 Xa/LIC. DNA sequencing results show that the correct TrxR1 
sequence had been obtained and also show the presence of the SECIS, the 
double stop codon and the 3’ end of the gene (Appendix 7.11) (Figure 5.4). 
 
Figure 5.4. 1 % agarose gel showing the PCR amplification of the TrxR1 gene. Lane 1, 
marker (Hyperladder 1, BIOLINE, (Appendix 7.3)); Lane 2, TrxR1 PCR band at ~1.5 
kbp. 
5.3.2. Expression of recombinant TrxR1 
The pET30 Xa/LIC/TrxR1 construct was transformed into the E. coli expression 
strain BL21 (DE3)-pLysS. TrxR1 protein expression was under the control of the 
T7 promoter and induced using IPTG. The over-expression of TrxR1 was 
investigated by induction studies to obtain the best conditions for over-
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expression. The optimal over-expression was achieved by addition of a final 
concentration 0.3 mM IPTG when the cells had reached an OD600nm of 0.6 with 
further incubation for 16 hours at 15oC. 1 µM sodium selenite was also added at 
induction as a source of selenium for the selenocysteine. The over-expression 
of TrxR1 resulted in soluble protein being produced at the expected size (~61 
kDa). The protein was also co-expressed with the pSUABC component. When 
over-expressed with this component the amount of TrxR1 produced was not 
affected. This was confirmed by observing the strength of a band on SDS-
PAGE as well as the calculation of total protein using A280. 
5.3.3. Purification of recombinant TrxR1 
One litre of culture produced 1.7 g of cell paste and after cell lysis (methods 
2.2.4.1) and centrifugation the supernatant was purified using nickel affinity and 
gel filtration chromatography as described in methods 5.2.3.2. 
5.3.3.1. Nickel affinity and gel filtration chromatography 
The clarified cell extract was applied to a nickel column as described in 
methods 5.2.3.2 (figure 5.5). The fractions were analyzed using SDS-PAGE 
(data not shown) as described in methods 2.2.3.6. The fractions containing 
TrxR1 were pooled and concentrated (methods 2.2.4.5), in preparation for gel 
filtration chromatography. 
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Figure 5.5. Elution profile of TrxR1 (red line) from nickel affinity chromatography. 10 ml 
fractions were collected throughout the entire elution volume. The green line shows the 
% imidazole concentration. The fractions that showed a band of the correct size on 
SDS-PAGE (result not shown) are indicated by the red bar. 
Gel filtration was used as a final step of the purification process and the use of a 
calibrated gel filtration column allowed the size and therefore the oligomeric 
state of the protein to be estimated. The concentrated protein sample was 
loaded onto the gel filtration column as described in methods 5.2.3.2 (figure 
5.6). The peak fractions were analyzed by SDS-PAGE (figure 5.7) and those 
that contained TrxR1 were pooled and concentrated (as in methods 2.2.4.5). 
 
Figure 5.6. Elution profile of TrxR1 (blue line) from a calibrated HiLoad 16/60 Superdex 
200 gel filtration column. 1 ml fractions were collected throughout the elution volume. 
Peak 1 corresponds to the columns void volume (~44 ml); Peak 2 contained the 
dimeric form of TrxR1 (~66 ml) (~128 kDa). 
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Figure 5.7. SDS-PAGE analysis of the peak from gel filtration chromatography 
showing the purified TrxR1. Lane 1, molecular weight marker (Precision Plus Protein 
Standard, BioRad Laboratories); Lane 2, sample of TrxR1 after gel filtration 
chromatography (elution volume ~66 ml). 
5.3.4. TrxR1 DTNB activity assay 
The activity assay was carried out with both TrxR1 co-expressed with pSUABC 
and without pSUABC. The assay was also carried out without the presence of 
the TrxR1 enzyme as a control (figure 5.8). 
hTrxR1 
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Figure 5.8. DTNB activity assay run over a period of ten minutes from when the 
NADPH was added. The green line shows the assay run with TrxR1 that did not 
possess the C-terminal SECIS element. The blue line shows the assay run with TrxR1 
that possessed the SECIS element but was not co-expressed with pSUABC. The red 
line shows the assay run with TrxR1 that possessed the SECIS element and was co-
expressed with the pSUABC component. 
The TrxR1 expressed without pSUABC showed an activity of 1.42 µmol/min but 
when pSUABC was co-expressed the activity showed a six fold increase to 8.54 
µmol/min. The TrxR1 cloned without the SECIS was shown to have no activity 
at all. The protein over-expressed without the pSUABC plasmid was unable to 
incorporate the selenocysteine and may have read the stop codon used to code 
for the selenocysteine to terminate the gene missing the last three residues. 
5.3.5. Reconstitution of the PrxII pathway 
The reconstitution of the PrxII pathway in this case proved unsuccessful and 
was not finished due to time constraints.  
5.4. Discussion 
5.4.1. Activity of hTrxR1 
An active thioredoxin reductase recombinant protein was successfully cloned 
and over-expressed allowing the completion of the PrxII pathway and therefore 
0
0.005
0.01
0.015
0.02
0.025
0 20 40 60 80 10
0
12
0
14
0
16
0
18
0
20
0
22
0
24
0
26
0
28
0
30
0
32
0
34
0
36
0
38
0
40
0
42
0
44
0
46
0
48
0
50
0
52
0
54
0
56
0
58
0
60
0
A
4
1
2
n
m
Time (sec)
169 
 
the production of a working assay. TrxR1 that was co-expressed with the 
pSUABC component was found to have activity of 8.54 µmol/min, although this 
is fivefold less than that observed for some native thioredoxin reductases 
(Goratov and Stadtman, 1998). It is however comparable to literature values 
obtained from other recombinant forms of TrxR1 (Arner et al., 1999; Cao et al., 
2007). 
It can be seen from the assay that the minimal SECIS adapted from SECIS 
from E. coli formate dehydrogenase is essential for the insertion of a 
selenocysteine as removal of the SECIS results in no activity being observed. It 
is postulated that this is due to the lack of a SECIS causing the protein to be 
terminated at the position of the UGA codon instead of using it as the site of 
selenocysteine insertion. The presence of a double stop codon as part of the 
SECIS element before the main part of the stem-loop structure shows that the 
SECIS only needs to be present in the mRNA and its translation is not required 
for the insertion of a selenocysteine.  
The other major element required for the insertion of the selenocysteine and 
therefore the activity of TrxR1 was the co-expression of the protein with the 
pSUABC component. This co-expression greatly increased the activity of this 
over-expressed TrxR1. The co-expression of the pSUABC component seemed 
to have no effect on the amount of TrxR1 produced (the same band intensity 
was seen on a SDS-PAGE and the same total protein calculated using A280) but 
had a six fold increase on the activity of the protein in the DTNB assay. This 
result reiterates the importance between the ratio of the mRNA SECIS and the 
selA, B and C genes in producing an active TrxR1 (Tormay et al., 1996). The 
protein over-expressed without these genes was unable to incorporate the 
selenocysteine and may have read the stop codon used to code for the 
selenocysteine to terminate the gene missing the last three residues. 
5.4.2. Reconstitution of the PrxII pathway 
Due to the late stage in the project at which TrxR1 was cloned and over-
expressed in its active form the assay for the entire pathway was unable to be 
formed. The cloning of the TrxR1 proved to be very problematic. The SECIS 
presence in traditional primers yielded no results with traditional PCR methods 
as the Loop-Stem structure resulted in the SECIS being added backwards or 
not at all. The failure in getting the whole pathway assay to be functional could 
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be down to a number of different reasons but it is suggested that the major 
problems could be the activity of the proteins hPrxII and Trx as their activity has 
not been determined. 
The hPrxII protein could possibly not be active in its current form. Either all of 
the protein is being converted to the sulfinic acid form (as seen in the structure 
(Schroder et al., 2000)) or the disulfide decamer is unable to be reduced by Trx. 
The hPrxII protein was reduced with DTT (and the DTT removed by gel filtration 
chromatography) prior to the assay being run, but this does allow for the hyper-
oxidation to re-occur although it is unlikely that this would result in the 
inactivation of all the PrxII (Jonsson et al., 2008). If the PrxII was all in the 
hyperoxidised state this would mean that the Trx could not act upon the sulfinic 
acid moiety and so would leave the protein inactive in this assay as Srx is the 
only known protein to be able to reduce the sulfinic acid form (Biteau et al., 
2003). Although it has been shown previously that the disulfide decamer and 
the Trx protein interact this has only been shown using chemical methods and 
the in vivo relationship has not been demonstrated. It could be the case that the 
Trx is unable to reduce the disulfide decameric state suggesting the protein is 
inactive in this form. Once again this is unlikely as although the interaction was 
shown chemically, the disulfide decameric structure of the protein observed 
above shows no structural reason as to why the Trx protein would be unable to 
reduce it. 
The Trx protein has not been tested for activity as all of the assays require the 
TrxR1 enzyme. The activity of this protein would have to be tested to confirm it 
is not a broken link in the chain. The Trx protein does seem to purify well with 
no degradation, although the protein does originally form a dimer that is then 
reduced back to its functional monomer (Weichsel et al., 1996) chemically. Gel 
filtration of the protein used just before the assay was run still showed the Trx to 
be present as a monomer. It is likely that the problem lies in the assay itself as 
due to time constraints this assay was run only twice and although following a 
protocol that yielded results for a mitochondrial PrxIII (Cao et al., 2007), the 
assay would have to be modified to achieve results. 
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6. Summary and further work 
6.1. Summary 
hPrxII was originally cloned with a point mutation in the fourth residue leading to 
an amino acid change of glycine to valine. The hPrxII protein was unstable 
during purification and was unable to be purified and concentrated to 
satisfactory concentrations. The re-cloning of this protein with the correct 
residue allowed purification of this protein to homogeneity using nickel and gel 
filtration chromatography. This correction in the amino acid sequence also 
resulted in a shift in the oligomeric state of the protein with the protein being 
produced in the same oligomeric state as the native protein. 
The hPrxII protein was over-expressed in the decameric state with a disulfide 
bond between the peroxidatic and the resolving cysteines. The hPrxII(S-S) was 
purified to homogeneity using nickel and gel filtration column chromatography 
and diffraction quality crystals obtained. Structural analysis of the enzyme 
resulted in the 3.3 Ǻ resolution structure of the disulfide form of the enzyme. 
The structure was solved using molecular replacement using the native hPrxII 
(PDB: 1QMV) as a model and revealed a disulfide bond between the 
peroxidatic (Cys52) and resolving (Cys171) cysteines but lacked the C-terminus 
of the protein (due to poorly defined electron density). The structure revealed a 
movement in the loop region consisting of residues 47-54 resulting in a 6 Ǻ 
movement of Cys52 towards the neighbouring monomer within the homodimer. 
In the neighbouring subunit a large structural movement in the region consisting 
of residues 170-202 is observed to form the disulfide bond. The residues 170-
175 displace the C-terminal αH6 in the hyperoxidized/thiol structure which 
results in a 10 Ǻ movement in the Cα of Cys172. The structure also revealed 
that the rearrangements needed to bring the two redox active cysteines 
together did not result in the breakdown of the dimer:dimer interface and 
revealed the protein to be decameric in structure contrary to what was 
postulated when the original native structure was solved.  There was only one 
observed change in the residues involved in the dimer:dimer interface which 
occurred at Phe47. It was shown that the movement of this residue would not 
have resulted in the breakdown of the dimer:dimer interface. 
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An engineered truncation of Srx and a mutant Prx (C70S/C172S) were purified 
to homogeneity using nickel and gel filtration chromatography. The ET-Srx 
lacked the first 31 residues of the amino acid sequence removing a glycine rich 
region that is thought to be problematic in the crystallization of the complex. A 
covalent complex was then formed between the two cysteine residues using the 
chemical conjugating agent DTNB.  Size exclusion chromatography revealed 
the binding stoichiometry of this complex to be a 5:1 ratio of Srx to hPrxII 
decamer. Modelling of the known structure of a highly similar complex reveals 
that a large conformational change that occurs upon binding could result in the 
need for co-operation between the two active sites on the hPrxII homodimer. 
This could result in only one active site being used per homodimer hence the 
5:1 ratio. The complex was also studied using SPR but no meaningful results 
were obtained from these experiments. One of the reasons behind this could be 
due to C-terminal embrace that is seen when the two proteins interact. The Srx 
protein was attached to the carboxylic acid surface of the gold chip by amide 
coupling (through lysine residues). The largest group of surface accessible 
lysine residues appears along the site of this interaction meaning that tethering 
to the surface by these residues may have left the protein unable to interact with 
hPrxII. Also it was suspected that the protein was denatured by the amide 
coupling procedure. Crystal dishes were put down using the mPrxII-ET-Srx 
complex but unfortunately to date have yielded no crystals. If the Srx molecule 
is able to bind to only one active site in the homodimer this could result in a lack 
of homogeneity in the sample preventing crystallisation.  
A mutant Trx (C46S/C73S) and mutant Prx (C70S/C172S) were purified to 
homogeneity using nickel and gel filtration chromatography. A covalent complex 
was then formed between the two cysteine residues using the chemical 
conjugating agent DTNB. Size exclusion chromatography revealed the binding 
stoichiometry of this complex to be a 10:1 ratio of Trx to hPrxII decamer. The 
previously obtained disulfide structure of hPrxII was used to model the 
interaction with Trx. The model showed interaction between the hPrxII(S-S) and 
Trx at three conserved binding motifs. The binding in these regions consisted of 
hydrogen bonds and hydrophobic interactions. The minimal conformational 
change in the hPrxII protein is postulated to be the reason why binding can be 
observed at all 10 redox active centers in the hPrxII decamer. The complex was 
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also studied using SPR but no meaningful results were obtained from these 
experiments. The reasons for this are unclear and would require further 
investigation. Crystal dishes were put down using the mPrxII-mTrx complex but 
unfortunately to date have yielded no crystals. 
Whilst working with Professor Willison (Institute of Cancer Research) an 
interaction was confirmed between hPrxII and PDCL3 using sucrose gradients. 
The nature of the hPrxII/PDCL3 interaction suggests a chaperone function for 
hPrxII.   
The selenocysteine containing TrxR1 was cloned with a minimal SECIS 
attached to the 3’ end of the DNA sequence that allowed over-expression and 
purification of the active enzyme. The activity of this enzyme was increased 
when co-expressed with a plasmid containing the selA, selB and selC genes. 
When co-expressed with this plasmid a six-fold increase in activity was 
observed from 1.42 µmol/min to 8.54 µmol/min with the TrxR1 over-expressed 
without the SECIS showing no activity at all. The reconstitution of the hPrxII 
pathway was never achieved due to the time constraints of the PhD. Two 
preliminary experiments were carried out to obtain an active pathway without 
success. The activity of TrxR1 has been demostrated with an assay but hPrxII 
or Trx could be inactive providing a break in the chain needed for the assay to 
function. Further work is required to optimise the system. 
6.2. Further work 
There are a number of ways in which the work contained within this thesis can 
be taken forward with most of the further work focusing on the interaction 
between hPrxII, Srx and Trx. Now that the individual component enzymes are 
available a working hPrxII assay needs to be developed. 
The investigation into the hPrxII-Srx and hPrxII-Trx complex could be continued 
with extensive investigation into the structure, binding stoichiometry and binding 
kinetics. Since there is no structure of either of the hPrxII-Srx and hPrxII-Trx 
complexes published, the complexes remain an interesting target for structural 
biology. Further studies could be undertaken to grow diffraction quality crystals, 
with the aim of solving these structures. Structural studies on the complexes 
could provide a greater insight into the mechanisms for binding between the two 
proteins as well as a further understanding of the interaction between 
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decameric hPrxII and the two reducing enzymes. Of particular interest would be 
the location of the C-terminal arm that is missing from the hPrxII(S-S) structure 
and performs a large structural movement in the hPrxI-ET-Srx complex 
structure. Another analytical tool for obtaining a structure for this complex could 
be to use biological small angle X-ray scattering (SAXS). SAXS has the 
advantage that a structure can be obtained without the need for a crystalline 
sample. Obtaining greater information on the structure of the hPrxII-Srx 
complex may help to understand any co-operation between the redox active 
sites in binding Srx and help to understand the 1:5 ratio observed from size 
exclusion chromatography. 
There is still little information on the binding stoichiometry of these complexes 
as well as the kinetics of association and dissociation. Further evidence of the 
binding stoichiometry could be obtained using cryo-electron microscopy (cryo-
EM). Pictures have been obtained of the toroidal shape of hPrxII using TEM and 
it would be interesting to see if the presence of the Srx/Trx protein can be seen 
attached to the hPrxII toroid. The binding stoichiometry could also be analyzed 
further using analytical techniques such as ultracentrifugation and sucrose 
gradients. Information on this binding stoichiometry would help to provide an 
understanding into the mechanism of complex formation and may provide 
information of the biological relevance of the decameric form of the protein.   
Further development of the SPR assays could be continued to obtain kinetic 
data on these complexes. Extensive work must go into the design of these 
experiments to remove the issue of non-specific binding. Non-specific binding 
was identified as an electrostatic interaction and was partially removed by the 
addition of NaCl to the buffer. Future work could include changing different 
experimental conditions, or by altering the chemical layer through which the 
ligand and the gold interact. The proteins must be tested to see if amide 
coupling is rendering them inactive and if so an alternative to amide coupling 
can be used, such as binding to the gold surface through a tag attached to the 
protein, such as biotin or the His-tag. Binding through the His-tag would require 
removal of the His-tag from one of the proteins. Data obtained from these SPR 
studies would help to further understand the interactions between these 
proteins. 
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Now that all the proteins in the Prx pathway have been cloned, over-expressed 
and purified, formation of an assay for these proteins can be carried out. 
Formation of a working assay would allow the reaction of the hPrxII to be 
studied further. Information could be obtained on the range of concentrations of 
H2O2 at which hPrxII is functional. The assay could also be used to allow for 
studies into the effect of different inhibitors on the hPrxII and particular the 
interaction with Srx which could be used in cancer therapy to stimulate apotosis. 
Additionally, mutagenesis studies of key residues could investigate how 
different structural changes within hPrxII could alter its activity. 
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7. Appendix  
7.1. Superdex 200 gel filtration column calibration 
 
7.2. BioRad Precision Plus Protein Standard 15 – 250 kDa 
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7.3. Hyperladder I (BIOLINE) 
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7.4. MDL 1 & 2 Crystal screen (Molecular Dimensions 
Laboratories) 
7.4.1. MD1-01 
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7.4.2. MD1-02 
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7.5. Sigma crystal screens 
7.5.1. Sigma 8007 Crystal Screen (Sigma) 
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7.5.2. Sigma 70437 Crystal Screen (Sigma) 
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7.6. JCSG Crystal Screen (Molecular Dimensions 
Laboratories) 
7.6.1. Box 1 
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7.6.2. Box 2 
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7.7. Ramachandran plot for the hPrxII(S-S) structure 
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7.8. ET-Srx mutation 
7.8.1. DNA sequence 
3’ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGC
GCGGCAGCCATATGATCCACTCGGGCCGCATCGCCGCGGTGCACAACGT
GCCGCTGAGCGTGCTCATCCGGCCGCTGCCGTCCGTGTTGGACCCCGCC
AAGGTGCAGAGCCTCGTGGACACGATCCGGGAGGACCCAGACAGCGTGC
CCCCCATCGATGTCCTCTGGATCAAAGGGGCCCAGGGAGGTGACTACTTC
TACTCCTTTGGGGGCTGCCACCGCTACGCGGCCTACCAGCAACTGCAGC
GAGAGACCATCCCCGCCAAGCTTGTCCAGTCCACTCTCTCAGACCTAAGG
GTGTACCTGGGAGCATCCACACCAGACTTGCAGTAG 5’ 
7.8.2. Protein sequence 
MGLRAGGTLGRAGAGRGAPEGPGPSGGAQGGSIHSGRIAAVHNVPLSVLIRP
LPSVLDPAKVQSLVDTIREDPDSVPPIDVLWIKGAQGGDYFYSFGGCHRYAAY
QQLQRETIPAKLVQSTLSDLRVYLGASTPDLQ 
7.9. mPrxII mutation 
7.9.1. DNA sequence (Mutation in bold) 
ATGGCCTCCGGTAACGCGCGCATCGGAAAGCCAGCCCCTGACTTCAAGG
CCACAGCGGTGGTTGATGGCGCCTTCAAAGAGGTGAAGCTGTCGGACTAC
AAAGGGAAGTACGTGGTCCTCTTTTTCTACCCTCTGGACTTCACTTTTGTG
TGCCCCACCGAGATCATCGCGTTCAGCAACCGTGCAGAGGACTTCCGCAA
GCTGGGCTCAGAAGTGCTGGGCGTCTCGGTGGACTCTCAGTTCACCCAC
CTGGCTTGGATCAACACCCCCCGGAAAGAGGGAGGCTTGGGCCCCCTGA
ACATCCCCCTGCTTGCTGACGTGACCAGACGCTTGTCTGAGGATTACGGC
GTGCTGAAAACAGATGAGGGCATTGCCTACAGGGGCCTCTTTATCATCGA
TGGCAAGGGTGTCCTTCGCCAGATCACTGTTAATGATTTGCCTGTGGGAC
GCTCCGTGGATGAGGCTCTGCGGCTGGTCCAGGCCTTCCAGTACACAGA
CGAGCATGGGGAAGTTTCACCCGCTGGCTGGAAGCCTGGCAGTGACACG
ATTAAGCCCAACGTGGATGACAGCAAGGAATATTTCTCCAAACACAATTAG 
Protein sequence (Mutation in bold) 
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPT
EIIAFSNRAEDFRKLGSEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADV
TRRLSEDYGVLKTDEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQA
FQYTDEHGEVSPAGWKPGSDTIKPNVDDSKEYFSKHN  
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7.10. Spectra™ multicolour broad range protein ladder 
(Fermentas) 
 
7.11. hTrxR1 
7.11.1. DNA sequence (SECIS in bold) 
atgaacggccctgaagatcttcccaagtcctatgactatgaccttatcatcattggaggtggctcaggaggtctg
gcagctgctaaggaggcagcccaatatggcaagaaggtgatggtcctggactttgtcactcccacccctcttg
gaactagatggggtcttggaggaacatgtgtgaatgtgggttgcatacctaaaaaactgatgcatcaagcagc
tttgttaggacaagccctgcaagactctcgaaattatggatggaaagtcgaggagacagttaagcatgattgg
gacagaatgatagaagctgtacagaatcacattggctctttgaattggggctaccgagtagctctgcgggaga
aaaaagtcgtctatgagaatgcttatgggcaatttattggtcctcacaggattaaggcaacaaataataaaggc
aaagaaaaaatttattcagcagagagatttctcattgccactggtgaaagaccacgttacttgggcatccctggt
gacaaagaatactgcatcagcagtgatgatcttttctccttgccttactgcccgggtaagaccctggttgttggag
catcctatgtcgctttggagtgcgctggatttcttgctggtattggtttagacgtcactgttatggttaggtccattcttct
tagaggatttgaccaggactggccaacaaaattggtgaacacatggaagaacatggcatcaagtttataaga
cagttcgtaccaattaaagttgaacaaattgaagcagggacaccaggccgactcagagtagtagctcagtcc
accaatagtgaggaaatcattgaaggagaatataatacggtgatgctggcaataggaagagatgcttgcaca
agaaaaattggcttagaaaccgtaggggtgaagataaatgaaaagactggaaaaatacctgtcacagatga
agaacagaccaatgtgccttacatctatgccattggcgatatattggaggataaggtggagctcaccccagttg
caatccaggcaggaagattgctggctcagaggctctatgcaggttccactgtcaagtgtgactatgaaaatgtt
ccaaccactgtatttactcctttggaatatggtgcttgtggcctttctgaggagaaagctgtggagaagtttgggga
agaaaatattgaggtttaccatagttacttttggccattggaatggacgattccgtcaagagataacaacaaatg
ttatgcaaaaataatctgtaatactaaagacaatgaacgtgttgtgggctttcacgtactgggtccaaatgctgg
agaagttacacaaggctttgcagctgcgctcaaatgtggactgaccaaaaagcagctggacagcacaattg
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gaatccaccctgtctgtgcagaggtattcacaacattgtctgtgaccaagcgctctggggcaagcatcctccag
gctggctgctgaggttaataatcggttgcaggtctgcacc  
7.11.2. Protein sequence 
MNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVTPTPLGTRW
GLGGTCVNVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEA
VQNHIGSLNWGYRVALREKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERF
LIATGERPRYLGIPGDKEYCISSDDLFSLPYCPGKTLVVGASYVALECAGFLAGI
GLDVTVMVRSILLRGFDQDMANKIGEHMEEHGIKFIRQFVPIKVEQIEAGTPGR
LRVVAQSTNSEEIIEGEYNTVMLAIGRDACTRKIGLETVGVKINEKTGKIPVTDE
EQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAGSTVKCDYENVPTTVFT
PLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIPSRDNNKCYAKIICNTK
DNERVVGFHVLGPNAGEVTQGFAAALKCGLTKKQLDSTIGIHPVCAEVFTTLS
VTKRSGASILQAGCUGSTOPSTOP 
7.12. Sigma SDS 7 molecular weight marker 
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